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Toxoplasma gondii is an intracellular protozoan parasite that infects warm-blooded animals 
including an estimated thirty percent of humans world-wide. In immunocompetent host, 
primary infection is usually asymptomatic but fast-replicating tachyzoites partially undergo 
developmental switching into slow-replicating, dormant bradyzoites preferentially within 
muscular and neural tissues. Stage differentiation from tachyzoites to bradyzoites enables 
the parasite to establish chronic infection and facilitates transmission of the parasite to new 
hosts via predation or ingestion of raw or undercooked meat from infected livestock. 
Bradyzoite differentiation and tissue cyst development is spontaneously triggered in 
terminally differentiated skeletal muscle cells (SkMCs), i.e in myotubes but not in 
proliferating myoblasts or fibroblasts. The factors that trigger bradyzoite differentiation in 
myotubes are only partially known. Herein, host cell transcriptomes, metabolomes and cell 
cycle regulation were determined to identify host cell factors that might regulate bradyzoite 
differentiation in myotubes.  
RNA sequencing-based transcriptome analysis of non-infected and T. gondii-infected 
myotubes and myoblasts revealed that these cell types differed significantly in the 
expression of ~6500 genes (DEGs) irrespective of T. gondii infection. Gene ontology 
analysis revealed that these DEGs predominantly regulated cellular component 
organization or biogenesis, cell cycle processes including mitotic cell cycle, muscle 
structure development and cellular metabolic processes. Surprisingly, infection with T. 
gondii had only a minor impact on gene expression in myoblasts and myotubes. Further 
analyses of the transcriptomes from infected and non-infected myoblasts and myotubes 
showed differential expression of various enzymes of the central carbohydrate metabolism. 
For example, genes encoding most glycolytic enzymes, some tricarboxylic acid (TCA) 
cycle enzymes, particularly the pyruvate carboxylase of TCA cycle anaplerosis, and 
multiple genes encoding glycogen metabolic enzymes were upregulated in myotubes as 
compared to myoblasts. In contrast, genes encoding enzymes of the pentose phosphate 
pathway (PPP) including glucose-6-phosphate dehydrogenase (G6PDH)2 or G6PDH(X-
linked) and 6-phosphogluconate dehydrogenase (6PGDH) were upregulated in myoblasts 
compared to myotubes. In addition, myotubes showed upregulation of various cell cycle 
inhibitors including p21
Waf1/Cip1
 as compared to myoblasts whereas many cyclin-dependent 
kinases and their cyclins were upregulated in myoblasts compared to myotubes irrespective 
of whether the cells were non-infected or infected with T. gondii. Differential expression of 
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these molecules in myoblasts and myotubes irrespective of infection was further confirmed 
by RT-qPCR. 
GC-MS analyses of non-infected and T. gondii-infected myotubes and myoblasts after 
labeling with 
13
C-glucose indeed indicated increased PPP activities in myoblasts, 
accelerated TCA cycle anaplerosis via the pyruvate carboxylase in myotubes, but no 
differences in glycolysis between the cell types. Remarkably, pharmacological inhibition 
of the PPP using the G6PDH inhibitor dehydroepiandrosterone and the 6PGDH inhibitor 6-
aminonicotinamide upregulated T. gondii bradyzoite antigen (BAG) 1 mRNA expression 
and tissue cyst formation while it reduced parasite replication in both cell types but to a 
higher extent in myoblasts. This indicated that lower PPP activities as observed in 
myotubes compared to myoblasts favors T. gondii stage conversion. In contrast, addition of 
the TCA cycle intermediate analogue dimethyl-α-ketoglutarate accelerated BAG1 mRNA 
expression without increasing tissue cyst formation by T. gondii in myoblasts but not in 
myotubes. Modulation of anaerobic glycolysis using sodium-L-lactate showed a trend of 
increased T. gondii bradyzoite differentiation in myoblasts only. Lower PPP activity as 
observed in myotubes led to reduced levels of NADPH and higher NADP
+
/NADPH ratios 
in myotubes than in myoblasts.  Despite lower NADPH levels in myotubes, reactive 
oxygen species (ROS) levels were however nearly doubled in myoblasts than in myotubes. 
Modulation of endogenous ROS using the antioxidant N-acetyl cysteine inhibited T. gondii 
bradyzoite differentiation in both myotubes and myoblasts. Interestingly, inducing ROS in 
myotubes and myoblasts using the oxidants luperox or H2O2 accelerated T. gondii 
bradyzoite differentiation in both cell types. Thus, physiological concentration of 
endogenous ROS as observed in myotubes but not myoblasts might favor T. gondii stage 
conversion in myotubes.  
Modulation of the host cell cycle of T. gondii-infected myotubes and myoblasts using 
pharmacological inhibitors aphidicolin and mimosine accelerated BAG1 mRNA 
expression in T. gondii within SkMCs but only partially induced tissue cyst formation. 
Furthermore, complete halting of parasite replication by higher concentrations of these 
inhibitors suggested a possibly direct effect on the parasites. To specifically modulate the 
host cell cycle and since myotubes showed upregulation of the cell cycle inhibitor 
p21
Waf1/Cip1
 as compared to myoblasts, p21 was inhibited in SkMCs using RNA 
interference. Knock-down of p21 in myoblasts sustained cell cycle progression and 
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inhibited differentiation of myoblasts into myotubes. However, host cell p21 knock-down 
surprisingly even increased BAG1 mRNA expression by T. gondii but also strongly 
accelerated parasite replication in SkMCs. Thus, differentiation of SkMCs to myotubes 
promotes T. gondii bradyzoite formation independently of p21
Waf1/Cip1
. 
Together these data unravel large differences in the transcriptomes, the central 
carbohydrate metabolism and the cell cycle regulation between myoblasts and myotubes 
before and after infection with T. gondii. Out of these differences, the lower PPP activities, 
the higher TCA cycle activities and the physiological concentrations of endogenous ROS 
as observed in mature myotubes can regulate T. gondii bradyzoite formation in SkMCs.  
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1.1 Toxoplasma gondii 
Toxoplasma gondii (T. gondii) is an obligate intracellular protozoan parasite of the phylum 
Apicomplexa. Other important parasites of the Apicomplexa include Plasmodium spp. 
(malaria), Eimeria spp. (coccidiosis), Neospora spp. (neosporosis), Babesia spp. 
(babesiosis), Theileria spp. (theileriosis) and Cryptosporidium spp. (cryptosporidiosis) 
(Kim and Weiss, 2004). Among them,  T. gondii is the most prevalent and successful 
parasite in nature that can infect a wide variety of warm-blooded animals including 
humans and is responsible for the disease toxoplasmosis (Tenter et al., 2000; Montoya and 
Liesenfeld, 2004). More than 100 years ago, T. gondii was initially identified by Nicolle 
and Manceaux in the blood and tissues of a North African rodent, namely Ctenodactylus 
gundi (Nicolle and Manceaux, 1908). T. gondii and other parasites of the phylum 
Apicomplexa contain distinct structures at their apical end as for instance the conoid, the 
micronemes and the rhoptries which are essential for invasion into host cells (Dubey et al., 
1998; Baum et al., 2008). T. gondii uses diverse strategies to circumvent or to inhibit 
effective host defense mechanisms and thereby is able to lead to lifelong persistence in the 
host (Lüder et al., 1999).  
Acute toxoplasmosis by T. gondii infections is regularly asymptomatic or a mild disease 
with flu-like symptoms in immunocompetent host. However, infection of pregnant women 
can lead to transmission of actively proliferating  parasites (i.e. the tachyzoites) to the fetus 
through vertical transmission that can cause congenital toxoplasmosis (Havelaar et al., 
2007; Pappas et al., 2009) with severe neurological disability, retinochorioiditis, physical 
deformities (hydrocephalus) and severe tissue destruction (toxoplasmic encephalitis) or 
even death of the fetus (Tenter et al., 2000; Gross et al., 2004; Moncada and Montoya, 
2012). Importantly, latent reactivated toxoplasmosis can also cause severe symptoms in 
immunocompromised patients such as those with acquired immune deficiency syndrome 
(AIDS) (Luft and Remington, 1992), transplant recipients (Barcan et al., 2002; Grosu et 
al., 2007) and cancer patients (Lu et al., 2015).  
Phylogenetic analysis of T. gondii isolates from Europe and North America showed that 
the parasite population consists of three major clonal lineages that are called type-I, type-II 
and type-III (Howe and Sibley, 1995). Among these, type-II strains predominate in 
infected human and domestic animals and are prevalent from Northern Europe (Jokelainen 
et al., 2011) to Southern Europe (Sousa et al., 2006). In Germany, 71% 
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isolates from infected humans are type-II strains (Maksimov et al., 2012) whereas in 
France, more than 90% of isolates from humans and animals are type-II strains (Ajzenberg 
et al., 2002; Aubert et al., 2010). Similar prevalences of type-II stains of T. gondii have 
been found in North America (Howe and Sibley, 1995). While type-III strain are abundant 
in animals and are rarely seen in humans (Howe and Sibley, 1995; Ajzenberg et al., 2002), 
type-I strains and atypical strains are mostly isolated from HIV-infected toxoplasmosis 
patients particularly from Africa and South America (Ajzenberg et al., 2009). According to 
virulence, type-I strains are highly virulent in mice whereas type-II and III are less virulent 
(Sibley and Ajioka, 2008). 
  
1.2 Life cycle of Toxoplasma gondii 
T. gondii has a complex life cycle that takes place in two different hosts. It has both sexual 
and asexual stages in its life cycle where sexual reproduction takes place in definitive 
feline hosts such as the cat and asexual reproduction takes place in a wide variety of 
intermediate mammalian and avian hosts including humans. Sexual reproduction takes 
place in the intestine of cats after ingestion of bradyzoite-containing tissue cysts that are 
present in the tissues of chronically infected intermediate hosts. After destruction of the 
cyst wall by gastric enzymes,  bradyzoites undergo self-limiting asexual multiplication 
within enterocytes to produce merozoites that lead to the formation of male and female 
gametes (Dubey, 1998; Ferguson, 2002). After fertilization, oocysts are formed within 
enterocytes followed by the release of unsporulated oocysts into the environment through 
cat feces. Shedding of oocysts starts within 3-15 days after the ingestion of tissue cysts and 
may continue up to 20 days (Dubey and Frenkel, 1972). Within the environment, the 
unsporulated oocysts undergo meiosis and division to yield eight haploid sporozoites 
contained within the infective oocysts. Oocysts are capable of surviving in the environment 
for more than a year and can contaminate food and water which are taken up by the 
intermediate host (Figure 1.1) where asexual reproduction occurs. After the release of 
sporozoites in the intestine of intermediate hosts and infection of enterocytes, acute 
infection with T. gondii is characterized by proliferation of fast-replicating tachyzoites 
which can disseminate throughout the body via the blood and lymphatic systems (Dubey, 
1997). Robust innate and adaptive immunity in the intermediate host is able to largely 
eliminate the proliferating tachyzoites during acute infection but a portion of them 
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transform into slowly replicating bradyzoites preferentially in neural and muscular tissue 
(Dubey et al., 1998). Developmental switching from tachyzoites into bradyzoites in brain 
and skeletal muscle is responsible for the long term chronic infection and transmission of 
the parasite to new hosts. Ingestion of tissue cysts via omnivorous or carnivorous feeding 
can lead to transmission of the parasite to either other intermediate hosts or to a cat for 
reinitiating the sexual phase of the cycle. Humans become infected by eating bradyzoite-
containing undercooked meat (Cook et al., 2000), by ingesting sporulated oocyst 
contaminating food and water (de Moura et al., 2006; Jones and Dubey, 2012) and/or by 
vertical transmission from infected pregnant women to their fetus (Dunn et al., 1999). This 
clearly shows that stage conversion from tachyzoites to bradyzoites is a key factor for 
parasite pathogenesis and provides a major route of transmission between intermediate 
hosts including humans due to long term persistence in skeletal muscle or brain cells. 
 
Figure 1.1: Life cycle of Toxoplasma gondii (Modified from Hunter & David Sibley 2012). 
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1.3 Epidemiology and importance of meat from livestock in 
transmission of T. gondii to humans 
As T. gondii can infect any warm-blooded animal including livestock and humans, it is 
both of medical and veterinary importance. Congenital toxoplasmosis for example can lead 
to abortions in humans and animals, particularly in sheep (Tenter et al., 2000). Recently, it 
has been reported that approximately 30-50 % of the human population is infected by T. 
gondii world-wide (Flegr et al., 2014). The infection rate varies from 10 to 80% depending 
on environmental and socioeconomic factors including food habits, health-related practices 
and geographic areas (Pappas et al., 2009). Relatively low prevalences (10-30%) of T. 
gondii infections have been found in North America, South East Asia, Northern Europe 
and Sahelian countries of Africa whereas moderate prevalences (30-50%) have been 
observed in countries of central and southern Europe, and in parts of Asia and Middle East. 
High prevalences (50-80%) have been found in some countries of Europe, Latin America 
and in tropical countries of Africa (Pappas et al., 2009). Recently, a nationwide cross-
sectional study was conducted in Germany, which showed that 55% of adult individuals 
are seropositive for T. gondii thus indicating a high prevalence in Germany. The rate of 
seroprevalence was found to increase with age from 20% in younger adults (age group 18-
29 years) to 77% in older ones (age group 70-79 years).  Furthermore, males showed a 
higher prevalence than females possibly because  males are considered to consume more 
meat (Wilking et al., 2016).  
As discussed above, bradyzoite-containing tissue cysts in skeletal muscle of warm-blooded 
animals including livestock (pigs, sheep, goats, poultry, cattle) provide a major source of T. 
gondii infection in humans (Schlüter et al., 2014). It has been shown before that eating raw 
and undercooked meat is one of the major routes of T. gondii transmission to humans 
(Tenter et al., 2000; Ferguson, 2004). According to a European multicenter case control 
study, 30-63% of acute Toxoplasma infections of pregnant women were due to 
consumption of undercooked or cured meat products (Cook et al., 2000). Another study 
conducted in the USA identified eating raw and cured meat as significant risk factor for T. 
gondii infection (Jones et al., 2009; Jones and Dubey, 2012).This clearly points out the 
importance of meat and particularly skeletal muscles from chronically infected livestock 
for the transmission of T. gondii to humans. It has to be stressed that pig, cattle and poultry 
are the three major meat-producing animals consumed in Germany (Voth, 2015) and in the 
USA (Daniel et al., 2011) that can harbor T. gondii. According to the German nutrition 
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society (DGE) from 2012, the average consumption of meat and meat products has been 
estimated to range from ~0.6 kg/person/week (women) to 1.1 kg/person/week (men). The 
amount of consumption of selected meat per capita in 2012 has been estimated ~52 kg for 
pork, ~18 kg for poultry and ~12 kg for beef (Voth, 2015). In Europe and USA, infected 
pork meat has been considered a major source of T. gondii infection in humans (Tenter, 
2009; Dubey et al., 2012). The reason is that pork is more likely to be infected with T. 
gondii than cattle and poultry due to a higher susceptibility of infection (Hill and Dubey, 
2013). In Germany, the seroprevalence of T. gondii in pigs ranges from 2.8% (finishing 
pigs) to 31.6% (sows pigs) (De Buhr et al., 2008). Consumption of infected poultry meat is 
also likely to play an important role in transmission of T. gondii to humans (Dubey et al., 
2005). A seroprevalence study conducted with chicken showed that 60% of chicken carried 
antibodies against T. gondii (Aigner et al., 2010). Like the seroprevalence of pigs, it 
depends on the species and housing conditions where nearly 100% of backyard chickens 
are infected with T. gondii (Dubey, 2010a). For this reason, chickens are also considered an 
important source for transmission of T. gondii to humans. Prevalences of T. gondii in other 
meat-producing animals such as sheep, goats and horses vary with age. In Europe, the 
seroprevalence of T. gondii in farm sheep is increasing with age and ranges from 18% 
(lambs) to 89% (adults) (Halos et al., 2010). Rates of seropositivity reported for goats vary 
from 4-77% (Dubey et al., 2011) while they are generally lower in horses (Dubey, 2010b). 
These above data emphasize the importance of transmission of T. gondii through meat 
from chronically infected livestock to humans and request for an urgent attention to study 
mechanism of T. gondii persistence in skeletal muscle in order to limit spreading of the 
disease. 
 
1.4 Developmental biology of skeletal muscle cells (SkMCs) 
Skeletal muscle, a complex and heterogeneous tissue of animals, is mostly composed of 
highly specialized and large syncytial myotubes or muscle fibers. Myotubes are poly-
nucleated and terminally differentiated SkMCs which develop from pluripotent progenitor 
cells during embryonic myogenesis or from uncommitted satellite stem cells during adult 
myogenesis (Bentzinger et al., 2012). During embryonic myogenesis, pluripotent 
progenitor cells skip the uncommitted satellite cell stage and directly become committed 
satellite cells or proliferating myoblasts which further differentiate into myotubes 
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(Bentzinger et al., 2012). Furthermore, some progenitor cells develop as a heterogeneous 
population of uncommitted and committed stem cells where the committed stem cells can 
eventually return into the uncommitted cell pool to compensate for the loss of terminally 
differentiated myotubes in adult skeletal muscles. However, adult myogenesis proceeds 
from uncommitted satellite stem cells to committed proliferating myoblasts which 
differentiate into non-proliferating mature myotubes (Bentzinger et al., 2012). This in vivo 
muscle developmental process can be replicated in vitro using C2C12 murine myoblasts 
(Burattini et al., 2004; Curci et al., 2008; Abmayr and Pavlath, 2012). Subsequently, 
murine SkMCs has been used for studying the host-parasite interaction of T. gondii 
(Takács et al., 2012; Swierzy and Lüder, 2014). Actively proliferating C2C12 myoblasts 
can be propagated in vitro in medium containing growth factors. C2C12 myoblasts start 
differentiating into myocytes in medium with reduced serum concentration referred to as 
differentiation medium. During differentiation, individual myocytes migrate, adhere and 
fuse with one another to form nascent myotubes with few nuclei. Afterwards, nascent 
myotubes fuse with other myocytes to form multinucleated, myosin heavy chain positive, 
mature myotubes (Abmayr and Pavlath, 2012; Bentzinger et al., 2012; Swierzy and Lüder, 
2014). Differentiation of C2C12 myoblasts into myotubes has been studied before by using 
differentiation medium comprising 2% horse serum (Rajan et al., 2012). Both in vivo and 
in vitro differentiation of myoblasts into myotubes is regulated through several 
interconnected processes including (i) expression of four muscle-specific basic helix-loop-
helix transcription factors, i.e MyoD, Myf5, myogenin, and myogenic regulatory factor 
(MRF4) (Huang and Thayer, 2002; Swierzy and Lüder, 2014), (ii) a permanent cell cycle 
withdrawal by upregulating the cell cycle inhibitors p21
Waf1/Cip1 
and p27, inhibition of 
cyclin-dependent kinases CDK1, CDK2, CDK4 and phosphorylation of retinoblastoma 
(RB) protein (Shen et al., 2003; Casadei et al., 2009), (iii)  expression of muscle specific 
contractile proteins and (iv) fusion of mono-nucleated myoblasts together with myocytes 
(Huang and Thayer, 2002). In vitro differentiation of myoblasts into myotubes is shown in 
Figure 1.2. 
 
Chapter 1: Introduction 2017 
 
Page | 8  
 
 
Figure 1.2: Differentiation of myoblasts into myotubes (Modified from Abmayr & Pavlath 2012). 
 
1.5 Glucose metabolism in proliferating and differentiating cells and its 
impact on ROS 
As a general rule, cell proliferation and differentiation is accompanied by a high demand 
on carbon sources, preferentially glucose, for the synthesis of membranes, organelles, 
biomass and energy (Fajas, 2013). After entering into cells, glucose can be metabolized in 
three major pathways; (i) it can undergo complete oxidation via glycolysis, tricarboxylic 
acid (TCA) cycle and oxidative phosphorylation, (ii) it can be metabolized through the 
pentose phosphate pathway (PPP) to produce ribose sugars for synthesis of nucleotides or 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) for anabolic reactions and 
to defeat oxidative stress, (iii) and it can shift into glycogen synthesis for storage (Gottlieb, 
2011). In proliferative cells, glucose metabolism is directed towards either glycolysis to 
rapidly generate energy equivalents and/or can be oxidized in the PPP to produce NADPH 
for synthesis of macromolecules including lipids, proteins and nucleotides (Aguilar and 
Fajas, 2010; Fajas, 2013). In contrast, carbohydrates in most differentiated cells are 
primarily completely oxidizes to produce carbon dioxide through  glycolysis in the 
cytoplasm followed by TCA cycle in mitochondria (Heiden et al., 2009; Aguilar and Fajas, 
2010). This metabolic shift is a key event for initiating cellular differentiation. This has 
been demonstrated by increased mitochondrial function and enzyme activity during 
differentiation of myoblasts to myotubes (Barbieri and Sestili, 2012; Wagatsuma and 
Sakuma, 2013). The evidences suggest that the metabolic shift from glycolysis to oxidative 
phosphorylation is the major energy source required for myogenesis. Aguilar and 
colleagues have described that cell proliferation requires an adaptive change of metabolism 
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and thereby have established a link between cell cycle regulation and metabolic control 
(Aguilar and Fajas, 2010).  Cell cycle progression of proliferating cells from G1 into S-
phase depends on the activation of G1 phase-specific cyclins/cyclin-dependent kinases 
(CDKs) and retinoblastoma (RB) protein pRB-E2F (Aguilar and Fajas, 2010). As 
myoblasts and myotubes differ largely in their cell cycle regulation (Shen et al., 2003), 
they might also have different metabolic activities to support cellular proliferation and 
differentiation. 
Differences of metabolic activities in a cell may generate differences in the redox 
homeostasis. Reactive oxygen species (ROS) are considered metabolic byproducts of 
normal cellular metabolism and are mainly composed of superoxide anions (O2
-
), hydroxyl 
radicals (•OH) and H2O2. Initially, ROS was identified as a deleterious species in SkMCs 
(Barbieri and Sestili, 2012). However, accumulating evidence suggest that ROS at 
physiological concentration may play beneficial roles in cells through multiple cellular 
functions using a wide variety of signaling cascades. For example, low levels of cellular 
ROS may act on cell survival, proliferation and differentiation, immune responses and 
other factors. On the contrary, high levels of ROS may create oxidative stress for the cell 
thereby contributing to deleterious effects as for instance  muscle atrophy, apoptosis, 
inhibition of differentiation,  and mitochondrial dysfunction (Barbieri and Sestili, 2012). In 
addition, ROS has recently been identified as a key modulator for microbial persistence 
and chronic infection (Spooner and Yilmaz, 2011). However, the beneficial or detrimental 
functions of ROS depend on multiple intrinsic and extrinsic factors as for instance 
concentration and duration of ROS signals in target cells, the site of ROS production, or 
the antioxidant status of the cell. In SkMCs, ROS can be produced from a variety of 
sources. Among these, mitochondria are considered the major source of ROS production as 
oxidative metabolism occurs to a large extent in mitochondria (Davies et al., 1982). 
Complex-I and complex-III of the electron transport chain are indeed important sites for 
mitochondrial ROS production (Barja, 1999; Muller et al., 2004). Another important 
source of ROS production is the enzyme NADPH oxidase (NOX) which is located in the 
sarcoplasmic reticulum and in transverse tubules of SkMCs (Piao et al., 2005; Acharya et 
al., 2013). Membrane-bound phospholipaseA2 (PLA2) may also play a passive role in 
intracellular ROS production by releasing membrane phospholipids, i.e. arachidonic acid 
which is a substrate for the ROS generating enzyme lipooxygenase-2 (Zuo et al., 2004). In 
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addition, xanthine oxidase which is an important enzyme for purine metabolism also 
contributes to ROS production in SkMCs (Steinbacher and Eckl, 2015). 
 
 
1.6 Host factors regulating T. gondii stage conversion 
T. gondii establishes chronic infections in animals and humans through stage conversion 
from its fast-replicating tachyzoite stage to its slow-replicating bradyzoite stage. This stage 
conversion of the parasite is a complex process where tachyzoite-specific genes are 
switched off and bradyzoite-specific genes are upregulated (Lyons et al., 2002). 
Upregulation of bradyzoite-specific gene expression leads to the development of 
bradyzoites and conversion of parasitophorous vacuoles into tissue cysts that may contain 
several hundreds of bradyzoites. Importantly, the tissue cyst distribution during chronic 
infection shows a predilection for distinct tissues with a preferential localization in skeletal 
muscles  and brain (Dubey et al., 1998). The factors that induce stage conversion in 
SkMCs and brain are not completely known. Nevertheless, research of the last decade has 
brought significant contributions to understand the biology of bradyzoite development in 
SkMCs. 
 
1.6.1 Host immune responses can trigger T. gondii stage conversion 
The host immune response is important for controlling any type of microbial infection. 
During acute T. gondii infection, the interferon (IFN)-γ-dependent cell-mediated host 
immune response eliminates the majority of T. gondii tachyzoites and controls 
pathogenesis (Suzuki et al., 1988). However, IFN-γ can also induce tachyzoite-to-
bradyzoite differentiation in vitro in certain cell types. This has been demonstrated by 
treatment of murine macrophages with IFN-γ and/or lipopolysaccharides (LPS) that 
inhibits parasite replication and induces bradyzoite differentiation (Bohne et al., 1993, 
1994). It has to be stressed that intermediate levels of macrophage activation are important 
because reduced parasite replication is required for induction of bradyzoite differentiation 
(Bohne et al., 1994). This can be explained by the fact that too strongly activated 
macrophages may completely halt parasite cell cycle progression prior to reaching a cell 
cycle checkpoint that is required for T. gondii to enter into the bradyzoite-inducing 
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developmental program or may even kill the parasite. In contrast, non-activated 
macrophages support tachyzoite replication by directing cell cycle progression through S-
phase to mitosis (Radke et al., 2001). A key determinant of IFN-γ-mediated bradyzoite 
differentiation in murine macrophages is the production of nitric oxide (NO) by stimulation 
of the inducible nitric oxide synthase (iNOS) (Bohne et al., 1994; Ibrahim et al., 2009). 
This view is supported by using sodium nitroprusside (SNP), a donor of NO which induces 
bradyzoite differentiation not only in murine macrophage (Bohne et al., 1994) but also in 
other cell types, i.e in rat brain cells (Lüder et al., 1999) and human foreskin fibroblast 
(HFF) (Kirkman et al., 2001) in vitro. NO is possibly exerting its effect by acting on 
mitochondrial functions of the host cell and/or the parasite by reacting with iron-sulfur 
centers of enzymes. It provides a link between mitochondrial metabolism and T. gondii 
bradyzoite differentiation.  
In SkMCs, a number of cytokines and chemokines including chemokine ligand (CCL)-2, 
monocyte chemoattractant protein (MCP)-1, interleukin (IL)-1α, IL-1β and IL-23 are 
upregulated in mature myotubes as compared to myoblasts after T. gondii infection 
(Swierzy et al., 2014). Whether these cytokines and chemokines induce T. gondii stage 
conversion in myotubes has not been determined. However, pro-inflammatory IL-6 has 
been shown to induce bradyzoite differentiation and tissue cysts formation in human 
fibroblasts (Weiss et al., 1995). This raises the possibility that one or more of the above 
proinflammatory molecules may initiate bradyzoite development in myotubes which needs 
experimental validation. 
 
1.6.2 Exogenous stress factors can induce T. gondii stage conversion 
Several in vitro studies have shown that T. gondii stage conversion can also occur in the 
absence of inflammatory factors (McHugh et al., 1993; Bohne et al., 1994). Ferreira de 
Silva and colleagues have summarized numerous in vitro studies where stress factors were 
identified as inducers of bradyzoite development (Ferreira da Silva et al., 2008). For 
example alkaline pH (pH 8.0-8.2) induces bradyzoite differentiation if infected cells are 
continuously exposed to this conditions (Soête et al., 1994; Weiss et al., 1995; Fux et al., 
2007). However, bradyzoite differentiation via alkaline pH does not provide sufficient 
evidence about the in vivo condition since such a high pH does not represent a 
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physiological condition. Applying heat shock (temperature >43
0
C) is another factor that 
induces bradyzoite development in T. gondii-infected cells (Soête et al., 1994). Here, the 
author exposed host cells to a heat shock at 43°C before and after T. gondii infection 
(Soête et al., 1994). Besides, many chemicals and drugs have been shown to restrict 
parasite replication but also to induce bradyzoite-specific gene expression. For example, a 
combination of pyrimethamine and sulfadiazine has been shown to be most effective in the 
reduction of parasite replication and induction of bradyzoite antigen (BAG) 1 expression 
(Bohne et al., 1994; Gross and Pohl, 1996). Similarly, hydronapthoquinone and 
atovaquone show significant reduction of parasite replication and strong effect on BAG1 
expression (Araujo et al., 1992; Ferguson et al., 1994). Other chemicals as for example 
sodium arsenite has been studied in vitro and shown to induce bradyzoite-specific genes 
but not to lead to development of tissue cysts (Soête et al., 1994). Several mitochondrial 
inhibitors (oligomycin, antimycin-A, rotenone, myxothiazole) have been studied 
previously and found to induce bradyzoite-specific antigens without development of tissue 
cysts (Bohne et al., 1994; Tomavo and Boothroyd, 1995). 
T. gondii stage differentiation via these stress factors raises the question whether they act 
directly on the parasite or indirectly through the host cell or both. Nevertheless, the data 
provide useful information for T. gondii stage differentiation in infected cells in vitro and 
offer a link between stage conversion and host stress factors. But whether these factors 
induce bradyzoite development in vivo remains unclear. 
 
1.6.3 Cell type-specific T. gondii stage conversion 
T. gondii can infect any nucleated cell of mammalian and avian intermediate hosts 
including humans and stage conversion can occur in multiple tissues or cell types including 
brain, skeletal and heart muscle, eye, liver, kidney and others. However, it has to be 
stressed that T. gondii stage conversion preferentially occurs in skeletal muscle and brain, 
thereby leading to chronic infection. One explanation could be reduced inflammatory 
responses within both tissues which may allow T. gondii cyst development and survival. 
Another reason might be that they are post-mitotic, terminally differentiated cells which 
are permanently withdrawn from cell cycle progression and may thus present 
characteristics that are particularly suitable for parasite differentiation (Swierzy and Lüder, 
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2014; Lüder and Rahman, 2017). Primary SkMCs has been used as a model for studying 
development of T. gondii in vitro (Guimarães et al., 2008). At the same time it has been 
shown that SkMCs support bradyzoite differentiation and tissue cyst formation. 
Remarkably, T. gondii stage conversion from its tachyzoite stage to the bradyzoite stage 
spontaneously occurs in primary SkMCs more readily than in fibroblasts and this does not 
require any exogenous stress factor (Guimarães et al., 2008; Ferreira-da-Silva et al., 2009). 
Recently, Swierzy and colleagues have shown that mouse SkMCs after differentiation into 
myosin heavy chain (MyHC)-positive poly-nucleated myotubes accelerate bradyzoite 
differentiation and tissue cysts formation whereas proliferating and MyHC-negative 
myoblasts support parasite growth and tachyzoite replication. This clearly shows that not 
only the cell type but the state of host cell is important for T. gondii stage conversion 
(Swierzy and Lüder, 2014). 
 
1.6.4 Host cell cycle withdrawal is associated with T. gondii bradyzoite 
differentiation 
One of the major differences between myoblasts and myotubes is the permanent cell cycle 
arrest of myotubes at G1/G0 phase (Shen et al., 2003), which has been confirmed by lack 
of incorporation of Bromodeoxyuridine (BrdU) in DNA in myotubes (Swierzy and Lüder, 
2014). Here the authors have thus confirmed that myotubes do not enter into the S phase of 
the cell cycle and hence do not replicate their DNA (Swierzy and Lüder, 2014). Since 
myotubes but not myoblasts trigger stage differentiation in T. gondii, it is therefore of great 
importance to study the impact of the host cell cycle on T. gondii bradyzoite differentiation 
in myotubes and myoblasts. Radke and colleagues have shown for the first time that 
overexpression of a host cell cycle regulator, namely human cell division autoantigen 
(CDA)-1 by using a trisubstituted pyrrole (designated compound-1) inhibits parasite 
growth and induces bradyzoite-specific proteins in T. gondii and formation of the cyst wall 
(Radke et al., 2006). Consequently, knock-down of host CDA-1 prevented compound-1-
mediated inhibition of parasite growth and bradyzoite differentiation (Radke et al., 2006). 
CDA-1 in mice is known as testis specific Y-encoded like protein 2 (Tspyl2). It is a 
negative cell cycle regulator which inhibits cell growth and proliferation by inducing 
expression of p21
Waf1/Cip1
 via activation of p53 and extracellular signal regulated kinase 
(ERK)1/2 (Tu et al., 2007; Tao et al., 2011). Recently, the role of host CDA-1/Tspyl2 in 
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regulating stage differentiation in T. gondii has been confirmed under more physiological 
conditions using mouse SkMCs for T. gondii bradyzoite differentiation (Swierzy and 
Lüder, 2014). Here, the authors showed that differentiation of C2C12 murine myoblasts 
into poly-nucleated myotubes induces CDA-1/Tspyl2 mRNA expression, and this was 
accompanied by cell cycle arrest in myotubes. Remarkably, siRNA-mediated knockdown 
of CDA-1/Tspyl2 in C2C12 myoblasts accelerated host cell cycle progression even after 
induction of differentiation with low serum medium (2% horse serum) and this was 
accompanied with sustained parasite growth and abolished T. gondii stage conversion. The 
state of differentiation and withdrawal from cell cycle progression in SkMCs thus impact 
T. gondii stage conversion (Swierzy and Lüder, 2014). It is important to note that 
knockdown of CDA-1/Tspyl2 in C2C12 myoblasts also inhibits myotubes formation 
suggesting multiple effects on host cells including cell cycle acceleration along with 
inhibition of myotube formation and others (Swierzy and Lüder, 2014). However, these 
studies provide a link between the host cell cycle and T. gondii stage conversion. The 
mechanism of how CDA-1/Tspyl2 impacts T. gondii stage conversion is currently 
unknown. Importantly, CDA-1/Tspyl2 upregulates the negative cell cycle regulator 
p21
Waf1/Cip1
 mRNA in myotubes (Swierzy and Lüder, 2014). However, whether increased 
levels of p21
Waf1/Cip1
 have any role in T. gondii bradyzoite differentiation in myotubes is 
still unknown. 
 
1.6.5 Host cell metabolism and T. gondii stage conversion 
T. gondii is an obligatory intracellular protozoan parasite. It must thus satisfy nutritional 
needs for replication and survival from its host cell. Through genome and transcriptome 
sequencing it has been revealed that T. gondii is auxotrophic for some metabolites (Blader 
et al. 2001; Gail et al. 2001; Crawford et al. 2006). Thus, they are unable to synthesize 
some essential metabolites and have to scavenge them from the host cell as for example 
arginine (Fox et al., 2004), tryptophan (Pfefferkorn, 1984), phospholipids (Charron and 
Sibley, 2002), cholesterol (Coppens and Joiner, 2003; Sehgal et al., 2005), polyamines 
(Cook et al., 2007), purines (Krug et al., 1989; Chaudhary et al., 2004), cysteine and other 
essential amino acids except lysine (Chaudhary and Roos, 2005). They have to take up also 
basic nutrients such as glucose and glutamine (Blader and Koshy, 2014) and metal ions as 
for example iron (Gail et al., 2004). Limited availability of these essential molecules from 
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host cells may thus inhibit parasite growth and favor T. gondii bradyzoite differentiation. 
For instance, starvation for arginine (Fox et al., 2004) or  pyrimidine in limited (0.03%)  
CO2 concentration (Dzierszinski et al., 2004) induces T. gondii bradyzoite differentiation. 
Similarly, it has been confirmed that starvation for low-density lipoprotein (LDL)-derived 
cholesterol also induces bradyzoite differentiation in chinese hamster ovary (CHO) cells 
(Ihara and Nishikawa, 2014). In addition to starvation for essential nutrients, there are 
some other metabolites that can induce stage conversion. For example, expression of ecto-
5′-nucleotidase (CD73) which is needed for synthesis of adenosine, i.e. a major component 
of purines for which T. gondii is auxotrophic (Chaudhary et al., 2004) promotes T. gondii 
bradyzoite differentiation and tissue cysts formation in the brain (Mahamed et al., 2012). 
This has been confirmed through in vivo studies where mice lacking CD73 were protected 
from T. gondii chronic infection suggesting their inability to bradyzoite differentiation 
(Mahamed et al., 2012).  
As T. gondii uses glucose from host cells as a major carbon source for its energy 
metabolism and for biosynthesis of macromolecules (Blader and Koshy, 2014), glucose 
metabolism in different host cells may also play a role in T. gondii stage differentiation. An 
impact of the host glucose metabolism in T. gondii stage differentiation is indeed 
beginning to emerge. Recently, Weilhammer and co-workers have shown that the 
metabolic state of the host cell may play role in growth and differentiation of T. gondii 
(Weilhammer et al., 2012).  Here, the authors identified the glycolytic end product lactate 
as an inhibitory metabolite for T. gondii stage conversion in distinct host cells. Indeed, 
increased lactate secretion in supernatant was judged as indicator of higher glycolytic 
activities of NIH/3T3 fibroblasts and 293T embryonic kidney cells that are resistant to 
stage conversion under stress conditions. More importantly, supernatant from these cells 
transmitted the inhibitory activities for bradyzoite differentiation  in Vero kidney cells but 
not in HFF which are normally permissive for T. gondii stage differentiation (Weilhammer 
et al., 2012). Furthermore, upregulation of glycolysis in HFF and Vero cells by either 
increasing glucose concentration or by overexpression of the host kinase Akt also inhibited 
stage conversion (Weilhammer et al., 2012). This data provide a link between higher levels 
of glycolysis in host cells and inhibition of T. gondii stage conversion which ultimately 
leads to continuous growth of the parasite. Since myotubes are terminally differentiated 
cells whereas myoblasts are actively proliferating cells, glucose metabolism may differ 
between these cell types. The complete picture of glucose metabolism in non-infected and 
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T. gondii-infected myotubes and myoblasts is thus a promising approach to understand the 
impact of host metabolic pathways on T. gondii stage conversion in myotubes. 
 
1.7 Importance of the study 
T. gondii appears to have a predilection for developmental switching from proliferative 
tachyzoites to dormant bradyzoites particularly in skeletal muscle and brain. The stage 
conversion in these tissues leads to the development of chronic infection in warm-blooded 
animals including livestock (Dubey et al., 1998; Ferreira-da-Silva et al., 2009). 
Furthermore, persistence of T. gondii in skeletal muscle of livestock animals (pigs, cattle, 
poultry, sheep and goat) provides a major route of parasite transmission to humans by 
eating raw or undercooked meat and meat products (Cook et al., 2000; Jones et al., 2009). 
This demonstrates the importance of T. gondii stage conversion and parasite persistence in 
skeletal muscle cell (SkMCs). It is thus important to identify the factors that induce T. 
gondii stage conversion in SkMCs. These factors are only partially known. In vitro, T. 
gondii can be induced to transform from tachyzoites to bradyzoites by exposure to external 
stress including alkaline pH, heat stress or chemicals (Ferreira da Silva et al., 2008). 
Recently, Swierzy et al. have demonstrated that in differentiated SkMCs, i.e myotubes, T. 
gondii spontaneously differentiates from tachyzoites to bradyzoites in the absence of 
exogenous stress factors. In contrast, this did not occur in proliferating myoblasts or 
fibroblasts (Swierzy and Lüder, 2014). In addition, inactivation of the negative cell cycle 
regulator Tspyl2 by RNA interference largely abolished stage differentiation in SkMCs. 
These results indicate that terminal differentiation and/or cell cycle arrest of SkMCs is 
critical in regulating stage conversion. However, the exact factor(s) that induces T. gondii 





Chapter 1: Introduction 2017 
 
Page | 17  
 
1.8 Hypothesis and aims of study 
It was hypothesized that T. gondii may encounter a distinct cellular microenvironment in 
myotubes that induces stage conversion in terminally differentiated SkMCs. 
Therefore, the major aim of this study was to identify the factors which favor spontaneous 
stage conversion of T. gondii in SkMCs. The following issues were of particular interest to 
be addressed in this study: 
i. To unravel transcriptome differences of non-infected and T. gondii-infected 
myotubes and myoblasts. 
ii. To identify differences in glucose metabolism via glycolysis, TCA cycle and 
pentose phosphate pathway in non-infected and T. gondii-infected myotubes and 
myoblasts. 
iii. To determine the impact of metabolic pathways, i.e glycolysis, TCA cycle and 
pentose phosphate pathway on T. gondii stage conversion in myotubes and 
myoblasts using pharmacological inhibitors or modulators. 
iv. To unravel differences in NADPH production and ROS levels in non-infected and 
T. gondii-infected myotubes and myoblasts and to determine the effect ROS on T. 
gondii stage conversion. 
v. To determine the impact of pharmacological cell cycle inhibitors on T. gondii stage 
conversion in SkMCs. 
vi. To knock-down the negative cell cycle inhibitor p21Waf1/Cip1 and to determine its 
impact on T. gondii stage conversion in SkMCs. 
 
Together, it was expected that the results of this study will further enhance our 
understanding of host cell factors which might provide the appropriate signal(s) that 
induces parasite stage differentiation and enables long term persistence of T. gondii in 
SkMCs
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2.1.1 Cell lines and organisms  
 L929 murine fibroblasts from mouse C3H (Institute for Medical Microbiology, 
Göttingen). 
 Murine C2C12 myoblasts from mouse C3H (European Collection of Authenticated 
Cell Cultures (ECACC), UK). 
 Murine C2C12 mutant myoblasts (p21 knock-down) after transfection with p21-
shRNA–pLKO.1 plasmids. 
 Murine C2C12 mutant myoblasts (negative control) after transfection with 
pLKO.1-puro plasmid. 
 Competent Escherichia coli NEB-5α (New England Bio-Lab, Frankfurt/Main). 
 Mission p21-shRNA bacterial glycerol stocks (Sigma-Aldrich, Munich). 
 Toxoplasma gondii mouse-avirulent NTE strain (type II). 
 





L929-growth medium Dulbecco's modified Eagle's 
medium (DMEM) 
1.0% FCS (Fetal calf serum) 
Penicillin-streptomycin 
(100 U/ml-100 μg/ml) 
1x Non-essential amino acid 









C2C12 growth medium  DMEM 
10% FCS 
Penicillin-streptomycin 









2.0% Horse serum 
Penicillin-streptomycin 
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Toxoplasma medium RPMI1640 
(Roswell Park Memorial Institute) 
1.0% FCS 
Penicillin-streptomycin 







Luria-Bertani (LB) broth/ 
LB-Agar (for E. coli) 
1.0% Bacto-tryptone 
 
0.5% Bacto-yeast extract 
 
1.0% NaCl 
1.5% Agar (LB-Agar only) 





Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
Sigma-Aldrich, Munich  
 




2.4% Bacto-yeast extract 
 
0.4% Glycerol 
1.0% Phosphate buffer 











2.1.3 Cell culture dishes and plastic ware 
Name Company 
Multi-well cell culture plates (6,12 and 24 
well) 
Greiner, Frickenhausen 
96-well polystyrene cell culture plates Greiner, Frickenhausen 
96-well polystyrene flat bottom plates Greiner, Frickenhausen 





 Greiner, Frickenhausen 
Glass cover slips (diameter 13 mm, round) Thermo Scientific, Braunschweig 
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Cryogenic vials (Nunc, 2mL) Thermo Scientific, Braunschweig 
Eppendorf tubes (1.5 ml and 2 ml) Sarstedt, Nümbrecht 
Centrifuge tubes (15 ml and 50 ml) Sarstedt, Nümbrecht 
Cell scrapers (24 cm)  Biochrom, Berlin  
Nitrocellulose membrane GE Healthcare, Buckinghamshire, UK 
Whatman filter papers GE Healthcare, Buckinghamshire, UK 
Parafilm BEMIS, Wisconsin, USA 
Glass slides (76x26 mm)  Thermo Scientific, Braunschweig 
Hemocytometer grid (cell counting chamber) Sigma-Aldrich, Munich 
Viva-spin filter (10 kDa cutoff) Sartorius, Göttingen 
Kimtech science kimwipes Kimberly Cark professional, Surrey, UK 
Star guard gloves STARLAB GmbH, Hamburg 
Pipette filter tips Sarstedt, Nümbrecht 
 
 
























Luperox (Tert-butyl hydroperoxide solution, 70 wt. % in H2O) 
Hydrogen peroxide solution (30% w/v in H2O) 
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2.1.5 Lysis buffer for protein isolation 
Item and Composition Company 
2x Stock solution: 
2% Triton-X 100 
300 mM NaCl 
100 mM Tris-HCl (pH 8.0)  
 
Sigma-Aldrich, Munich 
Merck, Darmstadt  
Merck, Darmstadt  
 
Other components:  
50 mM Sodium fluoride Merck, Darmstadt  
25 mM Sodium pyrophosphate Sigma-Aldrich, Munich 
1 mM Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Munich 
10 μM Leupeptin Sigma-Aldrich, Munich 
5 μg/ml Aprotinin Sigma-Aldrich, Munich 
5 μg/ml Pepstatin Sigma-Aldrich, Munich 
1 mM Sodium orthovanadate Sigma-Aldrich, Munich 
1 mM Ethylene diamine tetra-acetic acid (EDTA) Sigma-Aldrich, Munich 
Sterile dd H2O  
 
 











Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
 
Merck, Darmstadt  
Carl Roth, Karlsruhe  
 
 






0.01% Bromophenol blue 
ddH2O 
Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
 
Merck, Darmstadt  
Carl Roth, Karlsruhe  
Ameresco, Solon, USA 
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1x Running buffer 
(pH 8.5) 
25 mM Tris-HCl 
192 mM Glycine 
0.1% SDS 
Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
 
5x SDS sample buffer 0.3125 M Tris-HCl, pH 6.8 
10 % SDS 
162.5 mM Dithiothreitol 
50 % (v/v) Glycerol 
0.05% (w/v) Bromophenol blue 
ddH2O 
Carl Roth, Karlsruhe 
Carl Roth, Karlsruhe  
Sigma-Aldrich, Munich 
Merck, Darmstadt 
Ameresco, Solon, USA 
 
 
2.1.7 Western blot buffer and solutions 
Item Composition Company 
 
Tris-HCl buffer (0.3M) 
 
20 ml 1.5 M Tris-HCl (pH 10.4) 
20 ml 99% Methanol  
60 ml ddH20  
 
Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
Tris-HCl buffer (25mM) 
 
20 ml 125 mM Tris-HCl (pH 10.4) 
20 ml 99% Methanol  
60 ml ddH20  
 
Carl Roth, Karlsruhe  
Carl Roth, Karlsruhe  
Aminocaproic acid 
buffer (40mM) 
20 ml 200 mM Aminocaproic acid  
(pH 7.4) 
20 ml 99% Methanol  
60 ml ddH20  
Sigma-Aldrich, Munich 
 
Carl Roth, Karlsruhe  
Wash solution 1x TBS (Tris-buffered saline) 
0.05% Tween 20 
pH 7.4 






5% Dry skimmed milk powder 
1x TBS 
0.05% Tween 20 
pH 7.4 
Carl Roth, Karlsruhe  








0.05% Tween 20  
pH 7.4 
Carl Roth, Karlsruhe  
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2.1.8 Immunofluorescence staining buffer and solutions 
Item Composition Company 
 
Washing buffer 1x PBS, pH 7.4 
0.1 mg/ml Saponin 






1x PBS (pH 7.4) 
0.02% NaN3 
0.1 mg/ml Saponin 
Carl Roth, Karlsruhe  




Propidium iodide solution 5 µg/ml propidiumiodide 













Blocking solution for BrdU assay 5% BSA 
0.3% Triton-X100 
1x PBS (pH 7.4) 








1x PBS (pH 7.4) 




Wash solution for BrdU assay 1% BSA 
1x PBS (pH 7.4) 
Carl Roth, Karlsruhe  
Biochrom, Berlin  
 
 
2.1.9 Agarose gel buffer 
Item Composition Company 
1x TAE buffer 
 
40 mM Tris-HCl 
20 mM Acetic acid 
1.0 mM EDTA  
ddH2O 
pH 8.0 
Carl Roth, Karlsruhe 






Chapter 2: Materials & Methods 2017 
 
Page | 25  
 
2.1.10     Other chemicals 
Name Company 




) Biochrom, Berlin 




) Biochrom, Berlin 
Trypanblue Ferac, Berlin 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Munich 
Mowiol® 4-88 Merck, Darmstadt 
Immersion oil Sigma-Aldrich, Munich 
Sodium azide (NaN3) Sigma-Aldrich, Munich 




) Biochrom, Berlin 
Ethanol Carl Roth, Karlsruhe  
Laminine (murine) Sigma-Aldrich, Munich 
L-Polyornithine hydrobromide Sigma-Aldrich, Munich 
1,4-Diazabicyclo[2.2.2]octane (DABCO) Sigma-Aldrich, Munich 
Paraformaldehyde  Merck, Darmstadt 
Sodium cacodylate Carl Roth, Karlsruhe  
Propidium iodide Sigma-Aldrich, Munich 
DNA Loading dye Thermo Scientific, Braunschweig. 
Gene Ruler (1 Kb) Thermo Scientific, Braunschweig. 
PonceauS solution 
(0.1 % (w/v) in 5% acetic acid) 
Sigma-Aldrich, Munich 
Prestained protein marker Thermo Scientific, Braunschweig. 
Glycerol Merck, Darmstadt 
Saponin Sigma-Aldrich, Munich 
HCl Merck, Darmstadt 
Glycine Carl Roth, Karlsruhe  
ECL Western blot detecting solution GE Healthcare, Buckinghamshire, UK 
13
C-D-glucose (uniform labelling of all Cs) Euriso-top GmbH, Saarbrücken 
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2.1.11    Reagents/ kits for experimental analysis 
Name of Analysis Name of kits Company 
RNA isolation GenElute Mammalian Total RNA 
Miniprep Kit  
 
Sigma-Aldrich, Munich 




Reverse transcription Omniscript Reverse Transcription Kit 
 
Qiagen, Hilden 
RNase inhibitor RNasin 40 U/μl 
 
Promega, Madison, USA 
LightCycler qPCR LightCycler FastStart DNA 










/NADPH Assay Kit Sigma-Aldrich, Munich 
Plasmid isolation GenElute Plasmid Miniprep Kit 
 
Sigma-Aldrich, Munich 
Transfection FuGENE® HD Transfection Reagent 
 
Roche, Mannheim 
RNA analysis  RNA analysis kit, 15nt  Advance Analytical 
Technologies, California, 
USA 
RNA sequencing kit Illumina® TruSeq® RNA Sample 
Preparation Kit v2  
 
Illumina, California, USA. 
SOC outgrowth 
medium 
Transformation New England Bio-Lab, 
Frankfurt am Main 
 
 
2.1.12    Antibodies for immunofluorescence and Western blot staining 
Name Company 
Primary antibodies: 
Rabbit anti-Toxoplasma (serum) Prof. Dr. Uwe Groß, Institute for 
Medical Microbiology, 
Göttingen 
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Mouse anti-Toxoplasma (serum) Prof. Dr. Uwe Groß, Institute for 
Medical Microbiology, 
Göttingen 
Biotin-conjugated Dolichos biflorus lectin (DBL) Sigma-Aldrich, Saint Louis, 
USA 
Mouse anti-BrdU antibody Cell Signalling Technology, 
Massachusetts, USA 
Rabbit anti-mouse myosin heavy chain antibody Santa-Cruz Biotechnology, 
Heidelberg 
Mouse anti-mouse p21(F5) antibody Santa-Cruz Biotechnology, 
Heidelberg 
Mouse anti-mouse β-actin antibody Prof. Dr. James Lessard, 
Children’s Hospital Medical 




Cy5-conjugated donkey F(ab')2 anti-rabbit IgG (H+L) Jackson ImmunoResearch, 
Hamburg 
Cy2-conjugated streptavidin Jackson ImmunoResearch, 
Hamburg 




Cy5-conjugated goat anti-mouse IgG (Fcγ-specific) Jackson ImmunoResearch, 
Hamburg 
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2.1.13    List of primers used in qPCR 









































































mGlycogen synthase 1-for 
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2.1.14    Instruments 
Name Company 
LightCycler 1.5 Roche, Mannheim 
Nanodrop-2000c Spectrophotometer Thermo Scientific, Schwerte 
Leica confocal microscope SP2 Leica Microsystem, Heidelberg 
Leica microsystem (Light microscope) Wetzlar GmbH, Wetzlar 
Axiostar plus microscope Carl Zeiss, Göttingen 
Luminescent image analyzer (LAS-4000) Fujifilm Life Science, Düsseldorf 
Victor multilabel plate reader Thermo Scientific,Schwerte 
Gel doc XR system Bio-Rad, Munich 
Centrifuge megafuge 2.0 RS Thermo Scientific, Schwerte 
Eppendorf centrifuge 5417R Eppendorf, Hamburg 
Eppendorf thermomixer compact Eppendorf, Hamburg 
Heraeus CO2 incubator Thermo Scientific, Schwerte 
Refrigerators Liebherr, Dortmund 
Hemocytometer grid Sigma-Aldrich, Munich 
Biohazard safety hoods BDK, Sonnenbühl-Genkingen 
Reax top test tube shaker Heidolph, Schwabach 
Duomax 1030 Rocker shaker Heidolph, Schwabach 
Electrophoretic chamber Bio-Rad , Munich 
Electrophoresis power supply EPS 500/400 PharmaciaBiotech, Freiburg 
Comb Bio-Rad, Munich 
Semidry western-blotter Biometra, Göttingen 
CP224S Analytical balance Sartorius, Göttingen 
pH meter Mettler-Toledo , Giesen 
Fragment Analyzer
TM
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2.1.15    Software and online tools 
Name Company 
LightCycler software 1.5 Roche, Mannheim 
Leica confocal microscope software Leica Microsystem,  Heidelberg 
ImageQuant LAS-4000  Fujifilm Life Science, Düsseldorf 
Wallac 1420 workstation Thermo Scientific,Schwerte 
QuantityOne (Gel doc image analysis software) Bio-Rad, Munich 
DAVID (Database for Annotation, Visualization 
and Integrated Discovery) online tool (version 6.8) 
National Cancer Institute, Frederick, 
USA 
Venn diagram tool Gent, Belgium 
Microsoft Office 2010 Microsoft Corporation, Washington, 
USA 
GraphPadPrism 5 GraphPad software, California, USA 
Mendeley Reference Manager Mendeley, New York,USA 
Primer designing tools National Center for Biotechnology 
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2.2.1 L929 cell culture 
L929 fibroblast cells from a C3H mouse were used as host cells for co-culturing of T. 
gondii in order to maintain steady supply of parasites for experimental work. To avoid 
excessive confluency, L929 cells were sub-cultured twice a week in a 6-well cell culture 
plate. To this end, cells were examined microscopically to confirm their appropriate 
density and viability. Then, cells were scraped off with a cell scraper in order to detach 
them from the culture dish. They were then resuspended, followed by adding eight drops of 
cell suspension into each well of a 6-well plate. Thereafter, ~4.0 ml of L929 growth 
medium was added into each well. L929 cultures were kept in an incubator at 37°C with 
5% CO2 and humidified atmosphere. 
 
2.2.2 Parasite-L929 co-culture 
The mouse-avirulent T. gondii type II strain NTE (Gross et al., 1991) was used throughout 
this study. Parasites were maintained as viable, highly replicating and metabolically active 
tachyzoites through co-culturing with L929 host fibroblasts. To this end, different amounts 
of L929 cell suspension (see above) were distributed into the wells of a 12-well cell culture 
plate using 10 ml glass pipettes as follows: 5 drops in the first row, 4 drops in the second 
row and 3 drops in the third row. Thereafter, different amounts of viable extracellular 
parasites of appropriate density from previous co-cultures were added accordingly: 6 drops 
of parasite suspension into the 1
st




 column and 2 drops 
into the 4
th
 column of that 12-well plate. Finally, Toxoplasma medium was added into each 
well to a final volume of ~1.5 ml and plates were kept in a humidified atmosphere at 37°C 
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2.2.3 C2C12 cell culture 
The mouse skeletal muscle cell line C2C12 (seeding 1×10
5
 cells/flask) were propagated as 
myoblasts in 75cm
2
 cell culture flasks with ~30 ml C2C12 growth medium in a humidified 
atmosphere at 37°C with 5% CO2. C2C12 cells were grown and maintained in a 
proliferative state by keeping them subconfluent and by sub-culturing in fresh medium 










). Trypsin was inactivated by adding C2C12 growth medium and cells were then 
centrifuged at 400g for 5 minutes at room temperature. After discarding the supernatant, 
pellets were resuspended in 2.0 ml C2C12 growth medium and ~25 µl of cell suspension 
was added into the culture flask containing ~30 ml of fresh C2C12 growth medium. In 
order to maintain the ability to form myotubes, a frozen stock aliquot of C2C12 cells 
(frozen in liquid nitrogen in 70% DMEM medium, 20% FCS and 10% DMSO) were 
thawed every 1 to 2 months. To this end, the vial with the frozen cells was thawed in a 
37°C water bath and its content immediately poured into a centrifuge tube containing ~ 40 
ml C2C12 medium to neutralize the toxic effect of DMSO. The cells were then centrifuged 
at 400g for 5 minutes at room temperature and pellets were resuspended in 10 ml C2C12 
growth medium and transferred into the flask containing additional 20 ml of medium. Cells 
were kept in a humidified atmosphere at 37°C with 5% CO2. 
 
2.2.4 Parasite isolation for infection assays 
Parasites were isolated from L929-Toxoplasma co-cultures by differential centrifugation 
and were thoroughly washed in C2C12 growth medium as described (Goebel et al., 2001). 
Briefly, contaminating host cells were pelleted by centrifugation at 35g for 5 minutes at 
room temperature. Then the supernatant was collected and centrifuged at 1350g for 10 
minutes to pellet parasites. After discarding the supernatant, the parasites were washed 
with C2C12 growth medium and were centrifuged again at 1350g for 10 minutes. After 
discarding the supernatant, the parasites were finally resuspended in 1.0 ml medium and an 
aliquot was diluted 1:20 and counted in a hemocytometer grid. 
 
Chapter 2: Materials & Methods 2017 
 
Page | 33  
 
2.2.5 Myotubes and myoblasts preparation for experimental work 
(A) Terminal differentiation of C2C12 myoblasts to myotubes was performed by using 
differentiation medium containing 2.0% horse serum (Rajan et al., 2012). Briefly, C2C12 




) and by 




). They were then centrifuged at 
400g for 5 minutes at room temperature. After discarding the supernatant, the cells were 
resuspended in 2.0 ml C2C12 growth medium and counted in a hemocytometer grid using 
a 1:2 diluted samples in trypan blue. C2C12 myoblasts were then plated at a density of 1.0-
1.5×10
5 
cells/well of a 6-well plate with 3.0 ml/well of C2C12 growth medium.  
After ~24 hours of seeding, when the cells were attached to the surface, the C2C12 growth 
medium was replaced with differentiation medium. The differentiation medium was 
exchanged every 48 hours until day 7 of seeding when proliferating myoblasts have largely 
differentiated into poly-nucleated myotubes. Differentiation medium of myotubes was then 
replaced by C2C12 growth medium in order to maintain the same experimental condition 
as with myoblasts. In parallel, C2C12 myoblasts (1-2×10
5 
cells/well) were isolated as 
described above and were seeded in another 6-well plate. On the following day, both 
myotubes and myoblasts were subjected to treatment with different inhibitors or 
modulators (if required) and/or were parasite-infected with T. gondii tachyzoites.  
 
(B) For immunofluorescence microscopy, myotubes were similarly formed on 13 mm 
round glass coverslips within 24-well plates coated with laminin or a combination of poly-
L-ornithine and laminin. Briefly, sterile glass coverslips were placed into 24-well cell 
culture plates and treated with laminin (15 µg/ml in PBS, pH 7.4) for 2 hours at 37°C in a 
5% CO2 incubator. Alternatively, coverslips were first treated with poly-L-ornithine (0.5 
mg/ml in 125 mM borate buffer, pH 8.3) for 3 hours at 37°C in a 5% CO2 incubator. After 
having been washed with PBS three times, coverslips were further treated with laminin as 
described above. Thereafter, cover slips were washed again three times in PBS, and C2C12 
myoblasts cells (2×10
4 
cells/well) were plated in 0.5 ml of C2C12 growth medium. After 
~24 hours of seeding, when the cells had attached to the coverslips, the C2C12 growth 
medium was replaced with differentiation medium and cells were differentiated to 
myotubes as described above until day7 of seeding. Differentiation medium of myotubes 
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was then replaced by C2C12 growth medium and C2C12 myoblasts (2×10
4 
cells/well) 
were seeded on coverslips in 24-well plates in parallel. On the following day, both 
myotubes and myoblasts were subjected to treatment with different inhibitors or 
modulators (if required) and/or parasite-infected with T. gondii tachyzoites. 
 
2.2.6 Treatment of myotubes and myoblasts with pharmacological inhibitors 
or modulators and parasite infection  
C2C12 myotubes were generated as described (see 2.2.5). Both myotubes and myoblasts 
were treated with pharmacological inhibitors or modulators of the cell cycle, metabolic 
pathways or redox homeostasis at concentrations as indicated (Table 2.1) or were mock-
treated with the respective vehicle. One hour later (unless otherwise stated), cells were 
infected with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5. Total RNA was 
isolated at 4, 24 or 48 hours post infection for RT-qPCR or cell fixation was performed at 
48 and 72 hours post infection for immunofluorescence analysis. 
 
Table 2.1: Inhibitors/modulators used for experimental analysis 











































5-10 mM Modulates TCA cycle  TCA cycle 
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N-acetyl cystein 5-10 mM ROS scavenger Redox signaling  
Tiron 1-5 mM ROS scavenger Redox signaling 
Luperox 20-40 µM, 
200 µM 
ROS inducer Redox signaling 
Hydrogen peroxide 50-100 µM ROS inducer Redox signaling 
 
 
2.2.7 P21 knockdown in C2C12 myoblasts by RNA interference  
RNA interference (RNAi) has emerged as a widely used method for studying gene 
functions. In this study, RNAi was used to knockdown the p21 cell cycle inhibitor gene in 
C2C12 myoblasts in order to understand the impact of p21 on T. gondii stage conversion in 
myoblasts and myotubes. 
 
2.2.7.1  Structure of Mission® TRC1-pLKO.1 plasmid vector and p21-shRNA 
sequences 
In order to knockdown p21 gene in murine C2C12 myoblasts, TRC1-pLKO.1 lentiviral 
plasmid vectors encoding p21 targeted short hairpin RNA (shRNA) were used. The 
shRNA is processed intracellularly through the enzyme Dicer to create 18-22 nucleotides 
short small interfering RNA (siRNA), which then degrades p21 mRNA via p21-targeted 
siRNA/RISC complex.  
To increase the likelihood of obtaining an efficient p21 mRNA knockdown and to produce 
a stable transfectant, five different p21-targeted shRNA Mission® TRC1-pLKO.1 plasmids 
were commercially obtained as bacterial glycerol stocks. As a negative control, Mission® 
TRC1-pLKO.1-empty vector containing plasmid DNA without a p21-targeted shRNA 
insert was used where the RISC complex is not activated. The sequence of the p21-shRNA 
fragments and the structure of pLKO.1 plasmids are shown in Table 2.2 and in Figure 2.1, 
respectively. Ampicillin and puromycin resistance genes encoded markers for selection of 
successfully transformed bacteria or successfully transfected C2C12 eukaryotic cells, 
respectively. 
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Figure 2.1: (A) Structure of MISSION
®
pLKO.1 plasmid. Five lentiviral plasmid vectors carried different 
p21-shRNA sequences between the polymerase III promoter (U6) and the central polypurine tract (CPPT). 
Selection markers were encoded by the ampicillin and puromycin resistance genes. (B) Structure of 
MISSION
®
pLKO.1-puro Empty Vector Plasmid used as a negative control. This plasmid did not carry a p21-
targeted shRNA sequence. Selection markers were encoded by the ampicillin and puromycin resistance 
genes. Both pictures were collected from http://www.sigmaaldrich.com. 
 
Table 2.2: Sequences of p21-targeted shRNA. Nucleotides forming the RNA loop 
within the shRNA are indicated in red 































No p21-targeted shRNA insert 
Chapter 2: Materials & Methods 2017 
 
Page | 37  
 
2.2.7.2 Propagation of p21-shRNA pKLO.1 plasmid vectors 
Escherichia coli bacterial glycerol stocks were used for propagation of lentiviral plasmid 
vectors encoding p21-shRNA sequences. Fifty to onehundred µl of bacterial stock were 
added into sterile culture tubes containing 0.5 ml pre-warmed Terrific Broth (TB) medium 
without antibiotics. The culture was incubated at 37°C with shaking for 15-30 minutes. 
Using a sterile inoculation loop, 25-50 µl of the incubated culture were streaked onto 
freshly prepared plates containing Luria-Bertani (LB) agar and 100 µg/ml ampicillin. The 
plates were then incubated in a humidified atmosphere overnight (15-20 hours) at 37 °C. 
Thereafter, a single bacterial colony from overnight culture plates was inoculated and 
grown in a test tube with 5.0 mL of LB broth containing 100 µg/ml ampicillin. Then the 
bacterial culture was incubated overnight at 37°C with shaking at 200 rpm for propagation. 
 
2.2.7.3 Plasmid DNA isolation 
For transfection of C2C12 myoblasts, p21-shRNA pLKO.1 plasmid DNA was isolated 
from E. coli using the GenElute™ Plasmid Miniprep Kit as recommended by the 
manufacturer (Sigma-Aldrich). Five milliliters of bacterial overnight culture (see above) 
were centrifuged at 12000g for 1 minute at room temperature. The cell pellet was then 
mixed with 200 µl of resuspension solution and vortexed vigorously. Subsequently, the 
cells were lysed by addition of 200 µl of lysis buffer and gently inverted for 5 minutes to 
clear the solution. Three hundred and fifty µl neutralizing solution were added and again 
gently inverted six times and then centrifuged for 10 minutes at 12000g to pellet cell 
debris. In parallel, a binding column was prepared using 500 µl of column preparation 
solution, spun down at 12000g for 30 seconds, and the flow-through was discarded. 
Subsequently, the clear cell lysate was transferred to the binding column and spun through 
the column filter for 30 seconds at 12000g. The binding filter was then washed with 750 µl 
of wash buffer and centrifuged briefly at 12000g. After discarding the filtrate, the binding 
membrane was dried by re-centrifugation to remove residual ethanol. The plasmid DNA 
was then eluted by addition of 100 µl of elution solution and stored at -20 ° C for 
transfection into C2C12 myoblasts cells. 
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2.2.7.4 Transformation using p21-shRNA negative pKLO.1-puro plasmid vector  
In order to propagate negative control pKLO.1-puro plasmid DNA, E. coli NEB 5-alpha 
competent cells were transformed with the respective plasmid. To this end, E. coli NEB 5-
alpha competent cells were defrosted on ice for 10 minutes. After mixing gently, 50 µl of 
cells were carefully transferred into a transformation tube on ice. Then 1.0 µl containing 
100 ng of pKLO.1 empty vector plasmid DNA was added to the cells. After mixing the 
cells and DNA by flicking, the tubes were placed on ice for 30 minutes. Thereafter, cells 
were heat-shocked at 42°C for 30 seconds and then incubated on ice for 5 minutes. 
Thereafter, 950 µl pre-warmed (37°C) SOC medium was added to the mixture and the cells 
were incubated at 37°C for 60 minutes with vigorous shaking (250 rpm). The cells were 
thoroughly mixed by flicking the tube and inverting, and then 10-fold serial dilutions were 
prepared in SOC medium. Cells (50-100 µl) at each dilution were spread onto pre-warmed 
LB-agar plates with 100 µg/ml ampicillin and incubated overnight at 37°C. A single 
bacterial colony from overnight culture plates was used for propagation (see 2.2.7.2) and 
DNA isolation (see 2.2.7.3) of negative control pKLO.1-puro plasmid. 
 
2.2.7.5 Agarose gel electrophoresis 
To confirm negative control pLKO.1-puro plasmid isolated from transformed E. coli cells, 
qPCR was used to amplify DNA using specific primers of the pLKO.1-puro plasmid (see 
2.1.13). Amplified DNA fragments and water as negative control were resolved in a 1.0 % 
agarose gel in 1x Tris-acetate-EDTA buffer. The agarose suspension was boiled until 
agarose particles were completely dissolved. After briefly cooling of the agarose solution, 
5.0 µl/100 ml of Midori Green were added, followed by gentle mixing, and poured into a 
gel chamber with a plastic comb. After polymerization of the gel, 4.0 µl of qPCR 
amplicons were mixed with 4 µl of DNA Loading Dye and pipetted into the agarose gel 
well. In addition, 8.0 µl of 1 kb Gene Ruler DNA marker was used as a size standard. The 
electrophoretic separation of nucleic acid fragments was carried out at 110-120 V for 1 
hour. Nucleic acid bands were visualized using a UV trans-illuminator. 
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2.2.7.6 Transfection of C2C12 myoblasts with pLKO.1 plasmids 
The transfection of C2C12 myoblasts with pLKO.1 plasmids encoding p21-shRNAs or 
with an empty vector as a negative control was performed using the FuGENE
®
 transfection 
reagent (Roche). To this end, C2C12 myoblasts were seeded at a concentration of 7×10
4
 
per well in 24-well plates with 0.5 ml C2C12 growth medium (see above) and incubated at 
37°C in a humidified 5% CO2 atmosphere. After 24 hours, the C2C12 growth medium was 
replaced by transfection medium for 30 minutes. In parallel, 2 μg of each plasmid was 
mixed with 3 μl or 6 μl of transfection reagent (Table 2.3) and incubated at 37°C for 15 
minutes. Next, the plasmid-transfection reagent mixture was cautiously dropped onto the 
cells. After 4 hours of transfection at 37°C, the transfection medium was replaced again by 
C2C12 growth medium. After 48 hours of cell growth, 2.5 μg/ml puromycin were added to 
the transfected cells for selection. Surviving cells were propagated and were then cloned by 
limiting dilution in 96-well plates after adding one or two cells per well. Two different 
clones of each cell pool carrying the different p21 shRNA or negative control plasmids 
were selected and frozen in 70% DMEM, 20% FCS, 10% DMSO in liquid N2 for future 
experiments. During experimental analysis but not after infection with T. gondii, p21-
shRNA knockdown clones and negative control clones were cultured (see 2.2.3) in C2C12 
growth medium (see 2.1.2) with 2.5 μg/ml puromycin. 
 
Table 2.3: Transfection of C2C12 myoblasts cells with p21-shRNA or negative control  
pLKO.1 plasmids 
Plasmid name Plasmid  Transfection 
reagent 
pLKO.1-p21-shRNA 1 2 μg 3 μl or 6 μl 
pLKO.1-p21-shRNA 2 2 μg 3 μl or 6 μl 
pLKO.1-p21-shRNA 3 2 μg 3 μl or 6 μl 
pLKO.1-p21-shRNA 4 2 μg 3 μl or 6 μl 
pLKO.1-p21-shRNA 5 2 μg 3 μl or 6 μl 
pLKO.1-puro ( negative control) 2 μg 3 μl or 6 μl 
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2.2.8 Quantitative reverse transcription PCR 
 
2.2.8.1 RNA isolation 
Total RNA was isolated using the GenElute
TM
 Mammalian Total RNA Miniprep Kit as 
recommended by the manufacturer (Sigma-Aldrich) with slight modifications. Briefly, 
myotubes and myoblasts grown in 6-well plates and treated and/or infected as described 
above were washed gently with 1.0 ml of cold PBS and then 350 µl of lysis solution 
supplemented with 2-mercaptoethanol (1:100, stock solution provided with the kit) was 
added into each well. The plates were shaken smoothly to ensure complete lysis of all cells 
followed by transfer of cell lysate into a filtration column. Columns were centrifuged at 
14000g for 2 minutes at room temperature, filtrates were mixed with an equal volume (350 
µl) of 70% ethanol and were then transferred into binding columns. Binding columns were 
centrifuged for 15 seconds at 14000g and after discarding the flow-through, the binding 
membranes were washed by centrifuging 500 µl of wash solution-I for 15 seconds through 
the membranes. Thereafter, the columns were transferred into new collection tubes and 
washed twice with 500 µl each of wash solution-II previously supplemented with ethanol 
as indicated by the manufacturer. For the last washing step, columns were centrifuged for 2 
minutes at 14000g to remove residual ethanol. Finally, the columns were transferred into 
new collection tubes and RNA was eluted with 50 µl of elution solution by centrifuging at 
14000g for 1 minute. 
 
2.2.8.2 DNase I treatment 
After isolation, RNA samples were treated with DNaseI Amplification grade as 
recommended by the manufacturer (Sigma Aldrich) to remove contaminating genomic 
DNA. Briefly, 50 µl of RNA sample were mixed with 5.0 µl of 10x reaction buffer and 5.0 
µl of DNaseI Amplification grade (1 unit/ml) and incubated at room temperature for 15 
minutes. Thereafter, 5.0 µl of stop solution (provided with the kit) were added to bind 
calcium and magnesium ions and to inactivate DNase I. Samples were heated at 70°C for 
10 minutes to denature DNase I and were then stored immediately at -80°C. 
 
Chapter 2: Materials & Methods 2017 
 
Page | 41  
 
2.2.8.3 Quantification of RNA 
RNA was quantitated by measuring its absorbance at 260 nm (A260) using a NanoDrop-
2000c instrument. NanoDrop is a full spectrum spectrophotometer that can measure 
DNA/RNA/protein concentrations within 1.0 µl of sample with high accuracy and 
reproducibility. To this end, 1-2 µl of RNA sample was pipetted onto the end of a fiber 
optic cable and a second optic cable was then brought into contact with the sample to 
measure the concentration of RNA. The ratio between the absorbance values at 260 and 
280 nm estimated the RNA purity with a reference value of pure RNA being ~2.0. 
 
2.2.8.4 Reverse transcription (cDNA synthesis)  
Complementary DNA (cDNA) synthesis was carried out using the Omniscript Reverse 
Transcription kit as recommended by the manufacturer (Qiagen). Briefly, 1-2 µg RNA 
were mixed with variable amounts of RNase-free water and 6.4 µl (for total reaction 
volume of 20 µl) or 7.4 µl (for total reaction volume of 30 µl) of freshly prepared master 
mix (Table 2.4). Samples were then incubated at 37°C for 90 minutes with constant 
shaking. cDNAs were stored at -20°C for further analysis. 
 
Table 2.4: Reaction components for cDNA synthesis 
Component Volume/sample Final concentration (for 30 µl 
reactions in parenthesis) 
Master Mix 
10x Buffer RT   2.0 µl or 3.0 µl 1.0 x 
dNTP Mix (5 mM each dNTP) 2.0 µl   0.5 mM (0.33 mM) each dNTP 
Oligo-dT primer (50 µM) 0.4 µl   1.0 µM (0.6 µM) 
RNase inhibitor (10 units/µl) 1.0 µl  10 units  
Omniscript Reverse 
Transcriptase (4 units/µl) 
1.0 µl   4.0 units  
RNase-free water  Variable  
 
Template RNA 1-2 µg  
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2.2.8.5 Real Time qPCR 
In order to determine differences in mRNA levels, cDNA samples were diluted two-fold 
and twenty-fold and were amplified by real time quantitative PCR using SYBR Green 
FastStart
®
 DNA Master Plus kit as recommended by the manufacturer (Roche). First, 14.0 
µl of FastStart
®
Taq DNA polymerase were added to 114 µl premix containing reaction 
buffer, SYBR Green I dye, dNTP mix and MgCl2. Thereafter, a PCR master mix (15 µl per 
sample) was prepared using premix, forward and reverse primers and PCR grade water 
(Table 2.5). Fifteen µl of master mix was then added to each of the LightCycler capillaries 
followed by adding 5.0 µl diluted template cDNA (1:2 or 1:20) or PCR grade water as 
negative control before sealing the capillaries by a plug. The capillaries were then gently 
centrifuged for 10 seconds and samples were amplified in a LightCycler1.5. For each 
primer pair target gene, different amplification programs were used as specified in Table 
2.6. 
 
Table 2.5: Real time qPCR reaction mixture 
Component Concentration Volume/sample 
Master Mix 
Premix  4.0 µl   
Forward primer (10 µM) 0.5 µM 0.5 µl   
Reverse primer (10 µM) 0.5 µM 0.5 µl   
PCR grade water   10 µl 
Sample 
cDNA or PCR grade water as control  5.0 µl 
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Table 2.6: Real time qPCR programs for gene expression analysis 
Step  Temperature  Duration  Cycle  
Denaturation  95 °C 10 minutes  
Amplification 95 °C  
61-72 
(depending on  
different target gene) 
 
72 °C 























End  40 °C 10 seconds 
 
The relative fold change of mRNA levels as a measure of gene expression was calculated 




Herein, the fold change of the mRNA level of a target gene was normalized to a reference 
gene and the efficiency of amplification (E) was set 2. The reference gene corresponds to a 
'housekeeping' gene; for gene expression analysis in the parasite T. gondii actin (TgActin) 
or T. gondii glyceraldehyde-3-phosphate dehydrogenase (TgGAPDH) and for that of host 
genes mouse ß-actin was used. 
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2.2.9 Immunofluorescence staining 
 
2.2.9.1 Cell fixation 
After treatment of cells with inhibitors/modulators (see 2.2.6) and/or T. gondii infection, 
cells on coverslips of 24-well plates were fixed at 48 and/or 72 hours post infection using 
4% paraformaldehyde in 0.1 M sodium cacodylate/HCl, pH 7.4 (PFA) (or methanol or 
70% ethanol if indicated). To this end, cells were washed twice with PBS for 5 minutes 
each and were then fixed with 350µl/well of PFA for 60 minutes at room temperature. 




After removing the PBS, cells were quenched for 10 minutes with 50 mM NH4Cl in PBS 
and then washed once with PBS for 5 minutes at room temperature. Cells were 
permeabilised and unspecific binding sites were blocked with blocking buffer (1.0% BSA, 
0.1 mg/ml saponin in PBS) for one hour at room temperature. Thereafter, cells were 
washed once with washing buffer (0.1 mg/ml saponin in PBS) and incubated with primary 
antibodies or lectin (Table 2.7) diluted in blocking buffer for one hour at room 
temperature. After washing three times for 10 minutes each with washing buffer, cells 
were incubated for one hour with secondary antibodies or streptavidin (Table 2.7) diluted 
in blocking buffer. For both primary and secondary antibody incubations, cover slips were 
removed from the 24-well plate and inverted onto 30-40 µl drops of antibody solution on 
parafilm. In order to wash cells, coverslips were put back cell-side up into the wells of the 
24-well plate. Unbound antibodies were then removed by washing three times for 10 
minutes each with washing buffer and finally once with PBS for 5 minutes. To visualize 
the total cell population, cells were incubated with 5 µg/ml propidium iodide in PBS for 4 
minutes. After washing with PBS twice for 5 minutes each, coverslips were rinsed in 
demineralized water and mounted on slides with 10 µl mowiol per cover slip. Slides were 
kept in the dark to dry overnight at room temperature. The samples were stored at 4°C until 
examination using a Leica SP2 confocal laser scanning microscope. 
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Table 2.7: Antibodies used in immunofluorescence staining 
Antibodies Dilution (Concentration) 
 
Primary antibodies: 
Rabbit anti-Toxoplasma (serum) 1:400 (in case of Cy5-
conjugated sec. Ab) , 
1: 2000 (in case of 
DyLight488-conjugated sec. 
Ab) 
Mouse anti-Toxoplasma (serum) 1:200 
Biotin-conjugated Dolichos biflorus lectin (DBL) 1:400 (3.125 µg/ml) 
Mouse anti-BrdU antibody 1:1000 
Rabbit anti-mouse myosin heavy chain antibody 1:100 (2.0 µg/ml) 
Mouse anti-mouse p21(F5) antibody 1:200 (1.0 µg/ml) 
Secondary antibodies: 
Cy5-conjugated donkey F(ab')2 anti-rabbit IgG (H+L) 1:100 (7.5 µg/ml) 
Cy2-conjugated streptavidin 1:200 (4.0µg/ml) 
DyLight488-conjugated donkey F(ab')2 anti- rabbit IgG 
(H+L) 
1:200 (3.75 µg/ml) 
Cy5-conjugated goat anti-mouse IgG (Fcγ-specific) 1:100 (6.0 µg/ml) 
DyLight488-conjugated donkey F(ab')2 anti-mouse IgG 
(H+L) 
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2.2.10  Bromodeoxyuridine (BrdU) incorporation assay 
Myotubes were prepared from C2C12 myoblasts on coverslips within 24-well plates as 
described in section 2.2.5B. Both myotubes and myoblasts were treated with inhibitors or 
vehicle and/or were infected with T. gondii at a host cell-to-parasite ratio of 1:3.5. BrdU 
incorporation assay was also performed with undifferentiated and differentiated p21-
shRNA transfectants (see above) and wildtype C2C12 cells where BrdU was added at day 
1, day 3, day 5 and day 7 of differentiation. During the last two hours prior to fixation, 
cells were treated with 10 µg/ml BrdU at 37°C. Thereafter, BrdU containing medium was 
removed and 500 µl/well of 70% ethanol were added for 5 minutes at room temperature. 
The cells were washed three times in PBS and then incubated in 500 µl/well of 1.5 M HCl 
for 30 minutes at room temperature. After removal of HCl, cells were washed again three 
times in PBS and stored in PBS at 4°C for immunostaining (see 2.2.9.2) using blocking 
solution, antibody incubation solution and wash solution as specified in 2.1.8. 
 
2.2.11  P21 expression examined by Western blotting  
Western blotting is a fundamental technique used to separate and identify proteins from a 
complex mixture of proteins based on molecular weight through gel electrophoresis 
followed by transferring them onto a membrane and staining of protein of interest using 
appropriate antibodies. 
 
2.2.11.1 Sample preparation and protein isolation 
Proteins were isolated from p21-shRNA transfectants, negative control transfectants and 
wildtype C2C12 cells at 3, 5 and 7 days after onset of differentiation from myoblasts to 
myotubes. To this end, cells were seeded at a concentration of 1.0×10
5
/well in 6-well 
plates. After 24 hours, cells were induced to differentiate using differentiation medium as 
described (2.2.5). Proteins were isolated from differentiated cells at the indicated time 
points as well as from wild-type myoblasts. To this end, cells were collected from the 
culture dish by EDTA-trypsin treatment as described (2.2.3) and transferred into cold 
C2C12 medium and then centrifuged at 400g for 5 minutes. The supernatants were 
discarded and pellets were resuspended in 1.0 ml of C2C12 medium. An aliquot of cells 
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was then counted in a hemocytometer grid and remaining cells transferred into a 
microcentrifuge tube and centrifuged at 6000g for 5 minutes at 4°C. After discarding the 
supernatants, cell pellets were resuspended in 50 µl/1x10
6
 cells ice cold lysis buffer (see 
2.1.5). Cells were lysed on ice for 60 minutes with vortexing after every 15 minutes. 
Finally, cell lysates were centrifuged at 14000g for 5 minutes at 4°C and soluble proteins 
within the supernatant were stored at -80°C for further analysis. 
 
2.2.11.2 SDS-PAGE  
Proteins were separated by SDS-PAGE for subsequent detection by Western blotting. The 
separating and stacking gels comprised 12% and 5% acrylamide, respectively (see 2.1.6). 
Samples were diluted with 5x SDS sample buffer to a final concentration of 1x SDS 
sample buffer and heated with shaking at 99°C for 5 minutes. Thereafter, samples were 
shortly centrifuged and 20 µl of each sample were loaded onto the gel. Five µl of 
prestained protein markers were also loaded onto each gel. Proteins were separated in 1x 
SDS-PAGE running buffer (see 2.1.6) at 25 mA per gel for approximately 60 minutes. 
Following electrophoresis, proteins were transferred onto nitrocellulose membrane. 
 
2.2.11.3  Western blotting  
After protein separation by SDS-PAGE, proteins were transferred onto nitrocellulose 
membranes by semi-dry blotting using a discontinuous buffer system. To this end, the 
polyacrylamide gel and the nitrocellulose membrane were placed between filter papers that 
have been previously soaked in different buffer solutions (see 2.1.7 and Figure 2.2). 
Proteins were transferred at 32 mA per gel for 90 minutes towards the anode as indicated 
in Figure 2.2. 
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Figure 2.2: Protein transfer by Western blotting. Proteins were transferred from cathode (-) to anode (+). 
Filter papers were socked in different buffer solutions as follows: 9 filter papers in aminocaproic acid buffer 
(40 mM), 3 filter papers in Tris-HCl buffer (25 mM) and 6 filter papers in Tris-HCl buffer (0.3 M) (from 
cathode to anode). Filter papers were used to prepare a sandwich of filter papers, polyacrylamide gel with 
proteins and nitrocellulose membrane. 
 
2.2.11.4 Immunostaining of nitrocellulose membrane  
To confirm protein transfer during Western blotting, the nitrocellulose membrane was 
stained with ponceauS solution. For this, the membrane was incubated in ponceauS 
solution for 3 minutes and then washed with ddH2O until the background was destained 
and the protein bands were visible. An image of the protein bands was recorded using a gel 
documentation system with white top light illumination. Thereafter, unspecific binding 
sites were blocked in blocking solution containing 5% skimmed milk powder (see 2.1.7) 
for two hours with gentle shaking at room temperature. Primary antibodies, i.e  anti-mouse 
p21 (1.0 µg/ml) or anti-mouse β-actin antibody (1.0 µg/ml) were diluted in antibody 
incubation buffer (see 2.1.7 and Table 2.8) and then added to the membrane for overnight 
incubation with shaking at 4°C.  Thereafter, unbound antibodies were removed by washing 
three times 10 minutes each with wash solution (see 2.1.7). Then the membranes were 
incubated with peroxidase-conjugated anti-mouse IgG secondary antibodies diluted in 
antibody incubation buffer (see 2.1.7) for 90 minutes, followed by washing again three 
times 10 minutes each with wash solution. After adding chemiluminescent detection 
reagents, the presence of p21 and beta-actin proteins was detected on the membrane using 
Fujifilm Image reader. 
 
Chapter 2: Materials & Methods 2017 
 
Page | 49  
 
Table 2.8: Primary and secondary antibodies used in western blotting 
Antibodies Type Dilution (Concentration) 
Mouse anti-mouse p21(F5) antibody Primary antibody 1:200 (1.0µg/ml) 
Mouse anti-mouse β-actin antibody Primary antibody 1:5000 (1.0µg/ml) 
Peroxidase conjugated goat F(ab’)2  
anti-mouse IgG (H+L) 
Secondary antibody 1:2000 (0.2 µg/ml) 
 
 
2.2.12   Measurement of intracellular NADP+/NADPH 
Intracellular NADP
+
/NADPH were measured in non-infected and T. gondii-infected and/or 
DHEA/solvent-treated myotubes and myoblasts by using the NADP
+
/NADPH 
quantification kit as recommended by the manufacturer (Sigma-Aldrich). This assay is 
specific for NADP
+
 and NADPH and does not detect NAD
+
 or NADH. The principle of 
this method is based on a colorimetric measurement of NADPtotal (NADP
+
 and NADPH) or 
NADPH at 450 nm. 
Table 2.9: Major components of the NADP
+




/NADPH extraction buffer The extraction buffer was allowed to reach room 
temperature before use. 
NADP
+
 cycling buffer NADP
+
 cycling buffer was allowed to reach room 
temperature before use. 
NADP cycling enzyme mix  
NADPH developer NADPH developer was reconstituted in 1.2 ml of 
ddH2O, and stored at -80
0
 C until use. 
 
NADPH standard NADPH standard was reconstituted in 200 µl of 
DMSO to generate 1.0 nmole/µl (1 mM) solution, 
and stored at -80
0
 C until use. 
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2.2.12.1 Sample preparation 
C2C12 myoblasts were differentiated into myotubes using 2% HS for 7 days as described 
in section 2.2.5A. Then both myotubes and myoblasts were treated with DHEA or solvent 
(if required) and were infected with T. gondii at a host cell-to-parasite ratio of 1:3.5 or left 
non-infected. After 48 hours of infection, cells were washed gently with cold 1x PBS (pH 
7.4). Next, non-infected and T. gondii-infected cells were isolated using EDTA-trypsin as 




 cells from each sample were pelleted 
in a microcentrifuge tube by centrifuging at 376g for 5 minutes at 4°C. Cells were then 
extracted with 300 µl of NADP
+
/NADPH extraction buffer and placed on ice for 10 
minutes. Samples were centrifuged at 10000g for 10 minutes to remove insoluble material 
and the supernatants were filtered through a 10 kDa cut-off viva spin filter to largely 
deproteinize them in order to avoid consumption of NADPH by enzymes. Finally, samples 
were stored at -80°C for further analysis. 
 
2.2.12.2 Detection of NADP+/NADPH 
In order to determine NADPH concentration only, 100 µl of extracted samples were heated 
at 60°C for 30 minutes in a heating block. Under these conditions NADP
+
 will be 
decomposed leaving NADPH only within the samples. Then samples were cooled on ice 
and spun down at 15000g for 30 seconds to remove any precipitates. 
Colorimetric detection of NADP
+
/NADPH was performed in 96-well flat bottom plates. To 
this end, 10 µl of the NADPH standard stock solution (1.0 nmole/µl) was diluted with 990 
µl of NADP
+
/NADPH extraction buffer to generate 10 picomol/µl standard solution. Then 
different volumes of NADPH standard solution (0, 2, 4, 6, 8, and 10 µl) were added in 
duplicate into wells of the 96-well flat bottom plate. Thereafter, extraction buffer was 
added to a final volume of 50 µl to generate 0 (blank), 20, 40, 60, 80 and 100 
picomole/well of standards.  Fifty microliters of unknown samples either pretreated as 
described above for NADPH only determination or untreated for total NADP
+
/NADPH 
determination were added in duplicate into wells of the 96-well plate. Hundred µl of the 
master reaction mix (composed out of 98 µl of NADP
+
 cycling buffer and 2 µl of NADP
+
 
cycling enzyme mix per reaction) were added to each of the standards and samples and 
mixed using an orbital rotator. The samples were incubated for 5 minutes at room 
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temperature to convert all NADP
+
 (if present) to NADPH. Finally, 10 µl of NADPH 
developer were added into each well and incubated for ~30 minutes for color development. 
The absorbance at 450 nm was finally recorded repeatedly during 1 hour using a Victor 
multilabel plate reader. Concentrations of NADPH only or NADP
+
/NADPH in unknown 
samples were calculated from the formula of a standard curve obtained after linear 
regression of the values of NADPH standard concentrations. 
 
2.2.13   Determination of intracellular Reactive Oxygen Species (ROS) levels 
In order to determine the accumulation of intracellular reactive oxygen species (ROS) in 
C2C12 myotubes and myoblasts, the CellROX Green reagent (Thermo Scientific) was 
used. CellROX Green reagent is a DNA dye which upon oxidation, binds to DNA and thus 
localizes primarily in the nucleus and mitochondria. C2C12 myoblasts were differentiated 
to myotubes using 2% HS (see 2.2.5B). Both myotubes and myoblasts were infected by T. 
gondii at a host cell-to-parasite ratio of 1:3.5, leaving some samples as non-infected 
controls. After 48 hours of infection, infected or non-infected myoblasts and myotubes 
were treated with 200 µM luperox (tert-butyl hydroperoxide; as a positive control) for 1 
hour at 37°C and 5% CO2 or were left untreated. Thereafter, 5 µM CellROX Green reagent 
was added to each sample for another 30 minutes. Cells were then washed three times with 
1x PBS and fixed in 4% paraformaldehyde for 15 minutes at room temperature. After 
having been washed with 1x PBS twice, cells were incubated in 5 µg/ml propidium iodide 
for 5 minutes followed by washing twice with 1x PBS. Finally, coverslips were mounted 
onto glass slides using mowiol and analyzed by confocal laser scanning microscopy. 
 
2.2.14   RNA sequencing 
RNA sequencing (RNAseq) is a technique used for studying regulation of gene expression 
at the transcriptome level. It is considered a highly sensitive and accurate tool for 
measuring gene expression patterns in a cell population before and after any treatment 
including infection with pathogens and can provide an overview of the total changes in 
gene expression due to infection. Here, RNA sequencing was performed with T. gondii-
infected and non-infected myotubes and myoblasts to unravel their differences in gene 
expression at mRNA levels. 
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2.2.14.1 Sample preparation and quality control analyses 
Myotubes were prepared from C2C12 myoblasts in 6-well culture plates through 
differentiation using 2% HS (see 2.2.5A). Both myotubes and myoblasts were infected 
with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:5 or were left non-infected. 
After twenty-four hours of infection, total RNA was isolated from both non-infected and T. 
gondii-infected samples using the GenElute™ Mammalian Total RNA Miniprep kit as 
described above (2.2.8.1) and a portion of RNA was used for cDNA synthesis and qPCR to 
determine relative BAG1 mRNA expression (see 2.2.8). 
In parallel, both cell types were differentiated or seeded on laminin-coated glass coverslips 
in 24-well plates to determine the extent of myotube formation and T. gondii infection by 
means of an immunofluorescence test. To this end, both cell types were infected with T. 
gondii tachyzoites (host cell-to-parasite ratio 1:5) or were left non-infected. After 24 hours 
of infection, cells were washed twice with 1x PBS and fixed with 4% paraformaldehyde 
for one hour at room temperature. Then cells were washed again with 1x PBS three times 
and stored at 4 °C until immunofluorescence staining as described (see 2.2.9). 
After confirming the expected results by RT-qPCR and immunofluorescence microscopy, 
the RNA samples of non-infected and infected myotubes as well as myoblasts from three 
independent experiments were used for subsequent RNA sequencing analysis. RNAseq 
was performed in collaboration with Gabriela Salinas-Riester and Bryan Downie at the 
Transcriptome and Genome Analysis Laboratory of the Georg-August-University of 
Göttingen. 
 
2.2.14.2 Measurement of RNA quality and quantity 
Before starting RNA sequencing at the transcriptome laboratory, the integrity/quality and 
the quantity of all RNA samples were determined in a Fragment Analyzer
TM
 Automated 
CE system using the DNF-471 standard sensitivity RNA analysis kit and the Nanodrop-
2000 spectrophotometer, respectively. The Fragment Analyzer
TM
 provides a RNA quality 
number (RQN) between 1 and 10 for each RNA sample based on an algorithm that uses 
three values of the electropherogram, i.e the intensity in front of the 18S peak, the total 
intensity of the 18S and 28S peaks and the ratio of 28S and 18S peaks. The higher the 
RQN number, the better is the quality of the RNA sample. 
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2.2.14.3 Preparation of cDNA library and sequencing 
RNA sequencing of samples from non-infected and T. gondii-infected myotubes and 
myoblasts from three independent experiments was performed using the Illumina® 
TruSeq® RNA Sample Preparation Kit v2 and the Illumina Hiseq
TM
 4000 sequencer. 
Briefly, 0.1-1 µg RNA of each sample was used to construct transcriptome libraries. First, 
polyA-containing eukaryotic mRNA was purified using oligo-dT-conjugated magnetic 
beads. After purification, the mRNA was fragmented into small pieces using divalent 
cations under elevated temperature. The cleaved RNA fragments were reversely 
transcribed into first strand cDNA using reverse transcriptase and random primers 
followed by second strand cDNA synthesis using DNA polymerase I and RNase H. The 
cDNA fragments then underwent an end repair process, before addition of a single ‘A’ and 
the ligation of adapters. After binding of the libraries to the flow cells, cDNA fragments 
were amplified and clusters of amplified fragments were than sequenced by means of 
sequential addition of specific fluorescently labelled nucleotides. After excitation of the 
sequentially added fluorescent nucleotides, the emission for each nucleotide within each 
cDNA cluster was recorded until a length of 50 bases was reached. Thirty to 100 million 
sequences per sample were mapped to the mouse and the Toxoplasma reference genomes 
(read mapping). 
 
2.2.14.4 Analysis and statistical evaluation of the transcriptome data 
To normalize the transcripts, ‘reads per kilobase per million reads’ (RPKM) values were 
calculated for each gene. The RPKM value expresses the ratio of the number of read within 
a transcript to the length of the transcript/exons in kilobases and the total amount of the 
sequencing reads in millions. For further analysis, significantly regulated transcripts were 
identified by the χ² test. For graphical representation of the expression profiles, heat maps 
of differentially expressed genes (DEGs) between cell types before or after infection were 
constructed. Functional analyzes of the genes/transcripts were carried out using the 
DAVID analysis tool (https://david-d.ncifcrf.gov/) and the Venn diagram software of the 
VIB/UGent   (http://bioinformatics.psb.ugent.be/webtools/Venn/). 
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2.2.15  Isotope labeling and metabolite analysis via gas chromatography-
coupled mass spectrometry (GC-MS) 
Stable isotope labeling experiments were carried out in collaboration with Izabela Swierzy, 
Göttingen and Martin Blume, Melbourne as described previously (Blume et al., 2015) with 
the following modifications. Briefly, myotubes were prepared from 6×10
5
 C2C12 
myoblasts in  92mm cell culture plates through differentiation using 2% HS (see 2.2.5). 
One day before infection, differentiation medium was exchanged by glucose-free DMEM 
supplemented with 1 g/l 
12
C-glucose, 10% FCS and penicillin and streptomycin at 
concentrations as indicated (see 2.1.2). Myoblasts were seeded in parallel in the same 
medium. Both myotubes and myoblasts were infected with T. gondii tachyzoites at a host 
cell-to-parasite ratio of 1:3.5 or were left non-infected as controls. Six hours later, the 
medium was exchanged by medium where 
12
C-glucose was replaced by 
13
C-glucose and 
cells were incubated for additional four hours. Thereafter, cellular metabolism was 
terminated by rapid exchange of labeling media with 2.1 ml/sample cold 80% GC-MS 
grade methanol supplemented with 0.5 nmol scyllo-inositol as internal standard and 
transferring the plate onto an ice-water slurry. Cells were scraped and were transferred into 
a centrifuge tube. After washing each plate with 2.1 ml 80% methanol containing 0.5 nmol 
scyllo-inositol and transfer into the tubes, cells were sonicated in a water bath four times 
for 30 seconds with intermittent cooling on ice. After addition of chloroform and water to a 
ratio of chloroform:methanol:water of 1:11:6 (v/v), metabolites were extracted for 20 
minutes in a water bath at 60°C. Insoluble material was then pelleted at 14000g and 0°C 
for 10 minutes. Phase separation was induced by addition of water and by sonication in a 
water bath 4 times 10 seconds each. After centrifugation at 14000g and 0°C for 10 
minutes, the aqueous phase was dried in a heated speedvac and was shipped at room 
temperature to the University Of Melbourne, Australia. Polar metabolites were re-dried 
with methanol in a speed-vac and methoxymated with 20 mg/ml methoxyamine in pyridine 
at room temperature overnight  prior to trimethylsilylation with N,O-bis (trimethylsilyl) 
trifluoroacetamide with 1% trimethylsilyl (BSTFA-1% TMS) (Sigma-Aldrich) for 1 hour 
at room temperature . Samples were then analysed by gas chromatography mass 
spectrometry (GC-MS) using Agilents 7890A-5975C system equipped with a DB-5MS + 
DG column (J&W, Agilent, 30m × 0.25 mm, with 10 gap) .  Chromatograms were 
processed in MSD Chemstation D.01.02.16 software (Agilent). The incorporation of 
13
C-
atoms was estimated as the percentage of the metabolite pool containing one or more 
13
C-
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atoms after correction for natural abundance. Total metabolite counts were normalized to 
scyllo-inositol as an internal standard and to total protein content of each sample. 
 
2.2.16    Statistical analysis 
Each experiment was performed at least two times (unless otherwise stated). Data are 
expressed as means ± standard error of the mean (means ± SEM) from replicate 
experiments. The differences between two groups were considered significant if the p-
values were less than 0.05. The p-values between the means of two groups were calculated 
by means of the Student t-test using Microsoft Excel. In case of more than two groups, p 
values were calculated through analysis of variance (ANOVA). χ² test was used to 
calculate p-values for analyzing RNA sequencing data. Graphs were prepared using 
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3.1 Terminally differentiated SkMCs support T. gondii bradyzoite 
differentiation 
It has been established that skeletal muscle cells (SkMCs) and neurons are the preferred 
cell types for T. gondii bradyzoite differentiation and tissue cyst formation (Dubey et al., 
1998; Ferreira-da-Silva et al., 2009; Guimarães et al., 2009). Recently, Swierzy et al. have 
shown that T. gondii stage conversion from tachyzoites to bradyzoites occurs 
spontaneously in terminally differentiated SkMCs, i.e. in myotubes, but not in proliferating 
myoblasts (Swierzy and Lüder, 2014). In this study, it has been further confirmed that T. 
gondii stage conversion is accelerated in myotubes compared to myoblasts, prior to 
identifying factors which might induce tachyzoites to bradyzoites differentiation in 
myotubes (see below).  
 
3.1.1 T. gondii bradyzoite differentiation is accelerated in myotubes as 
compared to myoblasts 
In order to determine T. gondii stage conversion in myotubes, RT-qPCR was performed 
with T. gondii-infected myotubes and myoblasts to examine upregulation of bradyzoite 
antigen-1 (BAG1) mRNA between 4 and 48 hours post infection. Results showed that 
BAG1 mRNA increased five-fold in T. gondii residing in myotubes compared to those in 
myoblasts, although this was not statistically significant due to variable results from 
experiment to experiment suggesting some difficulties in reproducibility (Figure 3.1A). As 
bradyzoite development regularly leads to the formation of tissue cysts, fluorescence 
staining was performed to label cyst wall of T. gondii tissue cysts with Dolichos biflorus 
lectin. Data showed that cyst formation was increased in myotubes compared to myoblasts 
after 48 and 72 hours of infection (Figure 3.1B). Therefore, it was concluded that T. gondii 
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Figure 3.1: T. gondii bradyzoite differentiation and tissue cyst formation is preferentially triggered in 
mature myotubes. C2C12 myoblasts were induced to differentiate into poly-nucleated myotubes. Both 
differentiated myotubes and proliferating myoblasts were infected with T. gondii tachyzoites at a host cell-to-
parasite ratio of 1:3.5. (A) Total RNA was isolated at 4 and 48 hours post infection, followed by cDNA 
synthesis. Subsequently, cDNA was amplified using specific primers for T. gondii bradyzoite antigen 1 
(BAG1) and T. gondii actin (TgActin) by quantitative real-time PCR. The increase in BAG1 mRNA was 
calculated (ΔΔCP method) in myotubes and myoblasts and was normalized to that of TgActin mRNA. 
Results are depicted as means ± S.E.M. from five independent experiments. (B) Cells were fixed at 48 and 72 
hours post infection with 4 % paraformaldehyde. After fixation, tissue cysts of T. gondii were labeled with 
biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated streptavidin, and parasites were labeled with a 
polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary antibodies, and host cells were visualized 
using propidium iodide. The number of cysts was counted in 100 fields of vision (FV). Data represent means 
± S.E.M. from two independent experiments.  
 
3.2 Transcriptome analysis of SkMCs 
Transcriptome analysis is an important approach to identify differences between cells at 
the RNA level. In this study, the transcriptomes of non-infected and T. gondii-infected 
myotubes and myoblasts were analyzed in order to identify possible candidate genes or 
pathways that might regulate developmental switching of tachyzoites to bradyzoites in 
myotubes. 
 
3.2.1 RT-qPCR confirms higher BAG1 mRNA expression in T. gondii within 
myotubes as compared to those in myoblasts 
Before analyzing transcriptomes through RNA sequencing, RNA samples from non-
infected and T. gondii-infected myotubes and myoblasts were assessed by RT-qPCR to 
determine relative T. gondii BAG1 mRNA expression in both cell types.  
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To this end, RNA was isolated from non-infected and T. gondii-infected myotubes and 
myoblasts at 24 hours post infection and after reverse transcription, equal amounts of 
cDNA were used to determine T. gondii BAG1 mRNA expression. Results showed more 
than 35-fold higher BAG1 mRNA levels in myotubes compared to myoblasts, indicating 
clearly higher bradyzoite differentiation in myotubes than in myoblasts as expected (Figure 
3.2A). 
 
Figure 3.2: Myotubes support higher T. gondii BAG1 mRNA expression but similar parasite 
replication as compared to myoblasts. C2C12 myoblasts were induced to differentiate into poly-nucleated 
myotubes. Both myotubes and myoblasts were infected with T. gondii tachyzoites at a host cell-to-parasite 
ratio of 1:5. (A) Total RNA was isolated at 24 hours post infection, followed by cDNA synthesis by reverse 
transcription. Subsequently, cDNA was amplified using specific primers for T. gondii bradyzoite antigen 1 
(BAG1) and T. gondii actin (TgActin) by quantitative real-time PCR. The relative BAG1 mRNA expression 
in myotubes as compared to myoblasts was calculated (ΔΔCP method) and was normalized to TgActin 
mRNA. Results are depicted as means ± S.E.M. from three independent experiments. (B-C) Cells were fixed 
after 24 hours of infection using 4% PFA. Cells were labeled with anti-myosin heavy chain primary 
antibodies and Cy2-conjugated secondary antibodies (green fluorescence), and parasites were 
immunolabelled using a polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary antibodies (blue 
fluorescence). Host cells were visualized using propidium iodide (red fluorescence). After cells had been 
fluorescently labeled, the average size of parasitophorous vacuoles (PVs) in each sample was determined by 
counting the number of parasites in 100 PVs (B). Data represent means ± S.E.M. from three independent 
experiments. (C) Representative images of the labellings were recorded by confocal laser scanning 
microscopy and were superimposed. 
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3.2.2 Parasite replication and myosin heavy chain expression in myotubes and 
myoblasts 
It has been shown before that reduced parasite replication is a prerequisite for T. gondii 
bradyzoite differentiation (Bohne et al., 1994; Radke et al., 2003). It was thus important to 
determine parasite replication in myotubes and myoblasts. In order to evaluate parasite 
replication, the infection rate of both cell types was evaluated by immunofluorescence 
staining. In both myotubes and myoblasts, parasite infection could clearly be detected 
(Figure 3.2C). Parasite replication was slightly higher in myotubes than in myoblasts after 
24 hours of infection (Figure 3.2B). This data showed that the parasite was able to replicate 
in both myotubes and myoblasts to a similar extent. Lower parasite replication was 
expected in myotubes compared to myoblasts as reduced parasite replication is a hallmark 
of T. gondii bradyzoite differentiation in myotubes (Swierzy and Lüder, 2014). 
Immunofluorescence microscopy also revealed myosin heavy chain (MyHC) expression 
(green fluorescence) in poly-nucleated myotubes but not in myoblasts indicating formation 
of mature myotubes after in vitro differentiation in differentiation medium with 2 % horse 
serum (Figure 3.2C). 
 
 
3.2.3 Gene expression profiles of myoblasts and myotubes before and after T. 
gondii infection  
RNA sequencing was performed with non-infected and T. gondii-infected myoblasts and 
myotubes in order to identify genes that are differentially regulated in proliferating 
myoblasts or differentiated myotubes before and after T. gondii infection. To this end, 
RNA was isolated from three replicates of non-infected and T. gondii-infected myoblasts 
and myotubes at 24 hours post infection and was used for sequencing after confirming 
quality of the samples as described above. RNA sequencing data revealed that 6351 to 
6592 genes were differentially expressed in myoblasts versus myotubes irrespective of 
infection (Figure 3.4A). Surprisingly, T. gondii had only a minor impact on regulation of 
gene expression in myotubes and myoblasts. To visualize expression pattern of 
differentially regulated genes (DEGs), a heatmap of the top 50 DEGs with the lowest p-
values was constructed to visualize overall transcriptome differences between non-infected 
and T. gondii-infected myoblasts versus myotubes. Results confirmed that myotubes 
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largely differ from myoblasts in their gene expression pattern irrespective of infection. 
Within the group of these 50 genes, there were hardly any differences between non-
infected and infected myoblasts or myotubes (Figure 3.3).  
 
Figure 3.3: Heatmap illustrating differential gene expression in non-infected and T. gondii-infected 
myoblasts and myotubes. Three replicates each of non-infected (control) and T. gondii-infected myoblasts 
versus myotubes were hierarchically clustered based on an average linkage analysis using pearson correlation 
coefficients as the distance measure. Up to 6592 differentially regulated genes were identified in myoblasts 
and myotubes irrespective of infection. From these, the top 50 genes with the highest significance levels of 
regulation between infected myoblasts and infected myotubes were clustered in this heatmap. Levels of gene 
expression were visualized using a Z-score color code ranging from -1.5 to +1.5 where yellow color indicate 
highest expression and blue color indicate lowest expression of genes.  
 
3.2.4 DEGs in non-infected or infected myoblasts versus myotubes 
Among the total number of DEGs (6351) that were differentially expressed in non-infected 
myoblasts versus non-infected myotubes 2872 were upregulated and 3479 DEGs were 
downregulated. Besides, of the 6592 total DEGs that were identified in T. gondii-infected 
myoblasts versus infected myotubes 3013 DEGs were upregulated and 3579 DEGs were 
downregulated (Figure 3.4A). Venn analysis was then performed to identify DEGs that 
were uniquely regulated in non-infected myoblasts versus myotubes as compared to 
infected myoblasts versus myotubes. Results identified 657 and 897 DEGs that were 
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uniquely regulated between the two non-infected or T. gondii-infected cell types, 
respectively. Both non-infected and infected myoblasts versus myotubes shared a majority 
of 5657 DEGs (Figure 3.4B). Among the 657 DEGs uniquely regulated in non-infected 
myoblasts versus non-infected myotubes 343 DEGs were upregulated and 314 DEGs were 
downregulated. Similarly, among the 897 DEGs uniquely regulated in infected myoblasts 




Figure 3.4: Identification of DEGs in non-infected and T. gondii-infected myoblasts versus myotubes. 
(A) DEGs (p < 0.05) were identified after RNAseq by comparing non-infected myoblasts and myotubes or T. 
gondii-infected myoblasts and myotubes. Among total DEGs numbers of those up- or downregulated in 
myoblasts as compared to myotubes were identified. (B) Venn diagram showing the number of DEGs 
commonly regulated in both non-infected and infected myoblasts versus myotubes within the overlap area of 
both circles. Numbers outside the overlap correspond to unique DEGs of non-infected myoblasts versus 
myotubes (left) and infected myoblasts versus myotubes (right). (C) DEGs uniquely regulated in either non-
infected or infected myoblasts versus myotubes were grouped into genes up- and downregulated. 
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3.2.5 Gene ontology analysis of differentially regulated genes in infected 
myoblasts versus myotubes 
Gene ontology term enrichment analysis was performed with DEGs identified in T. gondii-
infected myoblasts versus infected myotubes in order to identify biological processes that 
differ between both cell types. Results showed that DEGs were highly enriched for genes 
predominantly associated with cellular component organization or biogenesis,  the mitotic 
cell cycle including organelle fission, muscle structure development and metabolic 
processes including primary metabolic process, organic substance metabolic process and 
cellular nitrogen compound metabolic process (Figure 3.5). This clearly indicated that 
muscle development, the cell cycle and metabolism are important biological processes that 
largely differ between T. gondii-infected myoblasts and myotubes. 
 
 
Figure 3.5: GO term enrichment analysis of differentially regulated genes in T. gondii-infected 
myoblasts and myotubes. The top 20 biological processes with the most significant enrichments among 
DEGs as compared to the reference genome are indicated. 
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3.2.6 Biological processes associated with DEGs uniquely upregulated in 
infected myoblasts versus infected myotubes 
In order to identify biological processes that are specifically associated with the 485 DEGs 
that were uniquely upregulated in infected but not non-infected myoblasts versus myotubes 
(Figure 3.4C) the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) online tools were used. Results showed that these DEGs were enriched in genes 
involved in various biological processes. Among these, the most prominent biological 
processes were transcription including mRNA processing, regulation of transcription, 
covalent chromatin modification, phosphorylation and protein phosphorylation, DNA 
repair and cellular responses to DNA damage stimulation (Figure 3.6). A list of the 30 
most strongly uniquely upregulated DEGs in infected myoblasts versus infected myotubes 
but not in non-infected myoblasts versus myotubes are shown in supplementary Table 3.1. 
 
Figure 3.6: GO term enrichment analysis of DEGs uniquely upregulated in T. gondii-infected 
myoblasts versus infected myotubes. Uniquely upregulated DEGs were identified from total DEGs of T. 
gondii-infected myoblasts versus infected myotubes based on the fold regulation value of gene expression 
data. Thereafter, the DAVID online tools were used to identify association of these DEGs to different 
biological pathways (https://david.ncifcrf.gov/tools.jsp). 
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3.2.7 GO term analysis of DEGs uniquely downregulated in infected 
myoblasts versus infected myotubes 
GO term enrichment analysis was also performed with those 412 DEGs that were uniquely 
downregulated in T. gondii-infected but not non-infected myoblasts versus myotubes 
(Figure 3.4C) using the DAVID tool. Results showed that differentially regulated genes 
were mainly involved in regulation of oxidation-reduction processes, axon guidance, 
transport, cell proliferation and others (Figure 3.7). A list of the 30 most strongly uniquely 
downregulated DEGs in infected myoblasts versus infected myotubes but not non-infected 
myoblasts versus myotubes are shown in supplementary Table 3.2. 
 
 
Figure 3.7: GO term enrichment analysis of uniquely downregulated DEGs in infected myoblasts vs 
infected myotubes. Uniquely downregulated DEGs were identified from total DEGs in T. gondii-infected 
myoblasts versus infected myotubes based on the fold regulation value of gene expression data. Thereafter, 
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3.2.8 Differential gene expression in non-infected and T. gondii-infected 
myotubes and myoblasts  
Whereas myotubes and myoblasts differed largely in their gene expression pattern (see 
Figure 3.3), T. gondii-infection had only a minor impact on these transcriptome. In total, 
only 38 genes were differentially regulated (p<0.05) by T. gondii in myotubes after 
infection. Most genes were identified as predicted or pseudogenes. Nevertheless, a list of 
the differentially regulated genes in T. gondii-infected versus non-infected myotubes is 
shown in supplementary Table 3.3. Similarly, 70 genes were differentially regulated 
(p<0.05) by T. gondii infection in myoblasts. Most genes were identified as predicted or 
pseudogenes. However, a list of the differentially regulated genes in T. gondii infected 
versus non-infected myoblasts is shown in supplementary Table 3.4. 
Because a main aim of this study was to identify candidates that might regulate differential 
development of T. gondii in myotubes versus myoblasts, I next concentrated on those 
genes that were differentially expressed in myoblasts and myotubes irrespective of 
infection. Since GO term enrichment analysis has identified the cell cycle and metabolism 
of the host cell largely differing between myoblasts and myotubes (Figure 3.5) I 
concentrated on expression of glucose metabolism enzymes and cell cycle regulators in 
non-infected and T. gondii-infected myotubes and myoblasts. Upregulation or 
downregulation of genes associated with glucose metabolic pathways and cell cycle 
regulation was calculated as fold change (FC) using their RPKM values in T. gondii-
infected myotubes versus myoblasts. Most of the genes encoding for glycolytic enzymes 
were significantly upregulated in infected myotubes as compared to infected myoblasts 
except glyceraldehyde-3-phosphate dehydrogenase, triphosphate isomerase-I and 
phosphoglycerate kinase-I and pyruvate kinase. The list of genes of glycolytic enzymes 
including their FC and p-value are shown in supplementary Table 3.5. Distinct genes 
encoding for enzymes of the TCA cycle, namely pyruvate dehydrogenase complex, 
aconitase-II, isocitrate dehydrogenase2 and pyruvate carboxylase were upregulated in 
infected myotubes as compared to infected myoblasts. Other genes such as citrate synthase 
and phosphoenol pyruvate (PEP) carboxykinase2 were downregulated in myotubes 
compared to myoblasts while most genes, i.e.  ketoglutarate dehydrogenase, succinate-CoA 
ligase, succinate dehydrogenase, fumarate hadratase-I and malate dehydrogenase-II were 
not differentially regulated between infected myotubes and myoblasts. The list of genes 
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encoding for TCA cycle enzymes including their FC and p-value are shown in 
supplementary Table 3.6. Interestingly, most of the genes encoding enzymes of both the 
oxidative and non-oxidative phases of the pentose phosphate pathway (PPP) including 
glucose-6-phosphate dehydrogenase2, glucose-6-phosphate dehydrogenase (X-linked), 6-
phosphogluconate dehydrogenase, ribose-5-phosphate isomerase and transketolase were 
downregulated in infected myotubes compared to myoblasts, suggesting their upregulation 
in infected myoblasts as compared to myotubes. The list of genes involved in the PPP 
including their FC and p-value are shown in supplementary Table 3.7. Genes encoding for 
enzymes of glycogen synthesis as for instance hexokinase-II, phosphoglucomutase-II, 
UDP-glucose pyrophosphorylase2, glycogenin, glycogen synthase-I and genes for 
glycogen degradation including glycogen phosphorylase and debranching enzymes were 
upregulated in myotubes as compared to myoblasts while the gene encoding for branching 
enzyme was not regulated. The list of genes involved in glycogen metabolism and their FC 
and p-value are shown in supplementary Table 3.8.  Finally, gene expression data for 
proteins of cell cycle regulation were analysed. Results showed that genes encoding 
different CDK inhibitors as for instance p21, p57, p27 and cell cycle proteins i.e p53 and 
DNA damage regulated-I, retinoblastoma (RB)-1 were upregulated in infected myotubes 
compared to myoblasts. In contrast, genes encoding various cyclins including cyclinA2, 
cyclinB1/B2, cyclinC, cyclinD1/D2, cyclinE1/E2 and cyclin dependent kinases i.e CDK1, 
CDK2, CDK4, CDK6, CDK8 and p18, CWF-19 like1, proliferating cell nuclear antigen 
were downregulated in infected myotubes as compared to myoblasts. The list of genes 
involved in cell cycle regulation and their FC and p-value are shown in supplementary 
Table 3.9. 
 
3.2.9 Differential gene expression of distinct glucose metabolizing enzymes 
and cell cycle regulators in myotubes and myoblasts 
Since GO term analysis and expression data indicated major differences in cell cycle and 
primary metabolism regulation between infected myoblasts versus myotubes (see Figure 
3.5), RNAseq data were further analyzed for expression of selected individual genes 
related to these pathways. Furthermore, their expression at the mRNA level was further 
validated by RT-qPCR. Glucose-6-phosphate dehydrogenase (G6PDH) 2 is an important 
enzyme of the pentose phosphate pathway (PPP) and catalyses the rate limiting reaction, 
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i.e. conversion of glucose-6-phosphate into 6-phosphogluconolactone. RNAseq data 
showed that the mRNA level of this enzyme was higher in myoblasts compared to 
myotubes. Interestingly, T. gondii further upregulated expression of G6PDH2 in both 
myoblasts and myotubes (Figure 3.8A). RT-qPCR was performed with mRNA isolated at 
4, 24 and 48 hours post infection. Results confirmed higher levels of G6PDH2 mRNA in 
myoblasts compared to myotubes at 4 and to a lesser extent also at 24 hours after infection 
in both infected and non-infected control myoblasts. However, the levels of G6PDH2 
mRNA did not differ between myoblasts and myotubes at 48 hours of infection (Figure 
3.9A). RT-qPCR analysis did not confirm increased G6PDH2 mRNA levels after T. 
gondii-infection as indicated by RNAseq (Figure 3.8A). G6PDH (X-linked) mRNA was 4-
fold higher in myoblasts as compared to myotubes irrespective of infection as revealed by 
RNAseq analysis (Figure 3.8B). RT-qPCR data confirmed upregulation of mRNA of this 
enzyme in myoblasts compared to myotubes at 4 and 24, but not at 48 hours post infection 
(Figure 3.9B). Messanger RNA of 6-phosphogluconate dehydrogenase (6PGDH) which 
catalyzes another important reaction of the PPP, i.e. decarboxylation of 6-
phosphogluconate into ribulose-5-phosphate was 2-fold higher in myoblasts compared to 
myotubes irrespective of infection as indicated by RNAseq analysis (Figure 3.8C). 
Surprisingly, RT-qPCR revealed upregulation of 6PGDH mRNA in myoblasts as 
compared to myotubes at 4 hours post infection only but not at 24 and 48 hours (Figure 
3.9C). In contrast to the enzymes of the PPP, mRNA expression of pyruvate carboxylase, 
i.e. an enzyme of TCA cycle anaplerosis which catalyzes the conversion of pyruvate into 
oxaloacetate, was upregulated in both T. gondii-infected and non-infected myotubes as 
compared to myoblasts as indicated by RNAseq analysis (Figure 3.8D). A similar pattern 
of relative mRNA expression of this enzyme was verified by RT-qPCR in myotubes and 
myoblasts at 24 and 48 hours post infection whereas such difference was not obvious at 4 
hours of infection (Figure 3.9D). Transcripts of the glycogen synthase-I which is a rate 
limiting enzyme of glycogen synthesis were 4-fold upregulated in myotubes compared to 
myoblasts irrespective of infection as revealed by RNAseq (Figure 3.8E). RT-qPCR 
confirmed higher mRNA levels of this enzyme in infected and non-infected myotubes at 4, 
24 and 48 hours of infection (Figure 3.9E). Similarly, expression of glycogen 
phosphorylase, an important enzyme of glycogen breakdown was upregulated in myotubes 
compared to myoblasts as observed after RNAseq (Figure 3.8F) and RT-qPCR (Figure 
3.9F).  
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Figure 3.8: RNAseq gene expression data of selected metabolic enzymes and cell cycle protein p21 in T. 
gondii-infected and non-infected myotubes and myoblasts. Gene expression levels are indicated based on 
‘reads per kilobase per million reads’ (RPKM) for metabolic enzymes and cell cyle protein p21(A) glucose-
6-phosphate dehydrogenase2 (B) glucose-6-phosphate dehydrogenase (X-linked) (C) 6-phosphogluconate 
dehydrogenase (D) pyruvate carboxylase (E) glycogen synthase-I (F) glycogen phosphorylase (G) p21. 
Results are depicted as means ± S.E.M. from three independent biological replicates. Significant differences 
were identified by χ² test (* p<0.05). 
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Figure 3.9: Validation of gene expression of selected metabolic enzymes and cell cycle protein p21 
using RT-qPCR. C2C12 myoblasts were induced to differentiate into poly-nucleated myotubes. Both 
differentiated myotubes and proliferating myoblasts were infected with T. gondii tachyzoites at a host cell-to-
parasite ratio of 1:3.5 or were left as non-infected control. Total RNA was isolated at 4, 24 and 48 hours post 
infection, followed by cDNA synthesis. Subsequently, cDNA was amplified using host cell specific primers 
for different metabolic enzymes- and cell cyle inhibitor p21 (A) glucose-6-phosphate dehydrogenase2  
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(B) glucose-6-phosphate dehydrogenase (X-linked) (C) 6-phosphogluconate dehydrogenase (D) pyruvate 
carboxylase (E) glycogen synthase-I (F) glycogen phosphorylase (G) p21. The relative mRNA expression in 
myoblasts as compared to myotubes was calculated (ΔΔCP method) and was normalized to mouse ß-actin 
mRNA. Results are depicted as means ± S.E.M. from three independent experiments. 
 
 
Finally, p21, a potent cyclin-dependent kinase inhibitor which can halt cell cycle 
progression was upregulated in infected and non-infected myotubes compared to myoblasts 
and this was consistently observed after RNAseq analysis (Figure 3.8G) and RT-qPCR 
(Figure 3.9G). The differences in gene expression pattern of glucose metabolic enzymes 
and cell cycle proteins in myotubes and myoblasts provided initial hints for analyzing 
metabolic characteristics of these cell types and their role in T. gondii bradyzoite 
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3.3 Impact of differential glucose metabolism in SkMCs on T. gondii 
stage conversion 
Since myoblasts and myotubes strongly differed in the mRNA levels of several key 
enzymes of the central carbohydrate metabolism further analyses were performed in order 
to validate differences in the metabolomes of both cell types. Furthermore, the impact of a 
differential glucose metabolism in SkMCs on T. gondii bradyzoite formation was assessed. 
 
3.3.1 Differences in carbohydrate metabolism in T. gondii-infected and non-
infected myotubes and myoblasts 
Glucose is the most important hexose sugar and has a central role as an energy source in 
most organisms including mammals and T. gondii. Glucose can be catabolized via the 
pentose phosphate pathway (PPP) to generate reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) and ribose sugars for synthesis of nucleotides. Alternatively, it may 
undergo complete oxidation via glycolysis and the TCA cycle for energy production. 
Finally, it can be utilized for synthesis of glycogen. In this study, glucose catabolism was 
monitored in non-infected and T. gondii-infected myotubes and myoblasts to determine 
differences in central carbohydrate metabolic pathways and their modulation by T. gondii 
in both cell types. To this end, gas chromatography-mass spectrometry (GC-MS) analysis 
of cells previously labeled with 
13
C-glucose was performed to measure labeled carbon 
incorporation into metabolites of the PPP, glycolysis and the TCA cycle (in collaboration 
with Izabela Swierzy, Göttingen and Martin Blume, Melbourne). Consistent with the 
increased expression of PPP enzymes in myoblasts as compared to myotubes (see 3.2.9), 
the percentage of 
13
C-incorporation into the PPP metabolite ribulose-5-phosphate was 
significantly higher in myoblasts compared to myotubes irrespective of infection. This 
suggested that myoblasts exhibit higher PPP activities than myotubes (Figure 3.10A). On 
the other hand, no significant differences in the percentages of labeled carbon 
incorporation into intermediates of glycolysis were detected between both non-infected or 
infected myotubes and myoblasts thus suggesting similar glycolytic activities in both cell 
types (Figure 3.10B). In contrast, statistically increased percentages of labeled carbon 
incorporation into the intermediates of the TCA cycle (i.e., citric acid, glutamic acid, 
succinic acid, fumaric acid, malic acid and aspartic acid) were detected in infected and 
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non-infected myotubes as compared to infected and non-infected myoblasts. Infection of 
both cell types with T. gondii had no impact on the percentages of 
13
C incorporation into 
TCA cycle metabolites.  This indicated that myotubes exhibit higher TCA cycle activities 
than myoblasts (Figure 3.10C). From these results it can be concluded that myoblasts and 




Figure 3.10: Mass spectrometric analysis of glucose catabolism in non-infected and T. gondii-infected 
myotubes and myoblasts. C2C12 myoblasts were induced to differentiate into poly-nucleated myotubes. 
Both myotubes and myoblasts were infected with T. gondii tachyzoites or were left non-infected. Six hours 
after infection, infected and non-infected myoblasts and myotubes were incubated in medium supplemented 
with 
13
C -Glucose for additional 4 hours. After metabolite extraction, incorporation of 
13
C into metabolites of 
the pentose phosphate pathway, glycolysis and the TCA cycle was analyzed by GC-MS. (A) Percentage of 
labeled carbon incorporation into ribulose-5-P generated by the pentose phosphate pathway. (B) Percentages 
of labeled carbon incorporation in metabolites of glycolysis. (C)  Percentages of labeled carbon incorporation 
in metabolites of the TCA cycle. Results are depicted as means ± S.E.M. from three independent 
experiments. Significant differences were identified by Students t-test and ANOVA (* p<0.05). 
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3.3.2 Myotubes preferentially channel glycolytic pyruvate into the TCA cycle 
via anaplerotic reactions 
Since myotubes showed higher incorporation of 
13
C from glucose into TCA cycle 
metabolites than myoblasts, it was important to understand how the labeled carbon atom of 
13
C-glucose entered into the TCA cycle. Glucose-derived pyruvate can enter the TCA cycle 
via acetyl-CoA and the pyruvate dehydrogenase complex or through the anaplerotic 
reaction of the pyruvate carboxylase.  
 
 
Figure 3.11: Myotubes channel glycolytic carbon into the TCA cycle more readily through anaplerotic 
reactions than myoblasts. C2C12 myoblasts were induced to differentiate into poly-nucleated myotubes. 
Both myotubes and myoblasts were infected with T. gondii tachyzoites. Six hours after infection, T. gondii-
infected and non-infected myoblasts and myotubes were incubated in medium supplemented with 
13
C-
glucose for additional 4 hours. After metabolite extraction, incorporation of 
13
C into metabolites of TCA 
cycle was analyzed by GC-MS. Relative abundance of labelled carbon (
13
C) within individual intermediates 
of the TCA cycle as for instance citrate, glutamate (right panel) and oxaloacetate, malate (left panel) are 
indicated. Data are derived from one experiment. The diagram in middle shows glucose metabolic pathways 
through glycolysis and TCA cycle. The abundance of glucose-derived 
13
C within TCA cycle intermediates 
are depicted when pyruvate preferentially enters into the TCA cycle through the pyruvate carboxylase 
reaction (red circles) or the pyruvate dehydrogenase complex reaction (blue circles). Higher abundance of 
three 
13
C atoms each within TCA cycle intermediates in myotubes as compared to myoblasts is highlighted 
by red boxes within the bar graphs. 
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To answer the question, SkMCs were fed with 
13
C-glucose and after extraction, masses of 
TCA cycle metabolites were measured by GC-MS. Data showed that oxaloacetate, malate, 
glutamate and citrate from infected and non-infected myotubes more readily presented 
masses that indicated the presence of three heavy carbon atoms (
13
C, indicated by red 
circles in Figure 3.11) but not two 
13
C (indicated by blue circles) when compared to 
myoblasts (Figure 3.11). This indicated that in myotubes, glucose-derived 
13
C entered into 
the TCA cycle more preferentially through the pyruvate carboxylase reaction (TCA cycle 
anaplerosis) than in myoblasts. Again, no differences were observed between T. gondii-
infected and non-infected SkMCs (Figure 3.11). 
 
3.3.3 Dehydroepiandosterone accelerates T. gondii bradyzoite differentiation 
in myotubes and myoblasts 
Results of this study have shown that enzymes of the PPP including G6PDH2 and G6PDH 
(X-linked) were upregulated in infected and non-infected myoblasts as compared to 
myotubes (Figures 3.8A,B and 3.9A,B). Furthermore, GC-MS analysis suggested higher 
PPP activities in myoblasts than in myotubes (Figure 3.10A). These results raised 
questions on the importance of the PPP on T. gondii bradyzoite development in SkMCs 
since differentiated myotubes but not proliferating myoblasts support bradyzoite 
differentiation (Figure 3.1; Swierzy & Lüder 2014). Therefore, I next established 
pharmacological inhibition of G6PDH, i.e. the rate-limiting enzyme of the PPP in T. 
gondii-infected myoblasts as well as myotubes to determine its impact on bradyzoite 
differentiation in the parasite. For this purpose, dehydroepiandosterone (DHEA) was used 
as an inhibitor of G6PDH (Figure 3.12; Schwartz & Pashko 2004). Myoblasts and 
myotubes were treated with 50 µM and 100 µM of DHEA or were mock-treated, followed 
by T. gondii infection one hour later. At 2 days of infection, total RNA was isolated and 
the expression of T. gondii BAG1 was examined by RT-qPCR. Interestingly, data showed 
significant upregulation of BAG1 mRNA from parasites in DHEA-treated myoblasts and 
myotubes compared to mock-treated cells. Furthermore, BAG1 induction by DHEA was 
much stronger in T. gondii within myoblasts than in myotubes (Figure 3.13A). This result 
suggested that inhibition of G6PDH by DHEA favor T. gondii bradyzoite development 
particularly in myoblasts and to a lesser extent also in myotubes. 
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As reduced parasite replication is considered a prerequisite for increased bradyzoite 
differentiation (Bohne et al., 1994), I also determined the effect of DHEA on parasite 
replication in myotubes and myoblasts. Parasite replication was assessed in DHEA-treated 
or mock-treated myoblasts and myotubes after 48 hours of infection by 
immunofluorescence staining. Increased replication of T. gondii was confirmed to occur in 
mock-treated myoblasts as compared to mock-treated myotubes as previously described 
(Swierzy and Lüder, 2014). DHEA at 100 µM reduced parasite replication by two-fold in 
myotubes as compared to treatment with the solvent. Interestingly, a three- and four-fold 
reduction in parasite replication was observed after treatment of myoblasts with 50 µM or 
100 µM DHEA (Figure 3.13C). Consistently, parasitophorous vacuoles were smaller in 
DHEA-treated samples compared to mock-treated ones in both myotubes and myoblasts 
(Figure 3.13B). Therefore, it can be concluded that inhibiting the G6PDH by DHEA 
inhibits parasite replication and enhances bradyzoite differentiation primarily in myoblasts 
but to a lesser extent also in myotubes. 
I next determined whether increased expression of bradyzoite specific genes (BAG1) and 
reduced parasite replication after DHEA treatment would also lead to the formation of 
tissue cysts. Cyst formation was thus evaluated in DHEA- or solvent-treated myoblasts and 
myotubes by staining of the cyst wall using the Dolichos biflorus lectin. Results showed a 
trend towards increasing numbers of cysts in DHEA-treated myoblasts and myotubes 
compared to mock treatment after 48 and 72 hours of infection. Cysts numbers were 
significantly increased in myoblasts treated with 100 µM DHEA at 72 hours of infection 
(Figure 3.13D).   
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Figure 3.12: Schematic diagram of glucose metabolism via pentose phosphate pathway, glycolysis and 
TCA cycle. Different inhibitors/modulators were used to analyse the impact of metabolic pathways on T. 
gondii bradyzoite differentiation in myotubes and myoblasts. Dehydroepiandosterone (DHEA) and 6-
aminonicotinamide (6-AN) inhibits glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate 
dehydrogenase (6PGDH), respectively. Phenylacetic acid (PAA) inhibits pyruvate carboxylase whereas 
sodium-L-lactate and dimethyl-α-ketoglutarate (DMKG) are used as modulators of anaerobic glycolysis and 
TCA cycle, respectively. LDH indicates lactate dehydrogenase which catalyses reversible conversion of 
pyruvate to lactic acid, the last reaction of anaerobic glycolysis. 
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Figure 3.13: Dehydroepiandosterone (DHEA) induces T. gondii bradyzoite differentiation and tissue 
cyst formation in myoblasts and myotubes. C2C12 myoblasts were induced to differentiate into myotubes. 
Both myotubes and myoblasts were treated with 50 µM and 100 µM of DHEA or were mock-treated, 
followed by T. gondii infection 1 hour later at a host cell-to-parasite ratio of 1:3.5.  (A) After 48 hours of 
infection, total RNA was isolated, mRNA was reverse transcribed and cDNA was amplified using specific 
primers for T. gondii bradyzoite antigen 1 (BAG1) and T. gondii actin (TgActin) by quantitative real-time 
PCR. The relative increase in BAG1 mRNA by DHEA as compared to mock treatment was calculated and 
was normalized to TgActin mRNA. Results were depicted as means ± S.E.M. from six independent 
experiments. Significant differences were identified by Student’s t-test (* p<0.05 and **p<0.01). (B) Cells 
were fixed at 48 hours post infection with 4 % paraformaldehyde and parasites were immunolabeled using a 
polyclonal anti-T. gondii antiserum and Cy2-conjugated  secondary antibodies (green fluorescence). Host 
cells were visualized using propidium iodide (red fluorescence). Representative images of both labelings 
were recorded by confocal laser scanning microscopy and were superimposed. (C) After cells had been 
fluorescently labeled as described in (B), the average size of parasitophorous vacuoles (PVs) in each sample 
was determined by counting the number of parasites in 100 PVs. Data represent means ± S.E.M. from two 
independent experiments. (D) Cells were fixed at 48 and 72 hours post infection with 4 % paraformaldehyde. 
Tissue cysts of T. gondii were labeled with biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated 
streptavidin, parasites were labeled with a polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary 
antibodies and host cells were visualized using propidium iodide. The numbers of cyst were counted in 100 
fields of vision (FV). Data represent means ± S.E.M. from two independent experiments. Significant 
differences were identified by Student’s t-test (* p<0.05). 
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3.3.4 NADP+/NADPH levels in T. gondii-infected myoblasts and myotubes and 
their modulation by DHEA-mediated inhibition of G6PDH 
A main function of the PPP is to provide NADPH for synthesis purposes and regulation of 
cellular redox homeostasis. In order to determine differences in NADP
+
/NADPH levels in 
T. gondii-infected myoblasts and myotubes their levels were measured using a colorimetric 
test system. Furthermore, this test was used to determine the relative impact of DHEA on 
providing NADPH through the PPP. To this end, relative amounts of NADP(total), 
NADPH and the NADP
+
/NADPH ratios were measured in DHEA-treated or mock-treated 
T. gondii-infected myoblasts and myotubes. The results showed similar NADP(total) levels 
(NADP
+
 and NADPH) in infected control myoblasts and myotubes whereas NADPH 
levels were clearly higher in myoblasts than in myotubes as expected (Figure 3.14A). 
Consequently, the NADP
+
/NADPH ratio was clearly higher in myotubes as compared to 
myoblasts (Figure 3.14B). Treatment of parasite-infected myoblasts and myotubes with 50 
or 100 µM of DHEA had no obvious impact on total NADP levels in both cell types.The 
NADPH level was slightly reduced in myotubes treated with 50 µM but not 100 µM of 
DHEA as compared to the mock control. However, reduced levels of NADPH were 
observed in DHEA-treated myoblasts (50 µM, 100 µM) as compared to the control and this 
was statistically significant when treated with 100 µM DHEA (Figure 3.14A). This 
confirmed that DHEA at least in myoblasts inhibited PPP-derived NADPH levels by 
inhibiting the G6PDH. Furthermore, the ratio of NADP
+
/NADPH was increasing after 
treatment of myoblasts with increasing amounts of DHEA (p<0.05 at 100 µM of DHEA) 
and after treatment of myotubes with 100 µM of DHEA (Figure 3.14B). In general, 
however, DHEA had only a limited impact on NADPH levels in T. gondii-infected 
myoblasts and myotubes. 
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/NADPH measurement in T. gondii-infected myotubes and myoblasts. C2C12 
myoblasts were induced to differentiate into myotubes. Both myotubes and myoblasts were treated with 
different concentration of DHEA (50 µM and 100 µM) or were mock-treated. Following one hour of 
treatment, cells were subjected to T. gondii infection at a host cell-to-parasite ratio of 1:3.5.  After 48 hours 
of infection, cells were isolated and NADP (total) was extracted using NADP
+
/NADPH extraction buffer. 
Then samples were filtered through 10 kDa spin filter to deproteinize them in order to avoid consumption of 
NADPH by the enzymes. The samples were then used for colorimetric measurement of NADP total (NADP
+
 
and NADPH) or NADPH at 450 nm using a multilabel plate reader. Levels of total NADP (NADP
+
 and 
NADPH) and NADPH are shown in (A) and the ratio of NADP
+
 to NADPH in (B). Results are depicted as 
means ± S.E.M. from four independent experiments. Significant differences were identified by Student’s t-
test (* p<0.05).  
 
3.3.5 6-aminonicotinamide induces T. gondii bradyzoite differentiation in 
myoblasts and myotubes 
To further validate that the effect of DHEA on T. gondii bradyzoite formation in myoblasts 
and myotubes was due to an inhibition of the PPP, an inhibitor of a second enzyme of the 
PPP, i.e. 6-aminonicotinamide (6-AN) was used. This inhibitor inhibits the 6-
phosphogluconate dehydrogenase (6PGDH) (see Figure 3.12; Lange & Proft 1970) which 
was also upregulated in myoblasts as compared to myotubes as shown in Figure 3.8C. RT-
qPCR was performed with 6-AN-treated T. gondii-infected myotubes and myoblasts to 
determine its impact on T. gondii BAG1 expression. Twenty and 100 µM of 6-AN induced 
BAG1 mRNA expression in T. gondii residing in both myotubes and myoblasts as 
compared to mock-treated controls. Remarkably, by far the highest induction of BAG1 
mRNA was observed in myoblasts treated with 100 µM of 6-AN (Figure 3.15A). Thus, 
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results obtained after inhibition of 6PGDH mirrored those as observed after inhibition of 
G6PDH. This result further indicated that pharmacologically reducing PPP activity in 
SkMCs can favor T. gondii bradyzoite development particularly in myoblasts, but also 
myotubes. 
As reduced parasite replication is a prerequisite for increased bradyzoite differentiation 
(Bohne et al., 1994), the impact of 6-AN on parasite replication was determined. To this 
end, both myotubes and myoblasts were treated with different concentrations of 6-AN or 
DMSO as the solvent. Then, parasite replication was assessed in inhibitor- and solvent-
treated cells by immunolabeling of the parasite and fluorescence confocal microscopy. 
Results indicated that parasite replication was moderately reduced in myotubes treated 
with 20 or 100 µM of 6-AN as compared to treatment with the solvent DMSO. In 
myoblasts which sustained higher parasite replication in mock-treated cells as compared to 
myotubes (Swierzy and Lüder, 2014), treatment with 20 µM and 100 µM of 6-AN 
inhibited parasite replication in a dose-dependent manner. Furthermore, 6-AN inhibited 
parasite replication in myoblasts to a clearly higher extent than in myotubes (Figure 
3.15C). The parasitophorous vacuoles were smaller in 6-AN-treated samples compared to 
mock-treated ones in both myotubes and myoblasts (Figure 3.15B). Inhibiting the PPP in 
myotubes and particularly in myoblasts by 6-AN thus slows down parasite replication and 
enhances bradyzoite differentiation. 
Next, the impact of 6-AN on T. gondii cyst formation was determined as bradyzoite 
differentiation regularly leads to the formation of a cyst wall surrounding the 
parasitophorous vacuole. Cyst formation was evaluated in 6-AN-treated or mock-treated 
myotubes and myoblasts by staining of the cyst wall using Dolichos biflorus lectin. Results 
showed mostly increased numbers of cysts in 6-AN-treated myotubes and myoblasts at 48 
and 72 hours of infection as compared to the solvent-treated control (Figure 3.15D).   
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Figure 3.15: 6-aminonicotinamide (6-AN) accelerates T. gondii bradyzoite differentiation in myoblasts 
and myotubes. C2C12 myoblasts were induced to differentiate into myotubes. Both myotubes and myoblasts 
were treated with 20 µM and 100 µM of 6-AN or were mock-treated with DMSO, followed by T. gondii 
infection at a host cell-to-parasite ratio of 1:3.5. (A) After 48 hours of infection, total RNA was isolated, 
mRNA was reverse transcribed, and cDNA was amplified using specific primers for T. gondii bradyzoite 
antigen 1 (BAG1) and T. gondii actin (TgActin ) by quantitative real-time PCR. The fold increase in BAG1 
mRNA between 6-AN-treated cells and mock-treated cells was calculated using the ΔΔCP method and was 
normalized to TgActin mRNA. Results are depicted as means ± S.E.M. from three independent experiments. 
Significant differences were identified by Student’s t-test (* p<0.05, **p<0.01). (B) Cells were fixed at 48 
hours post infection with 4 % paraformaldehyde and parasites were immunolabeled (green fluorescence) 
using a polyclonal anti-T. gondii antiserum. Host cells were visualized using propidium iodide (red 
fluorescence). Representative images of both labelings were recorded by confocal laser scanning microscopy 
and were superimposed. (C) After cells had been fluorescently labeled as indicated above, the average size of 
the parasitophorous vacuoles (PVs) in each sample was determined by counting the number of parasites in 
100 PVs. Data represent means ± S.E.M. from two independent experiments. (D) Cells were fixed at 48 and 
72 hours post infection with 4 % paraformaldehyde. After fixation, tissue cysts of T. gondii were labeled with 
biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated streptavidin, parasites were labeled with a 
polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary antibodies and host cells were visualized 
using propidium iodide. The numbers of cysts were counted in 100 fields of vision (FV). Data represent 
means ± S.E.M. from two independent experiments. 
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3.3.6 Phenyl acetic acid accelerates T. gondii BAG1 expression in myotubes 
but not in myoblasts 
Results presented before suggested that the activity of the TCA cycle enzymes were higher 
in T. gondii-infected and non-infected myotubes than in myoblasts (see Figure 3.10C). 
Furthermore, results suggested that myotubes channel glucose-derived carbohydrates more 
readily through the pyruvate carboxylase into the TCA cycle than myoblasts (Figure 3.11). 
Since myotubes and myoblasts differentially sustain bradyzoite formation in T. gondii, it 
was therefore important to unravel the impact of the pyruvate carboxylase on T. gondii 
bradyzoite differentiation in both cell types. Phenyl acetic acid (PAA) was used as an 
inhibitor of that enzyme (see Figure 3.12; Bahl et al. 1997) which catalyzes the 
carboxylation of pyruvate to oxaloacetate, an important anaplerotic reaction of the TCA 
cycle.  RT-qPCR was performed using mRNA from T. gondii-infected myotubes and 
myoblasts treated with 1 and 5 mM PAA or mock-treated to see its impact on BAG1 
expression. Unexpectedly, results indicated that PAA slightly (~1.5-fold) upregulated 
BAG1 mRNA expression in myotubes compared to mock. In contrast, PAA did not 
considerably affect BAG1 mRNA expression in T. gondii-infected myoblasts compared to 
mock with a ~20% reduction in BAG1 mRNA being observed (Figure 3.16A). In order to 
determine the effect of PAA on parasite replication in myotubes and myoblasts, 
immunofluorescence staining was performed. To this end, both myotubes and myoblasts 
were treated with concentrations of PAA as above or with ethanol as the vehicle. After 48 
hours of infection, parasite replication was assessed in inhibitor- and solvent-treated 
samples by immunolabeling of the parasite followed by confocal fluorescence microscopy. 
Results revealed no clear trend towards an altered parasite replication after PAA treatment 
with the strongest effect being a decline of parasite replication in myoblasts treated with 5 
mM PAA (Figure 3.16C). Representative images of the parasitophorous vacuoles in mock- 
and PAA-treated myotubes and myoblasts are shown in Figure 3.16B. 
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Figure 3.16: Impact of phenyl acetic acid on T. gondii BAG1 mRNA expression, parasite replication 
and cyst formation in myotubes and myoblasts. C2C12 myoblasts were induced to differentiate into 
myotubes. Both myotubes and myoblasts were treated with 1 mM and 5 mM of PAA or were mock-treated. 
After one hour of treatment, cells were infected with T. gondii at a host cell-to-parasite ratio of 1:3.5.  (A) At 
48 hours post infection, total RNA was isolated, mRNA was reverse transcribed and cDNA was amplified 
using specific primers for T. gondii bradyzoite antigen 1 (BAG1) and T. gondii actin (TgActin) by 
quantitative real-time PCR. The fold increase in BAG1 mRNA between PAA-treated and mock-treated cells 
was calculated according to the ΔΔCP method in myotubes and myoblasts and was normalized to TgActin 
mRNA. Results are depicted as means ± S.E.M. from three independent experiments. Significant differences 
were identified by Student’s t-test (* p<0.05). (B) Cells were fixed at 48 hours post infection with 4 % 
paraformaldehyde and parasites were immunolabeled (green fluorescence) using a polyclonal anti-T. gondii 
antiserum. Host cells were visualized using propidium iodide (red fluorescence). Representative images of 
both labelings were recorded by confocal laser scanning microscopy and were superimposed. (C) After cells 
had been fluorescently labeled as indicated above, the average size of parasitophorous vacuoles (PVs) in each 
sample was determined by counting the number of parasites in 100 PVs. Data represent means ± S.E.M. from 
two independent experiments. (D) Cells were fixed at 48 and 72 hours post infection with 4 % 
paraformaldehyde. After fixation, tissue cysts of T. gondii were labeled with biotin-conjugated Dolichos 
biflorus lectin and Cy2-conjugated streptavidin, parasites were labeled with a polyclonal anti-T. gondii 
antiserum and Cy5-conjugated secondary antibodies  and host cells were visualized using propidium iodide. 
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In order to determine the impact of PAA on T. gondii cyst formation, immunofluorescence 
and lectin-based staining was performed as described above. Surprisingly, cyst counts were 
decreased in PAA-treated myotubes after 48 hours of infection whereas increased cyst 
counts were observed after 72 hours of infection. Cysts formation was not prominently 
altered in PAA-treated myoblasts after 48 and 72 hours of infection compared to the mock 
control (Figure 3.16D). Together, these results indicate that inhibition of the pyruvate 
carboxylase has only a minor and ambiguous impact of T. gondii stage differentiation in 
SkMCs.  
 
3.3.7 Dimethyl-α-ketoglutarate accelerates T. gondii BAG1 expression in 
myoblasts 
As another approach to modulate TCA cycle activities in T. gondii-infected myotubes and 
myoblasts and to determine its impact on bradyzoite differentiation, dimethyl-α-
ketoglutarate (DMKG) was used to fuel the TCA cycle activities (see Figure 3.12). RT-
qPCR was performed on mRNA isolated from cells treated with 5 mM or 10 mM of 
DMKG or mock-treated. Results revealed no induction of BAG1 mRNA expression in T. 
gondii within myotubes treated with 5 mM DMKG but an increased BAG1 expression in 
those parasites within myotubes treated with 10 mm DMKG compared to mock. 
Interestingly, T. gondii within myoblasts clearly up-regulated BAG1 expression in both 5 
mM and 10 mM DMKG-treated cells and this reached statistical significance after 
treatment with 10 mM DMKG compared to mock (Figure 3.17A). In order to evaluate the 
impact of DMKG on parasite replication, immunofluorescence staining was performed. To 
this end, both myotubes and myoblasts were treated with concentrations of DMKG as 
above or were mock-treated. Then, parasite replication was assessed in DMKG-treated 
versus mock-treated samples by immunolabeling of the parasite. Unexpectedly, parasite 
replication was increased two times in DMKG-treated myotubes compared to the solvent 
DMSO. In contrast, parasite replication was clearly and dose-dependently reduced in 
myoblasts treated with increasing amounts of DMKG. Thus, it appeared from these results 
that fueling the TCA cycle with DMKG enhances parasite replication in myotubes but 
inhibits replication in myoblasts (Figure 3.17C). Representative images of parasitophorous 
vacuoles within the different host cells are shown in Figure 3.17B. 
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Figure 3.17: Dimethyl-α-ketoglutarate induces T. gondii BAG1 expression and reduces parasite 
replication in myoblasts. C2C12 myoblasts were induced to differentiate into myotubes.
 
Both myotubes and 
myoblasts were treated with 5 mM and 10 mM of dimethyl-α-ketoglutarate (DMKG) or were DMSO-treated 
(mock). After 1 hour, cells were infected with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5. 
(A) After 48 hours of infection, total RNA was isolated, mRNA was reverse transcribed and cDNA was 
amplified using specific primers for T. gondii bradyzoite antigen 1 (BAG1) and T. gondii GAPDH 
(TgGAPDH) by quantitative real-time PCR. The fold increase in BAG1 mRNA between DMKG-tretaed and 
mock-treated cells was calculated using the ΔΔCP method in myotubes and myoblast and was normalized to 
TgGAPDH mRNA. Results are depicted as means ± S.E.M. from three independent experiments. Significant 
differences were identified by Student’s t-test (* p<0.05). (B) Cells were fixed at 48 hours post infection with 
4 % paraformaldehyde and parasites were immunolabeled (green fluorescence) using a polyclonal anti-T. 
gondii antiserum. Host cells were visualized using propidium iodide (red fluorescence). Representative 
images of both labelings were recorded by confocal laser scanning microscopy and were superimposed. (C) 
After cells had been fluorescently labeled as indicated in (B), the average size of parasitophorous vacuoles 
(PVs) in each sample was determined by counting the number of parasites in 100 PVs. Data represent means 
± S.E.M. from two independent experiments. (D) Cells were fixed at 48 and 72 hours post infection with 4 % 
paraformaldehyde. After fixation, tissue cyst of T. gondii were labeled with biotin-conjugated Dolichos 
biflorus lectin and Cy2-conjugated streptavidin, parasites were labeled with a polyclonal anti-T. gondii 
antiserum and Cy5-conjugated secondary antibodies and host cells were visualized using propidium iodide. 
The number of cysts were counted in 100 fields of vision (FV). Data represent means ± S.E.M. from two 
independent experiments.  
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Finally, T. gondii cyst formation was evaluated in DMKG-treated versus DMSO-treated 
myotubes and myoblasts by staining the cyst wall with Dolichos biflorus lectin and the 
parasite population with a polyclonal antiserum. Data revealed a trend towards a decreased 
number of cysts in DMKG-treated myotubes compared to DMSO at 48 hours of infection. 
However, no differences were observed in cyst formation between DMKG-treated and 
mock-treated myoblasts at 48 hours of infection and in both cell types at 72 hours of 
infection (Figure 3.17D). Cyst counts could not be determined in cells treated with 10 mM 
DMKG due to a toxic effect on host cells during prolonged cultivation. Together, these 
data establish that fueling the TCA cycle in myoblasts with DMKG clearly increases 
BAG1 expression and reduces parasite replication but does not promote tissue cyst 
formation. 
 
3.3.8 Sodium-L-lactate induces T. gondii BAG1 expression in myoblasts but 
not in myotubes 
Through mass spectrometric analysis, it has been shown that myotubes and myoblasts do 
not considerably differ in the levels of carbon incorporation into metabolites of glycolysis 
irrespective of T. gondii infection (see Figure 3.10B). However, in a previous study it was 
shown that upregulation of glycolysis by the addition of glucose or forced expression of 
host kinase Akt release soluble metabolites including lactate from the cells which can 
inhibit bradyzoite differentiation in human foreskin fibroblasts (HFF) or Vero cells which 
are normally permissive for stage conversion under stress conditions (Weilhammer et al., 
2012). For this reason, anaerobic glycolysis was modulated here using sodium-L-lactate 
(see Figure 3.12) to determine its effect on BAG1 expression in T. gondii residing in either 
myotubes or myoblasts. RT-qPCR was performed on mRNA from T. gondii-infected 
myotubes and myoblasts treated with 1 and 3 mM of sodium-L-lactate or mock-treated. 
Sodium-L-lactate had no impact on BAG1 mRNA expression in myotubes as compared to 
mock-treated cells. In contrast, sodium-L-lactate-treated myoblasts clearly sustained 
increased BAG1 mRNA expression in T. gondii in a dose-dependent manner as compared 
to mock controls. However, this increase was not statistically significant due to high 
variances between individual experiments (Figure 3.18A). 
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Figure 3.18: Lactate can increase BAG1 expression and cyst formation and can inhibit parasite 
replication in T. gondii within myoblasts but not in myotubes. C2C12 myoblasts were induced to 
differentiate into myotubes.
   
Both myotubes and myoblasts were treated with 1 mM and 3 mM of sodium-L-
lactate or were treated with water as solvent. After 1 hour, cells were then infected with T. gondii tachyzoites  
at a host cell-to-parasite ratio of 1:3.5. (A) Total RNA was isolated after 48 hours of infection and mRNA 
was reverse transcribed to cDNA which was amplified using specific primers for T. gondii bradyzoite antigen 
1 (BAG1) and T. gondii GAPDH (TgGAPDH) as housekeeping gene by quantitative real-time PCR. The fold 
increase in BAG1 expression between sodium-L-lactate and mock-treated cells was calculated according to 
the ΔΔCP method and was normalized to TgGAPDH mRNA. Results were depicted as means ± S.E.M. from 
four independent experiments. (B) Cells were fixed at 48 hours post infection with 4 % paraformaldehyde 
and parasites were immunolabeled (green fluorescence) using a polyclonal anti-T. gondii antiserum. Host 
cells were visualized using propidium iodide (red fluorescence). Representative images of both labelings 
were recorded by confocal laser scanning microscopy and were superimposed. (C) After cells had been 
fluorescently labeled as indicated above, the average size of parasitophorous vacuoles (PVs) in each sample 
was determined by counting the number of parasites in 100 PVs. Data represent means ± S.E.M. from two 
independent experiments. (D) Cells were fixed at 48 and 72 hours post infection with 4 % paraformaldehyde. 
Tissue cysts of T. gondii were labeled with biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated 
streptavidin, parasites were labeled with a polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary 
antibodies  and host cells were visualized using propidium iodide. The number of cysts was counted in 100 
fields of vision (FV). Data represent means ± S.E.M. from two independent experiments.  
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In order to determine the impact of sodium-L-lactate on parasite replication in myotubes 
and myoblasts, immunofluorescence stainings were performed. Results showed that 
parasite replication was increased in sodium-L-lactate treated myotubes compared to mock 
controls. Remarkably, the opposite effect was seen in myoblasts where parasite replication 
was dose-dependently decreased by sodium-L-lactate compared to mock thus being 
consistent with the increased BAG1 expression in these cells (Figure 3.18C). 
Immunofluorescence microscopy also indicated that parasitophorous vacuoles were larger 
in lactate-treated myotubes as compared to mock control whereas they were smaller in 
lactate-treated myoblasts (Figure 3.18B). 
To determine the effect of sodium-L-lactate on T. gondii cysts formation in myotubes and 
myoblasts, staining of the cyst wall surrounding the parasitophorous vacuole was 
performed. Results showed similar patterns of cyst formation in sodium-L-lactate treated 
myotubes and myoblasts after 48 hours of infection with slightly higher cyst numbers in 
both myoblasts and myotubes treated with 1 mM sodium-L-lactate as compared to mock 
controls. After 72 hours of infection, cyst numbers had increased in myoblasts treated with 
1 and 3 mM sodium-L-lactate compared to mock controls, whereas a trend towards lower 
cyst numbers were observed in sodium-L-lactate-treated myotubes (Figure 3.18D). 
Together, these results suggest that increased lactate concentrations can accelerate BAG1 
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3.4 Impact of redox homeostasis on T. gondii bradyzoite differentiation 
in SkMCs 
Redox homeostasis is a balance between oxidative and reductive processes in a cell. 
Oxidative processes include formation of reactive oxygen species (ROS) that are normally 
produced as a byproduct of metabolic reactions. Reductive processes include formation of 
cellular antioxidants which are required in a cell for maintainenec of redox homeostasis. It 
was observed that myotubes and myoblasts differ in glucose metabolic pathways as for 
instance myotubes had lower PPP activities than myoblasts (Figure 3.10A). Hence, 
myotubes may contain lower levels of NADPH which might lead to differences in redox 
potential in myotubes and myoblasts. The redox potential might also have a role in T. 
gondii bradyzoite differentiation in myotubes. Previously, it was shown that host cell-
mediated ROS production suppresses T. gondii replication in human retinal pigment 
epithelial cell (ARPE-19). Subsequently, modulation of ROS level using siRNA 
knockdown of host NADPH oxidase-4 (NOX-4) therefore increased parasite replication 
(Zhou et al., 2013). Hence, it was hypothesized that cellular ROS may play a role in 
parasite replication and T. gondii bradyzoite differentiation in myotubes. 
 
3.4.1 Myotubes produce lower NADPH levels and higher ratio of 
NADP
+
/NADPH than myoblasts 
As hypothesized above reduced activities of PPP enzymes in T. gondii-infected myotubes 
may lead to the formation of lower NADPH levels in these cells. The levels of NADPH 
and total NADP (NADP
+
 and NADPH) were measured colorimetrically in myotubes and 
myoblasts using a NADP
+
/NADPH quantification kit. Both myotubes and myoblasts were 
infected with T. gondii or were left non-infected and cells were extracted for isolation and 
measurement of total NADP and NADPH. As already indicated in 3.3.4, infected 
myotubes and myoblasts did not differ in total NADP concentrations (i.e. NADP
+
 and 
NADPH) and the same also applied to non-infected SkMCs. However, NADPH 
concentrations were clearly lower in both infected and non-infected myotubes as compared 
to myoblasts being in agreement with their decreased PPP activities (Figure 3.19A). 
Importantly, the ratio of NADP
+
 to NADPH was consequently two fold higher in both non-
infected and T. gondii-infected myotubes than in myoblasts (Figure 3.19B). Thus, the 
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differences in the PPP as observed between myotubes and myoblasts resulted in significant 
differences in the levels of reducing equivalents in both cell types irrespective of infection.  
 
Figure 3.19: Myotubes produce reduced levels of NADPH as compared to myoblasts and have a higher 
NADP
+
/NADPH ratio. C2C12 myoblasts were induced to differentiate into myotubes. Both myotubes and 
myoblasts were infected with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5.  After 48 hours of 
infection, cells were isolated and total NADP (i.e. NADP
+
 and NADPH) was extracted using NADP/NADPH 
extraction buffer. Then, samples were filtered through 10 kDa spin filters to deproteinize them in order to 
avoid consumption of NADPH by the enzymes. The samples along with standard NADPH were then used for 
colorimetric measurement of NADP total (NADP
+
 and NADPH) or NADPH at 450 nm using a multilabel 
plate reader. (A) Concentrations of total NADP (i.e. NADP
+
 and NADPH) and NADPH only were measured 
in samples by comparing with the abosorbance of standard concentrations of NADPH. (B) Ratio of 
NADP
+
/NADPH was calculated from the concentration of NADP
+
 (i.e. total NADP minus NADPH) and 
NADPH only. Results are depicted as means ± S.E.M. from four independent experiments. Significant 
differences were identified by Student’s t-test (* p<0.05).  
 
3.4.2 CellROX staining indicates higher ROS levels in T. gondii-infected 
myoblasts than in myotubes 
Higher NADP
+
/NADPH levels in T. gondii-infected and non-infected myotubes (see 
Figure 3.19) due to decreased PPP activities (see Figure 3.10A) might favor T. gondii 
bradyzoite formation due to increased oxidative stress in these cells (Kuehne et al., 2015). 
I therefore wondered whether reduced levels of NADPH as observed in myotubes 
compared to myoblasts have any impact on the levels of reactive oxygen species (ROS) in 
myotubes.  
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Figure 3.20: ROS staining in T. gondii-infected and non-infected myotubes and myoblasts. C2C12 
myoblasts were induced to differentiate into myotubes. Both myotubes and myoblasts were infected with T. 
gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5. After 48 hours of infection, non-infected cells were 
partially treated with the oxidant luperox at 200 µM for 60 minutes. Infected and non-infected cells were then 
stained with 5 µM CellROX green for 30 minutes. (A) After fixation with 4% paraformaldehyde for 15 
minutes, cells were stained with propidium iodide (red fluorescence) and ROS-positive nuclei (green) per 
200 nuclei were counted. Data are shown as mean percentages ± S.E.M. from three independent experiments. 
Significant differences were identified by Student’s t-test (* p<0.05). (B) Representative images of both 
labelings were recorded by confocal laser scanning microscopy and were superimposed. To identify parasite-
positive cells (marked by arrows) images of the propidium iodide staining alone are also depicted. 
 
To address this question, CellROX green staining was used to stain intracellular ROS in 
both non-infected and T. gondii-infected myotubes and myoblasts. CellROX green is a 
DNA dye that binds to the DNA primarily in the nucleus and mitochondria upon oxidation 
and thereby produces a green fluorescence predominantly within nuclei but also the 
cytoplasm. Results showed less than 30% ROS-positive nuclei in myotubes whereas up to 
55 % of the nuclei were ROS-positive in myoblasts. Percentages of ROS-positive nuclei 
differed between myoblasts and myotubes irrespective of whether cells had been infected 
with T. gondii or not (Figure 3.20A). Thus, ROS levels appeared higher in myoblasts than 
in myotubes despite increased NADPH in these cells. Luperox (tert-butyl-hydroperoxide) 
at 200 µM was used as a potent oxidant that led to ~60% ROS-positive nuclei in both cell 
types (Figure 3.20A). Representative images of Luperox-treated, non-infected and T. 
gondii-infected myoblasts and myotubes are shown in Figure 3.20B. Infected cells were 
identified by staining of parasite nuclei with propidium iodide (indicated by arrows in 
Figure 3.20B) although their identification was hampered by the concomitant staining of 
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the host cell. Together, this result suggests that reduced levels of ROS are present in 
myotubes as compared to myoblasts. Hence, it was important to determine whether this 
low level of intracellular ROS in myotubes may play role in T. gondii bradyzoite 
differentiation. 
 
3.4.3 Modulation of ROS in SkMCs using antioxidants and its impact on T. 
gondii bradyzoite differentiation 
Antioxidants are compounds that can detoxify free oxygen radicals and thereby protect 
against ROS in cells including SkMCs (Sriram et al., 2011). I therefore aimed to modulate 
ROS levels in SkMCs in order to determine its putative impact on T. gondii bradyzoite 
differentiation in myotubes and myoblasts. 
 
3.4.3.1  N-acetyl cysteine inhibits T. gondii bradyzoite differentiation in myotubes and 
myoblasts 
Results presented above indicated ROS production in both myotubes and myoblasts 
irrespective of T. gondii infection but the level of ROS was lower in myotubes as 
compared to myoblasts (see Figure 3.20). Therefore, it was speculated that the lower level 
of endogenous ROS as observed in myotubes might provide an appropriate signal to the 
parasite for stage conversion. To further confirm a putative effect of intracellular ROS on 
T. gondii stage differentiation, ROS levels were modulated through scavenging by using a 
well known antioxidant, N-acetyl cysteine (NAC). NAC reduces intracellular ROS levels 
either by neutralizing  hydroxyl radicals (•OH) or by providing intracellular reduced 
glutathione (Aruoma et al., 1989; Lasram et al., 2015). To this end, RT-qPCR was 
performed with mRNA from NAC- or solvent-treated T. gondii-infected myotubes and 
myoblasts to examine BAG1 mRNA expression. Results showed that BAG1 mRNA 
expression was significantly reduced in both myotubes and myoblasts treated with 5 and 
10 mM NAC as compared to mock-treated cells. Interestingly, a particularly strong 
reduction of BAG1 mRNA expression was observed in T. gondii residing in NAC-treated 
myoblasts as compared to the mock control (Figure 3.21A).  
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In order to determine the effect of NAC on parasite replication, immunofluorescence 
staining was performed in NAC- and solvent-treated, T. gondii infected myotubes and 
myoblasts after 48 hours of infection. Results showed that NAC (5 mM and 10 mM) 
strongly induced (3-fold) parasite replication in myotubes compared to mock treated cells. 
However, statistically significant increase of parasite growth was also observed in NAC-
treated myoblasts compared to mock-treated but the induction of parasite replication was 
not as strong as seen in case of myotubes (Figure 3.21C). The microscopic images (Figure 
3.21B) confirmed that the sizes of the parasitophorous vacuoles increased in myotubes and 
myoblasts that had been treated with 5 mM and 10 mM NAC compared to mock-treated 
cells.  
Finally, the impact of NAC on T. gondii tissue cyst formation was evaluated after staining 
of the cyst wall with Dolichos biflorus lectin. Cyst formation was significantly inhibited in 
myotubes treated with 5 to 10 mM NAC compared to the mock controls at both after 48 
and 72 hours of infection (Figure 3.21D). In myoblasts, however, there was no effect of 
NAC on cysts formation after 48 hours of infection and only a slightly reduced cysts 
formation was observed in NAC-treated samples compared to mock after 72 hours of 
infection (Figure 3.21D). Above results indicated that ROS scavenging in myotubes and 
myoblasts using antioxidant NAC inhibits T. gondii BAG1 expression in both myoblasts 
and myotubes but inhibits tissue cyst formation in myotubes only.  
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Figure 3.21: N-Acetyl cysteine inhibits T. gondii bradyzoite differentiation in myotubes and myoblasts 
but tissue cyst formation in myotubes only. C2C12 myoblasts were induced to differentiate into myotubes.
 
Both myotubes and myoblasts were treated with 5 mM and 10 mM NAC or were mock-treated. After one 
hour, cells were infected with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5.  (A) Total RNA 
was isolated at 48 hours post infection and mRNA was reverse transcribed to cDNA which was amplified 
using specific primers for T. gondii bradyzoite antigen 1 (BAG1) and T. gondii actin (TgActin) by 
quantitative real-time PCR. The fold increase in BAG1 mRNA between NAC-treated and mock-treated cells 
was calculated using the ΔΔCP method and was normalized to TgActin mRNA. Results are depicted as 
means ± S.E.M. from five independent experiments. Significant differences were identified by Students t-test 
(* p<0.05 and ** p<0.01). (B) Cells were fixed at 48 hours post infection with 4 % paraformaldehyde and 
parasites were immunolabeled (green fluorescence) using a polyclonal anti-T. gondii antiserum. Host cells 
were visualized using propidium iodide (red fluorescence). Representative images of both labelings were 
recorded by confocal laser scanning microscopy and were superimposed. (C) After cells had been 
fluorescently labeled as described in (B), the average size of parasitophorous vacuoles (PVs) in each sample 
was determined by counting the number of parasites in 100 PVs. Data represent means ± S.E.M. from three 
independent experiments. Significant differences were identified by Students t-test (* p<0.05, ** p<0.01). 
(D) Cells were fixed at 48 and 72 hours post infection with 4 % paraformaldehyde.  After fixation, tissue 
cysts of T. gondii were labeled with biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated 
streptavidin, parasites were labeled with a polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary 
antibodies and host cells were visualized using propidium iodide. The numbers of DBL-positive cysts were 
counted in 100 parasitophorous vacuoles (PV) and were expressed as percentages. Data represent means ± 
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3.4.3.2 Tiron induces T. gondii BAG1 mRNA expression but not cyst formation in 
myotubes and myoblasts 
Tiron is another antioxidant that can scavenge ROS (Taiwo, 2008). In this study, tiron was 
used to scavenge intracellular ROS in myotubes and myoblasts and to evaluate its effect on 
T. gondii bradyzoite differentiation in order to validate the effect of NAC (see Figure 
3.21). RT-qPCR was performed with myoblasts and myotubes treated with tiron or solvent 
and infected with T. gondii. Results showed that tiron significantly and dose-dependently 
upregulated BAG1 mRNA expression in T. gondii within myotubes compared to mock. 
When T. gondii resided in myoblasts, tiron also induced BAG1 mRNA expression 
compared to mock controls but this did not reach statistical significance due to 
considerable variance between experiments (Figure 3.22A). However, the effect of tiron on 
BAG1 mRNA expression was clearly not consistent with the results obtained after NAC-
treatment.  
Next, the impact of tiron on parasite replication in myoblasts and myotubes was analysed. 
To this end, immunofluorescence staining was performed with tiron- or solvent-treated 
myotubes and myoblasts 48 hours after infection. Parasite replication was inhibited in 
myotubes and particularly in myoblasts after treatment with tiron compared to mock-
treated cells. It has to be stressed however, that parasite replication was completely 
blocked in myotubes and myoblasts treated with tiron at 3 mM and 5 mM (Figure 3.22C). 
It can thus not be ruled out that tiron had a direct and adverse effect on the parasite that 
might have caused induction of BAG1 mRNA expression in T. gondii within both cell 
types. Representative microscopic images confirmed that parasitophorous vacuoles 
contained only very few or single parasites after treatment of myoblasts and myotubes with 
1 to 5 mM tiron (Figure 3.22B). Finally, the effect of tiron on T. gondii cysts formation 
was determined. To this end, immunofluorescence and lectin-based staining of parasites 
and the cyst wall, respectively, was performed with tiron- (1 mM, 3 mM and 5 mM) or 
solvent-treated myoblasts and myotubes after infection with T. gondii. Despite induction of 
BAG1 expression and inhibition of replication, tiron clearly and dose-dependently 
inhibited T. gondii cyst formation in myotubes and myoblasts after 48 and 72 hours of 
infection (Figure 3.22D). The reduction of cyst numbers was particularly evident in 
myotubes and myoblasts at 72 hours of infection where high cyst numbers were present in 
mock-treated myotubes and to a lesser extent also in mock-treated myoblasts. 
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Figure 3.22: Tiron induces T. gondii BAG1 mRNA expression in myotubes and myoblasts but does not 
induce cyst formation. C2C12 myoblasts were induced to differentiate into myotubes.
 
Both myotubes and 
myoblasts were treated with 1 mM, 3 mM and 5 mM of tiron or were mock-treated. After one hour, cells 
were infected with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5.  (A) At 48 hours post 
infection, total RNA was isolated, mRNA was reverse transcribed and cDNA was amplified using specific 
primers for T. gondii bradyzoite antigen 1 (BAG1) and T. gondii actin (TgActin) by quantitative real-time 
PCR. The fold increase in BAG1 mRNA between tiron-treated and mock-treated cells was calculated by the 
ΔΔCP method and was normalized to TgActin mRNA. Results are depicted as means ± S.E.M. from three 
independent experiments. Significant differences were identified by Students t-test (* p<0.05). (B) Cells 
were fixed at 48 hours post infection with 4 % paraformaldehyde and parasites were immunolabeled using a 
polyclonal anti-T. gondii antiserum (green fluorescence). Host cells were visualized using propidium iodide 
(red fluorescence). Representative images of both labelings were recorded by confocal laser scanning 
microscopy and were superimposed. (C) After cells had been fluorescently labeled as described in (B), the 
average size of parasitophorous vacuoles (PVs) in each sample was determined by counting the number of 
parasites in 100 PVs. Data represent means ± S.E.M. from two independent experiments. (D) Cells were 
fixed at 48 and 72 hours post infection with 4 % paraformaldehyde. After fixation, tissue cysts of T. gondii 
were labeled with biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated streptavidin, parasites were 
labeled with a polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary antibodies and host cells 
were visualized using propidium iodide. The number of DBL-positive cysts were counted in 100 
parasitophorous vacuoles (PV) and were expressed as percentage of total PVs. Data represent means ± 
S.E.M. from two independent experiments. 
 
Chapter 3: Results 2017 
 
Page | 98  
 
3.4.3.3     Tiron inhibits host cell proliferation 
As Tiron possibly had a direct adverse effect on the parasite and thereby blocked parasite 
replication, I also tested its impact on the host cell, particularly on host cell proliferation. 
To this end, a BrdU incorporation assay which can visualize newly synthesized DNA was 
performed with myotubes and myoblasts treated with tiron or solvent as control. Results 
confirmed high levels of DNA synthesis in mock-treated myoblasts as sign of active 
proliferation whereas myotubes exhibited strongly reduced proliferation as expected. 
Importantly, tiron at 1 mM already strongly inhibited active SkMC proliferation as 
observed in mock-traeted myoblasts (Figure 3.23A). As myotubes were already largely cell 
cycle arrested, the effect of tiron was less evident in these cells. Representative 
microscopic images confirmed high levels of proliferation in mock-treated myoblasts but 
not myotubes which was completely inhibited after tiron treatment (Figure 3.23B). This 
result indicated that tiron, beside its function as an antioxidant also strongly inhibited 
myoblast proliferation thereby possibly contributing to increased BAG1 expression in T. 
gondii residing in these cells.  
 
Figure 3.23: Tiron inhibits DNA synthesis and proliferation of SkMCs. C2C12 myoblasts were induced 
to differentiate into poly-nucleated myotubes. Both myotubes and myoblasts were treated with 1 mM, 3 mM 
and 5 mM of tiron or were mock-treated. Cells were treated with BrdU (10 µg/ml) for 2 hours before fixation 
at 48 hours post infection. After fixation, proliferating cells were immunolabeled with antibodies recognizing 
BrdU followed by fluorescently labeled secondary antibodies (green fluorescence) and the total cell 
population was labeled with propidium iodide (red fluorescence). (A) The percentages of BrdU-labeled 
nuclei in tiron- and mock-tretaed myotubes and myoblasts were calculated by counting the number of BrdU-
positive nuclei as compared to the number of total nuclei. Data represent percentages of BrdU-positive nuclei 
from one experiment. (B) Representative images of both labelings were recorded by confocal laser scanning 
microscopy and were superimposed. 
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3.4.4 N-acetyl cysteine induces extracellular T. gondii BAG1 mRNA 
expression  
N-acetyl cysteine was found to inhibit T. gondii bradyzoite differentiation in infected 
myotubes and myoblasts (see Figure 3.21). In order to evaluate whether NAC had any 
direct effect on T. gondii thereby inhibiting stage conversion, its effect on extracellular 
parasite in the absence of host cells was determined. RT-qPCR was performed with NAC- 
or solvent-treated isolated T. gondii tachyzoites to quantify their BAG1 mRNA expression. 
Unexpectedly, results showed that NAC-treatment when compared to mock even induced 
BAG1 mRNA expression in the parasite in a dose-dependent fashion. This indicated an 
opposite effect of NAC when extracellular parasites were treated with NAC as compared to 
those treated intracellularly (Figure 3.24). From this data it can be concluded that NAC 
does not directly inhibit T. gondii stage conversion in infected myotubes and myoblasts but 
rather exerts its effect through modulation of the host cells. 
 
 
Figure 3.24: N-acetyl cysteine induces BAG1 mRNA expression in extracellular parasites.
  
T. gondii 
tachyzoites were cultivated in the absence of host cells in C2C12 growth medium. Parasites were treated with 
5 mM and 10 mM NAC or were mock-treated. Total RNA was isolated after 48 hours of adding NAC and 
mRNA was reverse transcribed into cDNA which was amplified using specific primers for T. gondii 
bradyzoite antigen 1 (BAG1) and T. gondii actin (TgActin) by quantitative real-time PCR. The increase in 
BAG1 mRNA was calculated between NAC-treated and mock-treated samples using the ΔΔCP method and 
was normalized to TgActin mRNA. Results are depicted as means ± S.E.M. from three independent 
experiments. Significant differences were identified by Students t-test (* p<0.05, ** p<0.01). 
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3.4.5 Modulation of ROS in SkMCs using ROS inducer and its impact on T. 
gondii bradyzoite differentiation 
It was shown above that scavenging endogenous ROS by NAC inhibits T. gondii 
bradyzoite differentiation in myotubes and myoblasts (Figure 3.21). Therefore, I wondered 
whether exogenous ROS can accelerate bradyzoite differentiation in T. gondii in SkMCs. 
 
3.4.5.1   Luperox accelerates T. gondii BAG1 expression in myotubes and myoblasts 
In order to accelerate ROS levels in myotubes and myoblasts, a well known ROS inducing 
agent, namely luperox (tert-butyl hydroperoxide) was used (Kučera et al., 2014). To this 
end, both myotubes and myoblasts were treated with increasing concentrations of luperox 
in the presence or absence of 10 mM of the antioxidant NAC or were mock-treated and 
then infected with T. gondii. RT-qPCR was performed to examine upregulation of BAG1 
mRNA by the parasite. Luperox clearly induces BAG1 mRNA in T. gondii within both 
myotubes and myoblasts in a concentration-dependent manner compared to the mock-
treated controls. However, up-regulation of BAG1 mRNA as induced by luperox in 
myotubes was reduced by concomitant treatment with NAC. Unfortunately, BAG1 
expression could not be determined in myoblasts treated with both luperox and NAC due 
to a toxic effect of NAC at 10 mM on these cells (Figure 3.25A). In order to determine the 
effect of luperox and NAC on parasite replication, immunofluorescence staining was 
performed. Parasites were immunolabeled with anti-Toxoplasma antibodies and parasite 
growth was evaluated by confocal microscopy. Results showed that parasite replication 
was inhibited in luperox-treated myoblasts whereas it was not clearly inhibited in luperox-
treated myotubes as compared to mock control. Concomitant treatment with luperox and 
10 mM NAC strongly accelerated parasite replication in myotubes to levels that were even 
higher than in mock-treated cells. In contrast, parasite replication was not induced by 
NAC-treatment of myoblasts due to its toxic effect on these cells (Figure 3.25C). The 
parasitophorous vacuoles were similarly small in luperox-treated and mock-treated 
myotubes but were clearly enlarged in myotubes treated with both luperox and NAC. 
However, vacuoles were of similar size in myoblasts treated with luperox with or without 
NAC (Figure 3.25B).  
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Figure 3.25: Luperox induces bradyzoite differentiation in myotubes and myoblasts. C2C12 myoblasts 
were induced to differentiate into myotubes.
  
Both myotubes and myoblasts were treated with 20 µM, 30 µM 
or 40 µM luperox (lup) in the presence or absence of 10 mM NAC, or elso were mock-treated. After one 
hour, cells were then infected with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5. (A) Total 
RNA was isolated after 48 hours post infection and was reverse transcribed into cDNA which was amplified 
using specific primers for T. gondii bradyzoite antigen 1 (BAG1) and T. gondii actin (TgActin) by 
quantitative real-time PCR. The fold increase in BAG1 mRNA was calculated between luperox-treated and 
mock-treated myotubes and myoblasts usingthe ΔΔCP method and was normalized to TgActin mRNA. 
Results are depicted as means ± S.E.M. from three independent experiments. (B) Cells were fixed at 48 hours 
post infection with 4 % paraformaldehyde and parasites were immunolabeled using a polyclonal anti-T. 
gondii antiserum (green fluorescence). Host cells were visualized using propidium iodide (red fluorescence). 
Representative images of both labelings were recorded by confocal laser scanning microscopy and were 
superimposed. (C) After cells had been fluorescently labeled as indicated above, the average size of 
parasitophorous vacuoles (PVs) in each sample was determined by counting the number of parasites in 100 
PVs. Data represent means ± S.E.M. from two independent experiments.  (D) Cells were fixed at 48 and 72 
hours post infection with 4 % paraformaldehyde.  After fixation, tissue cyst of T. gondii were labeled with 
biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated streptavidin, parasites were labeled with a 
polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary antibodies and host cells were visualized 
using propidium iodide. The numbers of DBL-positive cysts were counted among 100 parasitophorous 
vacuoles (PV) and were expressed as percentages. Data represent means ± S.E.M. from two independent 
experiments.  
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The impact of luperox alone or in combination with NAC on T. gondii cysts formation was 
then tested in myotubes and myoblasts. Immuno- and lectin-based fluorescence staining of 
T. gondii tissue cysts was achieved by using polyclonal anti-T.gondii antibodies and 
Dolichos biflorus lectin, respectively.  Data showed higher numbers of DBL-positive cysts 
in luperox-treated myotubes as compared to mock-treated cells after 48 and 72 hours of 
infection but luperox-induced cyst formation was abrogated by concomitant treatment with 
NAC. On the other hand, cysts formation was also increased in luperox-treated myoblasts 
compared to mock after 48 and 72 hours of infection although cyst counts were very low at 
48 hours post infection in these cells (Figure 3.25D). Again, NAC inhibited luperox-
induced cyst formation. These results suggest that luperox can induce ROS concentrations 
in myotubes and myoblasts that are appropriate for accelerating T. gondii bradyzoite 
differentiation. 
  
3.4.5.2 H2O2 induces BAG1 mRNA expression in myotubes and myoblasts  
To further confirm that exogenous oxidants can accelerate T. gondii bradyzoite 
differentiation in myotubes and myoblasts, H2O2 was tested as another ROS species. RT-
qPCR was performed with H2O2- or solvent-treated, parasite-infected myotubes and 
myoblasts and T. gondii BAG1 mRNA levels were determined. Data showed that H2O2 
also induced BAG1 mRNA expression in T. gondii within both myotubes and myoblasts in 
a dose-dependent manner. Upregulation of BAG1 mRNA by H2O2 was higher in parasites 
residing in myoblasts than in myotubes. It has to be mentioned however, that upregulation 
of BAG1 mRNA expression did not reach statistical significance due to considerably 
variances (Figure 3.26). Addition of 10 mM of the ROS scavenger NAC inhibited BAG1 
mRNA in both myotubes and myoblasts suggesting a role of ROS in induction of T. gondii 
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Figure 3.26: H2O2 induces BAG1 mRNA expression in T. gondii inside myotubes and myoblasts. 
C2C12 myoblasts were induced to differentiate into myotubes.
  
Both myotubes and myoblasts were treated 
with 50 µM and 100 µM of H2O2 and 10 mM NAC or were mock-treated. After one hour, cells were infected 
with T. gondii tachyzoites at a host cell-to-parasite ratio of 1:3.5. Total RNA was isolated after 48 hours of 
infection and mRNA was reverse transcribed into cDNA which was amplified using specific primers for T. 
gondii bradyzoite antigen 1 (BAG1) and T. gondii actin (TgActin) by quantitative real-time PCR. The 
increase in BAG1 mRNA was calculated in H2O2/NAC-treated myotubes and myoblasts as compared to the 
mock controls using the ΔΔCP method and was normalized to TgActin mRNA. Results are depicted as 
means ± S.E.M. from three independent experiments. Significant differences were identified by Students t-
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3.5 Impact of host cell cycle on T. gondii bradyzoite differentiation in 
SkMCs  
The irreversible cell cycle arrest is one of the major differences between terminally 
differentiated myotubes and its proliferating precursor myoblasts (Huang and Thayer, 
2002; Bentzinger et al., 2012). Consequently, transcriptome analysis identified the cell 
cycle and a variety of cell cycle-associated genes being major differences between 
myotubes and myoblasts irrespective of T. gondii infection (see Figures 3.5, 3.8G, 3.9G 
and supplementary Table 3.9). Furthermore, previous results indicated that the host cell 
cycle may influence T. gondii stage differentiation (Swierzy and Lüder, 2014). Therefore, 
it was hypothesized that cell cycle regulation of SkMCs impacts T. gondii bradyzoite 
differentiation. To validate this hypothesis pharmacological and genetic approaches were 
used. 
 
3.5.1 Pharmacological cell cycle inhibitors accelerate T. gondii bradyzoite 
differentiation in SkMCs  
In order to arrest cell cycle progression in myoblasts, two well-known pharmacological 
cell cycle inhibitors, namely aphidicolin (APH) and mimosine (MIM) were used (Ji et al., 
1997). To assess the effect of APH and MIM on T. gondii BAG1 mRNA expression in 
myoblasts, quantitative real time RT-PCR was performed. For comparison, myotubes that 
are already cell-cycle arrested were also included in these analyses. Data showed that 
BAG1 mRNA was significantly upregulated in T. gondii within myoblasts treated with 250 
or 500 ng/ml APH or those treated with 250 µM MIM as compared to mock-treated cells. 
A trend of increasing BAG1 mRNA expression was also observed in T. gondii within 
myotubes treated with these inhibitors but significant upregulation was only detected after 
treatment with 500 ng/ml APH (Figure 3.27A). 
I next addressed the question whether the cell cycle inhibitors APH and MIM had any 
effect on parasite replication in SkMCs. It has been reported previously that reduced 
parasite replication is necessary for induction of T. gondii bradyzoite differentiation in 
bone marrow-derived macrophages (Bohne et al., 1994). In order to determine the impact 
of APH and MIM on parasite replication, immunofluorescence staining was performed. To 
this end, C2C12 myotubes and myoblasts were treated with 250-500 ng/ml APH and 100-
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250 µM MIM followed by infection with T. gondii tachyzoites four hours later. The 
parasite replication was then analyzed microscopically at 48 hours post infection. A dose-
dependent inhibition of parasite replication was observed in both myotubes and myoblasts 
treated with APH and MIM compared to mock-treated cells (Figure 3.27C). Inhibition of 
parasite replication was particularly evident in myoblasts due to the higher parasite 
replication in mock-treated myoblasts. The higher concentrations of APH and MIM almost 
completely halted parasite replication in both cell types (Figure 3.27B). 
It was then determined whether increased expression of BAG1 mRNA in parasites residing 
in APH- and MIM-treated myoblasts and to a lesser extent myotubes also leads to the 
formation of T. gondii tissue cysts. In order to determine tissue cysts formation, staining 
was performed where the wall of the parasite tissue cyst was fluorescently labeled with 
biotin-conjugated Dolichos biflorus lectin (DBL). Thereafter, DBL-reactive tissue cysts 
were identified and counted in APH- and MIM-treated myotubes and myoblasts at 48 and 
72 hours post infection. Results showed only low numbers of cysts at 48 hours after 
infection in both mock- and inhibitors-treated myoblasts and myotubes, with the highest 
numbers observed in myotubes as expected. However, at 72 hours post infection, the 
number of cysts  has strongly increased in myotubes and myoblasts treated with 250 ng/ml 
APH and 100 µM MIM compared to mock-treated cells. In contrast, higher concentrations 
of both inhibitors were less effective or even completely failed in inducing tissue cyst 
formation by T. gondii  (Figure 3.27D). Thus, an intermediate concentration of both cell 
cycle inhibitors appeared to be required to trigger tissue cyst formation whereas BAG1 
mRNA levels were also increased by high inhibitor concentrations.  
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Figure 3.27: Cell cycle inhibitors can accelerate bradyzoite differentiation in myotubes and myoblasts. 
C2C12 myoblasts were induced to differentiate into poly-nucleated myotubes. Both myotubes and myoblasts 
were treated with 250 ng/ml or 500 ng/ml aphidicolin (APH), 100 µM or 250 µM mimosine (MIM) or with 
the respective solvents (mock). After 4 hours of treatment, cells were then infected with T. gondii tachyzoites 
at a host cell-to-parasite ratio of 1:3.5. (A) Total RNA was isolated after 48 hours of infection and mRNA 
was reverse transcribed into cDNA which was amplified using specific primers for T. gondii bradyzoite 
antigen 1 (BAG1) and T. gondii actin (TgActin) by quantitative real-time PCR. The increase of BAG1 
mRNA in inhibitor-treated compared to solvent-treated cells was calculated according to the ΔΔCP method 
and was normalized to TgActin mRNA. Results are depicted as means ± S.E.M. from three independent 
experiments. Significant differences were identified by Student’s t-test (* p<0.05). (B) Cells were fixed at 48 
hours post infection with 4% paraformaldehyde and parasites were immunolabeled using a polyclonal anti-T. 
gondii antiserum and Cy2-conjugated secondary antibodies (green fluorescence). Host cells were visualized 
using propidium iodide (red fluorescence). Representative images of both parasite and host cell labeling were 
recorded by confocal laser scanning microscopy and were superimposed. (C) After cells had been 
fluorescently labeled as indicated above, the average size of parasitophorous vacuoles (PVs) in each sample 
was determined by counting the number of parasites in 100 PVs. Data represent means ± S.E.M. from four 
independent experiments. Significant differences were identified by Student’s t-test (* p<0.05, **p<0.01).  
(D) Cells were fixed at 48 and 72 hours post infection with 4 % paraformaldehyde. After fixation, tissue cysts 
of T. gondii were labeled with biotin-conjugated Dolichos biflorus lectin and Cy2-conjugated streptavidin, 
parasites were labeled with a polyclonal anti-T. gondii antiserum and Cy5-conjugated secondary antibodies 
and host cells were visualized using propidium iodide. The numbers of DBL-positive cyst were counted in 
100 fields of vision (FV). Data represent means ± S.E.M. from three independent experiments.  
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3.5.2 Cell cycle inhibitors strongly arrest host cell proliferation 
In the experiments described above, host cell cycle progression was arrested by using APH 
and MIM in order to determine the effect of host cell cycle regulation on T. gondii 
bradyzoite differentiation (Figure 3.27). Therefore, it was important to validate whether or 
not the inhibitors APH and MIM arrested cell cycle progression in myoblasts and whether 
they had any effect of myotubes that are already cell cycle-arrested.  
 
Figure 3.28:  Cell cycle inhibitors inhibit host cells proliferation. C2C12 myoblasts were induced to 
differentiate into poly-nucleated myotubes. Both myotubes and myoblasts were treated with 250-500 ng/ml 
APH, 100-250µM MIM, or were mock-treated. Two hours prior to fixation, cells were treated with BrdU (10 
µg/ml). Then, cells were immunolabeled with antibodies recognizing BrdU followed by using DyLight488-
conjugated  secondary antibodies (green fluorescence) and  the total cell population was labeled with 
propidium iodide (red fluorescence). (A) The percentages of BrdU-labeled nuclei in inhibitor-treated samples 
and controls were calculated by counting the number of BrdU-positive cells compared to total number of 
cells. Data represent percentages of BrdU-positive nuclei from one experiment. (B) Representative images of 
both labelings were recorded by confocal laser scanning microscopy and were superimposed. 
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To this end, cell proliferation was evaluated by using 5-Bromo-2-deoxyuridine (BrdU) 
which is a thymidine analogue which incorporates into newly synthesized DNA during cell 
cycle progression. Thus, both myotubes and myoblasts were treated with 250-500 ng/ml 
APH and 100 -250 µM MIM or were mock treated and were cultivated in the presenece of 
BrdU (10 µg/ml) before fixation. Afterwards, the incorporated BrdU was identified using 
specific antibodies and cell cycle progression was analyzed by comparing inhibitor-treated 
samples with mock-treated ones. Data showed only minor differences in DNA synthesis 
between mock-treated and inhibitors-treated myotubes as determined by the lack of BrdU 
incorporation in the vast majority of cells. This was expected because myotubes are 
already cell cycle-arrested. In contrast, both APH and MIM strongly reduced BrdU 
incorporation and hence DNA synthesis in myoblasts compared to mock-treated controls 
thus confirming efficient inhibition of myoblast proliferation by both cell cycle inhibitors 
(Figure 3.28 A, B). 
 
3.5.3 RNA interference mediated knock-down of cell cycle regulator p21 
Waf1/Cip1   
and its impact on T. gondii bradyzoite differentiation on SkMCs 
It has been previously described that terminally differentiated and cell cycle-arrested 
SkMCs, i.e myotubes but not proliferating myoblasts support T. gondii bradyzoite 
differentiation (Swierzy and Lüder, 2014). The authors have also shown that inhibition of 
cell cycle withdrawal in SkMCs, i.e. inhibition of myotube formation by RNA interference 
mediated knockdown of a negative cell cycle regulator, namely testis-specific Y-encoded-
like protein-2 (Tspyl2) abolished T. gondii bradyzoite differentiation and tissue cysts 
formation (Swierzy and Lüder, 2014). These data suggested that arresting the host cell 
cycle is an important signal for T. gondii bradyzoite differentiation in SkMCs. However, 
Tspyl2 knockdown may have other consequences on host cells than inhibiting cell cycle 
withdrawal as well. Therefore, in order to further validate an impact of host cell cycle 
arrest on bradyzoite formation in myotubes, I herein determined whether knockdown of the 
negative cell cycle regulator and downstream target of Tspyl2 p21
Waf1/Cip1
 would also 
abolish T. gondii bradyzoite differentiation in SkMCs. 
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3.5.3.1 Validation of p21Waf1/Cip1 knock-down in SkMCs and its impact on myotube 
formation 
Since p21 mRNA levels are clearly higher in myotubes than in myoblasts irrespective of T. 
gondii infection as shown by both RNAseq (Figure 3.8G) and RT-qPCR analysis (Figure 
3.9G), it was speculated that p21 protein might have a role on T. gondii bradyzoite 
development in myotubes. In order to test the role of p21 on T. gondii bradyzoite 
development, stable p21-shRNA knock-down C2C12 cell lines were constructed by 
transfection of myoblasts with plasmid vectors carrying five different p21-targeted shRNA 
sequences. As a negative control, a mutant control C2C12 cell line was contructed by 
transfection of cells with a p21-shRNA-negative pLKO.1-puro plasmid vector. The 
negative control plasmid had been previously propagated in E. coli 5-alpha competent 
cells. Successful transformation of E. coli 5-alpha was examined through qPCR of clones 
using specific primers (see 2.1.13) targeting the pLKO.1-puro plasmid. The presence of 
nucleic acid fragments of the correct size was confirmed after electrophoretic separation in 
an agarose gel (data not shown). After antibiotic selection of transfectants and cloning by 
limiting dilution, two different p21-shRNA knock-down clones (p21-shRNA1 and p21-
shRNA2) and shRNA-negative control transfectants were selected for further analyses. 
Western blotting was used to examine p21 protein expression at day 3, 5, and 7 of 
differentiation from myoblasts to myotubes in p21-shRNA transfectants, shRNA-negative 
control transfectants and wildtype myotubes as well as in wildtype myoblasts at day 1 after 
seeding. P21 protein was highly expressed in wildtype myotubes at day 3 and 5 of 
differentiation compared to wildtype myoblasts (Figure 3.29A). In contrast to wildtype 
cells, p21-shRNA clones 1 and 2 expressed no or strongly reduced levels of p21 during 
incubation in differentiation medium for 3 to 7 days. On the other hand, negative control 
transfectant cells expressed p21 at similar levels during the differentiation period as 
wildtype cells. Control staining of Western blots with an anti-actin antibody confirmed 
equal protein loading (Figure 3.29A). These results thus indicated successful knockdown 
of p21 protein expression in p21-shRNA clones 1 and 2 but not negative control 
transfectants. In order to further evaluate p21 expression at the single cell level, 
immunofluorescence staining was performed by labeling of p21 with anti-p21 primary 
antibodies followed by Cy2-conjugated secondary antibodies.  
Chapter 3: Results 2017 
 
Page | 110  
 
 
Figure 3.29: Validation of RNA interference-mediated knock-down of p21
Waf1/Cip1 
in SkMCs and its 
impact on myotube formation. C2C12 myoblasts were transfected with lentiviral plasmid vectors encoding 
different p21 specific shRNAs or a shRNA-negative control plasmid vector. Stable transfectants were 
selected by culturing cells in presence of puromycin and were cloned by limiting dilution. Two different 
clones carring different p21-shRNAs (p21-shRNA1 and p21-shRNA2 which were derived from p21-targeted 
shRNA sequence #4) or carrying negative control plasmids were selected for further analyses.To this end, 
p21-shRNA knockdown clones, shRNA-negative control clone and wildtype C2C12 myoblasts were induced 
to differentiate for 3(D3), 5(D5), and 7(D7) days by using differentiation medium supplemented with 2% 
horse serum. Wildtype myoblasts at 1 day after seeding were included as additional control cell type. (A) 
Whole cell protein lysates were isolated from these clones and wildtype cells at the indicated time points 
along with wildtype myoblasts. Protein lysates were separated by SDS-PAGE and were analyzed by Western 
blot using antibodies recognizing p21
Waf1/Cip1
. Immune complexes were visualized by enhanced 
chemiluminescence. Detection of mouse β-actin was used as loading control. (B) Cells were fixed at the 
indicated time points using 100% methanol for 15 minutes at -20°C and were immunolabeled with anti-
p21
Waf1/Cip1
 primary antibodies and Cy2-conjugated secondary antibodies (green fluorescence). Host cells 
were labeled with propidium iodide (red fluorescence). Representative images of both labelings were 
recorded by confocal laser scanning microscopy and were superimposed. (C) Cells were fixed at the 
indicated time points using 4% PFA and mature myotubes were labelled with anti-myosin heavy chain-
specific primary antibodies followed by Cy2-conjugated secondary antibodies (green fluorescence). Cells 
were also labeled with propidium iodide (red fluorescence). Representative images of both labelings were 
recorded by confocal laser scanning microscopy and were superimposed. 
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Results showed no p21 in nuclei and cytoplasm of p21-shRNA1 and p21-shRNA2 clones 
at any time during incubation in differentiation medium whereas shRNA-negative control 
transfectants and wildtype cells clearly expressed considerable amounts of p21 in nuclei 
and/or in the cytoplasm in all cells during differentiation. Proliferating C2C12 myoblasts at 
1 day after seeding did also not express p21 at detectable levels using immunofluorescence 
staining (Figure 3.29B). Since p21 protein was highly expressed in C2C12 wildtype 
SkMCs during differentiation to myotubes as compared to proliferating myoblasts, 
immunofluorescence staining of p21-shRNA clones 1 and 2 was then performed to test its 
functional role in myogenic differentiation. After incubation of p21-shRNA1 and p21-
shRNA2 transfectants, shRNA-negative control transfectants and wildtype C2C12 cells in 
differentiation medium containing 2% horse serum for 3, 5, and 7 days, and cultivation of 
wildtype myoblasts for 1 day in growth medium, the differentiation marker myosin heavy 
chain (MyHC) was immunolabeled and analyzed by immunofluorescence microscopy. 
Results showed that p21-shRNA transfectants were unable to differentiate from myoblasts 
to MyHC-positive myotubes whereas shRNA-negative control transfectants and wildtype 
C2C12 readily differentiated to poly-nucleated myotubes expressing MyHC. As expected, 
proliferating myoblasts did also not express detectable amounts of MyHC (Figure 3.29C). 
 
3.5.3.2  P21 knockdown impact on host cell proliferation  
In order to validate the impact of p21 knockdown on the host cell cycle, host cell 
proliferation was examined in p21-shRNA knockdown cells, shRNA-negative control 
transfectants and wildtype C2C12 cells. The BrdU incorporation assay was used to 
measure the cell proliferation capacity as BrdU (an analogue of thymidine) incorporates 
into newly synthesized DNA. Results showed 40% BrdU-positive nuclei at day1 after 
induction of differentiation in p21 knockdown clone 2, shRNA-negative transfectants and 
wildtype cells whereas p21-shRNA clone 1 had 20% BrdU positive nuclei. At day 3 after 
induction of differentiation, the proliferation of all cells decreased as the BrdU-positive 
nuclei decreased to a similar percentage of about 12%. At day 5 and day 7, cell 
proliferation was found to be similar in p21 knockdown clone 1, shRNA-negative control 
transfectants and wildtype cells whereas only p21-shRNA2 showed higher percentage of 
BrdU-positive nuclei compared to the other cell lines (Figure 3.30A, B). 
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Figure 3.30: P21 knockdown in SkMCs does not generally accelerate host cell proliferation. P21-
shRNA transfectant clones 1 and 2, shRNA-negative control transfectants and wild type C2C12 cells were 
induced to differentiate into myotubes using differentiation medium containing 2% HS for 1 to 7 days as 
indicated. During the last 2 hours of cultivation, cells were treated with BrdU (10 µg/ml) before fixation 
using 70% ethanol. Thereafter, proliferating cells were immunolabeled with antibodies recognizing BrdU 
followed by Dylight-488 conjugated anti-mouse IgG secondary antibodies (green fluorescence). The total 
cell population was labeled with propidium iodide (red fluorescence). (A) The percentages of BrdU-labeled 
nuclei in p21-shRNA transfectants, shRNA-negative control transfectants and wildtype cells were calculated 
by counting the number of BrdU-positive nuclei as compared to the number of total nuclei. Data represent 
means ± S.E.M. from two independent experiments. Significant differences were identified by Student t-test 
(*p<0.05). (B) Representative images of both labelings were recorded by confocal laser scanning microscopy 
and were superimposed. 
 
 
3.5.3.3  P21 knock-down does not affect T. gondii bradyzoite differentiation in SkMCs 
but strongly accelerates parasite replication 
In order to investigate the functional role of p21 in myotubes on T. gondii bradyzoite 
development in SkMCs, upregulation of BAG1 mRNA expression was examined after 
infection of p21-shRNA1 and p21-shRNA2 transfectants, shRNA-negative control 
transfectants and wildtype myotubes induced to differentiate for 7 days as well as 
proliferating myoblasts with T. gondii. Remarkably, results indicated increased BAG1 
mRNA expression in T. gondii residing in the p21-shRNA transfectants clone 1 and 2 
compared to wildtype myotubes or shRNA-negative control transfectants but these 
differences were not statistically significant (Figure 3.31A). However, BAG1 mRNA 
expression was significantly lower in T. gondii within proliferating myoblasts as compared 
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to parasites within shRNA-negative control transfectants or wildtype myotubes as expected 
(see Figure 3.31A).  
In order to determine the impact of p21 on parasite replication, immunofluorescence 
staining of the parasites was performed after infection of p21-shRNA1 and p21-shRNA2 
knockdown cells, shRNA-negative control transfectants and wildtype SkMCs after 7 days 
of differentiation, along with infected proliferating wildtype myoblasts. Interestingly, both 
p21-shRNA1 and p21-shRNA2 transfectants sustained robust parasite replication 
compared to wildtype myotubes and shRNA-negative control transfectants after 48 hours 
of infection. At the same time, parasite replication was lower in myotubes and shRNA-
negative control transfectants than in myoblasts  (Figure 3.31C).Thus, parasitophorous 
vacuoles in p21-shRNA transfectants were clearly larger than in wildtype myotubes or 
shRNA-negative control transfectants, and they were even larger than in wildtype 
myoblasts (Figure 3.31B). Finally, cyst formation by T. gondii was compared within p21-
shRNA knockdown cells, negative control transfectants and wildtype cells.  The 
percentages of T. gondii tissue cysts generally increased within all cell types from 48 to 72 
hours after infection. Furthermore, cyst formation was clearly lower in wildtype myoblasts 
than in myotubes and this was statistically significant at 72 hours after infection. However, 
while the formation of DBL-positive cysts was lower in p21-shRNA transfectant clone 1 at 
48 hours of infection than in wildtype myotubes or shRNA-negative control transfectants, 
p21-shRNA clone 2 at 48 and 72 hours of infection showed nearly the same percentages of 
DBL-positve cysts than wildtype myotubes. Furthermore, at 72 hours after infection, p21-
shRNA knockdown clone 1 showed cyst formation as shRNA negative control transfecants 
(Figure 3.31D).  
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Figure 3.31: P21 knockdown in SkMCs does not impair bradyzoite differentiation but accelerates 
parasite replication. P21-shRNA transfectants clone 1 and 2, shRNA negative control transfectants and 
wildtype C2C12 cells were induced to differentiate into myotubes. Transfected cells, wildtype myotubes and 
proliferating myoblasts at day 1 after seeding were then infected with T. gondii tachyzoites at a host cell-to -
parasite ratio of 1:3.5. (A) Total RNA was isolated at 4 and 48 hours post infection and was reverse 
transcribed for cDNA synthesis which was amplified using specific primers for T. gondii bradyzoite antigen 
1 (BAG1) and T. gondii actin (TgActin) by quantitative real-time PCR. The fold increase in BAG1 mRNA in 
T. gondii between 4 and 48 hours was calculated using the ΔΔCP method and was normalized to TgActin 
mRNA. Results are depicted as means ± S.E.M. from three independent experiments. Significant differences 
were identified by Students t-test (* p<0.05). (B) Cells were fixed at 48 hours post infection with 4 % 
paraformaldehyde and parasites were immunolabelled (green fluorescence) using a polyclonal anti-T. gondii 
antiserum. Host cells were visualized using propidium iodide (red fluorescence). Representative images of 
both labelings were recorded by confocal laser scanning microscopy and were superimposed. (C) After cells 
had been fluorescently labeled as indicated above, the average size of parasitophorous vacuoles (PVs) in each 
sample was determined by counting the number of parasites in 100 PVs. Data represent means ± S.E.M. from 
five independent experiments. Significant differences were identified by Students t-test (* p<0.05, ** 
p<0.01). (D) Cells were fixed at 48 and 72 hours post infection with 4 % paraformaldehyde After fixation, 
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tissue cysts of T. gondii were labeled with biotin-conjugated Dolichos biflorus lectin (DBL) and Cy2-
conjugated streptavidin, parasites were labeled with a polyclonal anti-T. gondii antiserum and Cy5-
conjugated secondary antibodies  and host cells were visualized using propidium iodide. The numbers of 
DBL-positive cysts were counted among 100 parasitophorous vacuoles (PV) and were expressed as 
percentages. Data represent means ± S.E.M. from two independent experiments. Significant differences were 
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4.1 Terminally differentiated SkMCs support T. gondii stage conversion 
Toxoplasma gondii stage conversion from its tachyzoite to its bradyzoite stage in skeletal 
muscle and/or neurons is considered a major cause of establishing long term chronic 
infections (Dubey et al., 1998). Furthermore, persistence of the parasite in skeletal muscle 
cells (SkMCs) is associated with its transmission to new warm-blooded hosts including 
humans via eating raw and undercooked meat or meat products (Cook et al., 2000; Jones et 
al., 2009). Hence, it is an urgent need to understand the biology of T. gondii stage 
conversion in SkMCs. Recently, Swierzy and colleagues  have demonstrated that the 
transcriptomes of four different heterogeneous host cell types, i.e SkMCs, neurons, 
astrocytes and fibroblasts differ substantially after infection with T. gondii, thus 
highlighting host cell-type specific parasite-host interactions (Swierzy et al., 2017). This 
further argues for the necessity to determine stage differentiation specifically in SkMCs. 
C2C12 mouse SkMCs have been used as a suitable model to study the host-parasite 
interaction of T. gondii in vitro in skeletal muscle cells (Guimarães et al., 2008; Ferreira-
da-Silva et al., 2009; Takács et al., 2012; Swierzy and Lüder, 2014). It has to be stressed 
that T. gondii stage conversion spontaneously occurs in terminally differentiated mature 
SkMCs, i.e. in myotubes without any exogenous stress factor but not in proliferating 
myoblasts or fibroblasts (Ferreira-da-Silva et al., 2009; Swierzy and Lüder, 2014). 
Consistent with these previous results, it was further confirmed here that T. gondii within 
myotubes but not in myoblasts upregulated BAG1 mRNA expression and increased tissue 
cysts formation, indicating preferred stage conversion of T. gondii in myotubes. However, 
the factors that induce stage conversion of T. gondii in myotubes are only partially known. 
Therefore, this study has been designed to unravel the host factors that might induce T. 
gondii stage conversion in myotubes but not in myoblasts.  Myotubes and myoblasts differ 
largely in morphological aspects and in cell cycle regulation (Huang and Thayer, 2002; 
Shen et al., 2003) as myotubes are poly-nucleated, terminally differentiated and 
irreversibly cell cycle-arrested cells whereas myoblasts are mononuclear actively 
proliferating cells. Besides, these cell types differ also in other molecular and cellular 
aspects as for instance their transcriptomes (Tomczak et al., 2004; Rajan et al., 2012), their 
proteomes including enzymes of glucose and lipid metabolism, structural proteins, 
transcription factors and cell signaling molecules (Kislinger et al., 2005; Bentzinger et al., 
2012; Deshmukh et al., 2015), and in expression of immune regulatory factors as for 
instance cytokines and chemokines (Wiendl et al., 2005; Swierzy et al., 2014). Obviously, 
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there might also be large metabolic differences between these two different states of the 
cells. Therefore, it was hypothesized that different cellular and metabolic characteristics of 
myotubes and myoblasts may play a role in the preferred triggering of T. gondii stage 
conversion within myotubes. Hence, this study aimed to uncover potential host factors that 
might induce T. gondii stage conversion in myotubes.  
 
4.2 Transcriptome analyses provide candidates for experimental proof 
on T. gondii stage conversion in SkMCs 
Transcriptome analysis of T. gondii-infected host cells may provide useful information for 
understanding underlying mechanisms of the host-parasite interaction. It provides the 
opportunity to determine the gene expression pattern of host cells, parasites and the effect 
of parasite infection on the host transcriptome on a genome-wide scale. It can also identify 
candidate genes expression of which may regulate T. gondii stage conversion in distinct 
cells. Such candidates can be subsequently tested for their functional impact on T. gondii 
stage conversion in SkMCs. Here, RNA sequencing-based transcriptome analysis of non-
infected and T. gondii- infected myotubes and myoblasts were performed at 24 hours post 
infection to unravel their specific gene expression profiles before and after infection. 
Interestingly, infected and non-infected myotubes and myoblasts differed significantly in 
the expression of up to 6592 differentially regulated genes but surprisingly T. gondii 
infection had only a minor impact on host gene expression. It is important to note that T. 
gondii differentially modulated only 38 genes in myotubes after infection whereas 70 
genes were differentially regulated in myoblasts by T. gondii infection. Surprisingly, most 
of the genes were identified as predicted or pseudogene. Nevertheless, the large differences 
in gene expression profiles of myotubes and myoblasts both before and after infection may 
provide important information for the host-parasite interaction within myotubes versus 
myoblasts. A recent study on the transcriptomes of four heterogeneous host cell types, 
namely differentiated SkMCs, neurons, astrocytes and fibroblasts identified more than 
16,000 differentially expressed genes, and the large majority of them differed between host 
cell types but not between non-infected and infected cells. Thus, T. gondii also had only a 
minor impact on these transcriptomes (Swierzy et al., 2017). Furthermore, T. gondii 
infection up- and downregulated largely different sets of genes in the different cell types, 
indicating cell type-specific responses of the host to T. gondii. In that study however, the 
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authors nevertheless identified 492 genes to be differentially expressed in myotubes after 
T. gondii infection (Swierzy et al., 2017). The minor impact of T. gondii on host cell gene 
expression as observed in this study could be explained by two ways. First, although active 
and freshly egressed extracellular parasites, i.e. tachyzoites have been used for the 
infection experiments in this study, the presence of bradyzoites cannot be completely 
excluded. Due to the slower growth rate of bradyzoites, this parasite stage generally have a 
minor impact on the host cell transcriptome (Fouts et al., 2007). Second, although parasite 
replication in both myotubes and myoblasts has been examined using immunofluorescent 
test, there might be a lack of equal distribution of parasite in host cells during the 24 hours 
infection period. Lack of efficient infection of host cells by the parasite might thus have 
contributed to the low impact of the parasite on host cell transcriptomes. 
Gene ontology analysis confirmed that the large set of differentially expressed genes 
(6592) in T. gondii-infected myoblasts versus infected myotubes is associated with 
different biological pathways. Among these pathways, cellular component organization, 
mitotic cell cycle processes, cell cycle, metabolic processes and cellular metabolic 
processes were the most prominent differences between myotubes and myoblasts. The 
differences in cell cycle regulation between myotubes and myoblasts both before and after 
infection with T. gondii was expected because myotubes are terminally differentiated, cell 
cycle-arrested SkMCs which develop from their proliferating precursor myoblasts (Huang 
and Thayer, 2002; Bentzinger et al., 2012). The differences between myotubes and 
myoblasts in metabolic pathways as identified herein were more surprising since the 
metabolism of C2C12 SkMCs before and after differentiation has not yet been thoroughly 
investigated. Therefore, differentially expressed genes involved in cell cycle regulation and 
metabolic processes in myotubes and myoblasts were selected for further in-depth analysis 
and their role in T. gondii stage conversion.  
The group of genes that are involved in cell cycle regulation and that differed in expression 
between myotubes and myoblasts are shown in supplementary Table 3.9. The majority of 
them encode for different cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors 
including p21, p18, p27, p57 and the cell cycle regulatory proteins i.e retinoblastoma (RB) 
1, proliferating cell nuclear antigen (PCNA). Shen and colleagues have shown  before that 
cell cycle arrest is one of the major differences between myotubes and myoblasts (Shen et 
al., 2003). Here it was confirmed that p21, a cyclin-dependent kinase inhibitor of cell cycle 
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was 6.7-fold upregulated in differentiated myotubes compared to proliferating myoblasts 
irrespective of T. gondii infection (Figure 3.8G). This is consistent with other studies 
where p21 was also upregulated in the course of C2C12 myoblasts differentiation (Shen et 
al., 2003; Swierzy and Lüder, 2014). It has to be noted that the level of p21 expression did 
not change after T. gondii infection in these studies and this was confirmed herein. P21 is a 
member of the CDK-interacting protein/kinase-inhibitory protein (CIP/KIP) family of 
CDK inhibitors that can arrest the cell cycle in two different ways. First, p21 can directly 
block cell cycle progression at G1/S through inactivating CDK2 or by interacting with 
multiple cyclin-CDK complexes (Starostina and Kipreos, 2012). Second, it can also arrest 
cell cycle progression during the G2 phase in certain tissues either by inhibiting cyclinB1-
CDK1 and cyclinA-CDK1/2 complexes or by blocking the phosphorylation of 
retinoblastoma family proteins (Bunz et al., 1998; Baus et al., 2003). Gene expression data 
indicated that p27, p57 and RB1 were also upregulated in myotubes as compared to 
myoblasts while various cyclins as for instance cyclinA2, cyclinB1/B2, cyclinC, 
cyclinD1/D2, cyclin E1/E2, cyclin-dependent kinases i.e CDK1, CDK2, CDK4, CDK6, 
CDK8 along with p18 and PCNA were downregulated in myotubes as compared to 
myoblasts. In addition to p21, p27 and p57 are structurally similar and highly conserved 
CDK inhibitors that also induce cell cycle arrest of myotubes (Lee et al., 1995; Zhang et 
al., 1999; Myers et al., 2004). Furthermore, RB1 is a protein regulator of G1/S transition of 
the cell cycle that acts through repression of E2F family members of transcription factors 
which are required for cell proliferation (Weinberg, 1995). Contrary, downregulation of 
cell cycle activators including various CDKs and their cyclins in myotubes are important 
for skeletal muscle differentiation (Kitzmann and Fernandez, 2001). Lower expression of 
p18 in myotubes indicated higher expression in proliferating myoblasts.  P18 is a member 
of the INK4 family of CDK inhibitors which is differentially expressed during G1 exit by 
C2C12 cells (Phelps et al., 1998). Phelps and colleagues have further shown that the p18 
gene encodes two mRNA transcripts: one of 2.4 kb which is highly expressed in 
proliferating myoblasts and one of 1.2 kb which is expressed in differentiating myotubes 
(Phelps et al., 1998). In addition, Broxmeyer and colleagues have shown that p18 
positively influences the proliferation of hematopoietic progenitor cells as determined in 
p18 
(−/−)
 mice (Broxmeyer et al., 2012) which also justifies the presence of the higher level 
of p18 mRNA in proliferating myoblasts. Higher expression of PCNA in proliferating 
myoblasts accords with findings of previous studies in activated rat skeletal muscle 
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satellite cells where PCNA was highly expressed in the S phase of the cell cycle suggesting 
a role in DNA replication and cell proliferation (Johnson and Allen, 1993). Although many 
proteins of the cell cycle were differentially regulated in myotubes and myoblasts, p21 has 
been selected for functional analysis due to its high level of expression in myotubes as 
compared to myoblasts. In addition, p21 is a downstream molecule of Tspyl2, that has 
been previously shown to regulate T. gondii stage conversion in SkMCs (Swierzy and 
Lüder, 2014) (see below). 
Along with transcriptome differences in cell cycle regulators between myotubes and 
myoblasts, differentially regulated genes related to metabolic processes were of particular 
interest in this study for testing their role on T. gondii stage conversion. Genes involved in 
the central carbohydrate metabolism, i.e. glycolysis, the TCA cycle, the pentose phosphate 
pathway (PPP) and glycogen metabolism were particularly enriched among the DEGs of 
myotubes and myoblasts irrespective of infection. Most genes encoding glycolytic 
enzymes were upregulated in myotubes as compared to myoblasts suggesting a higher rate 
of glycolysis in differentiated cells. Genes related to the TCA cycle itself were mostly 
similarly expressed in myotubes and myoblasts. However, the gene encoding the pyruvate 
carboxylase (PC) was 3.49-fold upregulated in myotubes as compared to myoblasts 
suggesting higher TCA cycle anaplerosis in myotubes. Pyruvate carboxylase is a 
mitochondrial enzyme that catalyzes the carboxylation of pyruvate to oxaloacetate, 
replenishing an important intermediate of TCA cycle. This anaplerotic reaction in skeletal 
muscle is important because the lack of oxaloacetate impairs TCA cycle activity and 
withdrawal of TCA cycle intermediates for other biosynthetic pathways as for instance 
synthesis of glucose, fatty acids, amino acids etc (Owen et al., 2002; Jitrapakdee et al., 
2008). Minet and colleague have previously demonstrated the presence of PC in cultured 
human myotubes and human muscle tissue (Minet and Gaster, 2010). The absence of PC in 
human myotubes is fatal as shown by the fact that inhibition of PC using phenyl acetic acid 
abolishes enhanced glucose oxidation under high glucose concentration (Gaster, 2010) 
indicating the importance of PC-mediated anaplerotic reaction in human skeletal muscle. 
Remarkably, many genes encoding for enzymes of both the oxidative and non-oxidative 
branches of the PPP were upregulated in myoblasts compared to myotubes irrespective of 
T. gondii infection (see supplementary Table 3.7). The oxidative phase of the PPP is 
important in eukaryotic cells because it converts glucose-6-phosphate into ribulose-5-
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phosphate which is required for synthesis of nucleic acid and provides NADPH for the 
synthesis of anabolic macromolecules, i.e fatty acids, cholesterol and others as well as to 
maintain redox homeostasis under stress condition. On the other hand, the non-oxidative 
branch of the PPP uses glycolytic intermediates such as fructose-6-phosphate, 
glyceraldehyde-3-phosphate and sedoheptulose sugars for yielding ribose-5-phosphate for 
synthesis of nucleic acid, precursor of amino acids and vice versa depending on 
biochemical demand (Stincone et al., 2015). Remarkably, expression of glucose-6-
phosphate dehydrogenase (G6PDH)2, the rate limiting enzyme of PPP was clearly higher 
in myoblasts than in myotubes as determined by RNAseq and RT-qPCR. The results 
showed however discrepancy regarding the impact of parasite infection where T. gondii 
modulated its expression in both myoblasts and myotubes as determined by RNAseq 
analysis. This was not observed by RT-qPCR when G6PDH2 mRNA expression was 
compared between non-infected and T. gondii-infected myotubes and myoblasts. This 
might however be misleading in comparison to the absolute values obtained by RNAseq. 
G6PDH2 is an enzyme that catalyzes the conversion of glucose-6-phosphate to 6-
phosphogluconolactone thereby shifting glucose into the PPP. Importantly, higher 
expression of G6PDH2 and other PPP enzymes in myoblasts indicated a higher influx of 
glucose into the PPP in myoblasts as compared to myotubes irrespective of T. gondii 
infection. This may provide larger amounts of the reducing equivalent NADPH in 
myoblasts which is required for several anabolic reactions including synthesis of fatty 
acids and cholesterol and to protect cells from oxidative stress. Though T. gondii is capable 
of synthesizing fatty acids de novo, they also scavenge it from host cells for organelle 
biogenesis and parasite survival (Charron and Sibley, 2002; Mazumdar et al., 2006). On 
the other hand, T. gondii is auxotrophic for cholesterol and they must scavenge it from the 
host cells. Therefore, availability of cholesterol in T. gondii-infected myoblasts may affect 
parasite growth and stage conversion. Previous studies suggest that starvation of host 
cholesterol indeed induces tachyzoite-to-bradyzoite stage conversion in T. gondii in 
chinese hamster ovary cells (Ihara and Nishikawa, 2014). Higher NADPH in myoblasts 
may protect cells from ROS-induced oxidative stress through maintaining redox 
homeostasis. Higher ROS may damage lipids, proteins and nucleic acids of the parasite in 
T. gondii-infected cells which may hence affect parasite growth (see below). 
Nonetheless, higher activity of enzymes of the PPP due to their increased expression may 
also provide higher amounts of ribose-5-phosphate in myoblasts for synthesis of nucleic 
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acids reflecting the proliferating nature of these cells. Importantly, higher incorporation of 
glucose-derived carbon atoms into ribulose-5-phosphate in myoblasts than in myotubes 
was indeed confirmed herein using GC-MS-mediated metabolome analysis (see below). 
Finally, in this study, genes related to glycogen metabolism including glycogen synthase-I 
and glycogen phosphorylase were upregulated in myotubes compared to myoblasts 
irrespective of T. gondii infection (see supplementary Table 3.8). Glycogen synthase-I and 
glycogen phosphorylase are two key enzymes associated with glycogen synthesis and 
glycogen degradation, respectively. This difference between C2C12 myoblasts and 
myotubes is not surprising because mature muscle cells use glycogen as a carbohydrate 
store for supplying energy during phases of starvation.  
This study for the first time describes the gene expression profiles of myotubes and 
myoblasts infected with T. gondii or non-infected. The findings are similar to a  previous 
studies where it has been shown that myogenic differentiation of myoblasts into myotubes 
is accompanied by changes of gene expression that are predominantly involved in muscle 
contraction and cytoskeleton organization, carbohydrate metabolism and cell cycle 
regulation (Moran et al., 2002). However, the authors showed differential regulation of 
genes that are involved in carbohydrate metabolism including phosphofructokinase-1, 
glycogen phosphorylase, glycogenin, adenylosuccinate synthetase-1 and aldo-keto 
reductase family1 member B1 in 1-4 days differentiated myotubes. Besides, a number of 
genes were also  differentially regulated in myotubes that are associated with cell cycle 
regulation as for instance p21, p57, p19, retinoblastoma-1, cyclinA2, cyclin B1-related 
sequence, cyclinG2, CDK4, CDK inhibitor3, PCNA, G1 to phase transition 1, cell division 
cycle 25 homolog C U58633, cyclin-dependent kinase regulatory subunit 2, cell division 
cycle 2 homolog, protein regulator of cytokinesis 1, protein phosphatase 1 and regulatory 
subunit 7 (Moran et al., 2002). Importantly, Moran and colleagues used microarray based 
gene expression profiles of 1-4 days differentiated myotubes whereas RNAseq was used in 
this study to measure gene expression profiles of non-infected and T. gondii- infected 7 
days differentiated myotubes and proliferating myoblasts. Together, the transcriptome 
analysis of myotubes and myoblasts provided thus initial guidelines for in-depth analysis 
of the impact of the host cell metabolism and cell cycle regulation in T. gondii stage 
conversion in myotubes. 
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4.3 Differences in host glucose metabolism impacts T. gondii stage 
conversion in SkMCs 
SkMCs predominantly depend on glucose as a carbon source for their metabolic demands 
under normal physiological conditions. It has been shown that high levels of extracellular 
glucose accelerate proliferation of C2C12 myoblasts by inducing G1-cyclins which are 
important for cell cycle progression (Grabiec et al., 2014). In addition, starvation for 
glucose inhibits differentiation from myoblasts to myotubes as indicated by reduced 
expression of myosin heavy chain, a marker of muscle differentiation (Fulco et al., 2008; 
Brown et al., 2012; Elkalaf et al., 2013). Previous studies have also shown that 
undifferentiated C2C12 myoblasts largely depend on glycolysis as indicated by high 
lactate production, and it was estimated that 60% of energy comes from glucose in early 
stages of differentiation (Leary et al., 1998).  In contrast, increased expression of 
glycolytic enzymes was observed in myotubes (see above). These results suggest that 
glucose metabolism is important for myoblasts proliferation and differentiation as well. 
They also provide a link between metabolic activities of SkMCs and cell cycle regulation 
(Krylov et al., 1999). From this point of view, it can be hypothesized that glucose 
metabolism in SkMCs may regulate T. gondii stage conversion.  
Beside different metabolic demands of myoblasts and myotubes, T. gondii as an obligatory 
intracellular pathogen must meet all its metabolic demands for growth and survival within 
its host cells. For instance, T. gondii tachyzoites utilize glucose as a preferred carbon 
source for their energy production and  synthesis of macromolecules (Polonais and Soldati-
Favre, 2010; Macrae et al., 2012) but they can also use glutamine as an alternative carbon 
source under both normal or glucose starvation conditions (Blume et al., 2009; Macrae et 
al., 2012). Previous findings confirm that the lack of glucose has only a minor impact on 
parasite growth and motility in human foreskin fibroblasts (HFF) cells (Blume et al., 
2009). Nevertheless, limited availability of glucose or its metabolic products in SkMCs 
may impact parasite growth and thereby favor tachyzoite-to-bradyzoite stage conversion. 
Therefore, the central glucose metabolism in non-infected and T. gondii-infected myotubes 
and myoblasts was of particular interest. For the first time, mass spectrometric analysis of 
the central carbohydrate metabolism in infected and non-infected myotubes and myoblasts 
was performed. The results indicated that myotubes and myoblasts significantly differ in 
their central glucose metabolism irrespective of T. gondii infection. Interestingly, whereas 
incorporation of glucose-derived carbon atoms into intermediates of the glycolysis did not 
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consistently differ between myotubes and myoblasts, higher incorporation into the PPP 
product ribulose-5-phosphate or into TCA cycle intermediates was measured in myoblasts 
and myotubes, respectively (Figure 3.10). Unexpectedly, myotubes and myoblasts did not 
show major differences of glucose metabolism through glycolysis in mass spectrometric 
analysis. Nevertheless, higher concentrations of lactic acid was found in the cell culture 
supernatant of myoblasts compared to myotubes irrespective of T. gondii infection 
suggesting indeed increased glycolysis in myoblasts than in myotubes (Blume & Lüder, 
unpublished). Although transcriptome analysis suggested higher expression of glycolytic 
enzymes in myotubes than in myoblasts, increased glycolytic activities in myoblasts was 
rather more expected because according to previous observations, myoblasts rely 
predominantly on glycolysis to provide rapid supply of energy (ATP) for their continuous 
proliferation (Leary et al., 1998). The reason for the increased expression of glycolytic 
enzymes as observed here in myotubes is currently unknown. The evidences of higher 
TCA cycle activities in myotubes resemble results from other studies suggesting that 
differentiation of myoblasts into myotubes leads to a drastic increase of mitochondrial 
enzyme activities (Moyes et al., 1997; Barbieri and Sestili, 2012). Transcriptome analysis 
of myotubes and myoblasts revealed higher expression of PC in myotubes (see above) 
suggesting higher influx of glucose-derived carbon atoms into the TCA cycle through 
replenishing the TCA cycle intermediate oxaloacetate (Figure 3.8D). It has to be stressed 
that GC-MS confirmed higher flux of glucose-derived carbon atoms via PC but not 
pyruvate dehydrogenase (PDH) complex pathway in myotubes as compared to myoblasts 
irrespective of T. gondii infection. This further suggested that myotubes channel glucose-
derived carbon into TCA cycle through PC mediated TCA cycle anaplerosis. The 
functional significance of increased expression of glycogen metabolic enzymes was not 
validated by metabolomics and this would be an issue for future research.  
A higher PPP activity in the proliferating myoblasts may be critical for providing sufficient 
amounts of ribose-5-phosphate to synthesize nucleotides and/or for providing the reducing 
equivalent NADPH for synthesis of macromolecules such as fatty acids and cholesterol. It 
may also be required for generating intermediates of glycolysis, i.e. glyceraldehyde-3-
phosphate or fructose-6-phosphate through the non-oxidative phase of the PPP. Finally, it 
may serve  maintaining cellular redox homeostasis by supplying reduced glutathione via 
NADPH (Barcia-Vieitez and Ramos-Martínez, 2014). The increased PPP activity in 
myoblasts as compared to myotubes correlates with the upregulation of enzymes of both 
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the oxidative and non-oxidative phases of the PPP in myoblasts as detected in the 
transcriptome analysis (see above). Importantly, infection with T. gondii did neither 
significantly modulate incorporation of glucose-derived carbon atoms into intermediates of 
the central carbohydrate metabolism nor gene expression of metabolic enzymes involved 
in these pathways except G6PDH2. Indeed, RNAseq analysis indicated up-regulation of 
that enzyme after infection of both myoblasts and to a lower extent also myotubes with T. 
gondii. However, this effect of T. gondii on G6PDH2 expression was not confirmed by 
RT-qPCR. The reasons for this discrepancy is not entirely clear (see above), but the 
measurement of ribulose-5-phosphate in infected versus non-infected myoblasts and 
myotubes did also not reveal any significant impact of the parasite. This suggests that even 
if T. gondii upregulates G6PDH2 expression in SkMCs, this appears do not affect the 
overall PPP activity. Together, transcriptome and metabolome analyses revealed clear 
differences between the central carbohydrate metabolism of myotubes and myoblasts 
whereas parasite infection did not considerably regulate metabolic traits of SkMCs. 
However, Blader and colleague previously showed T. gondii-mediated modulation of 
several glycolytic enzymes in HFF cells as for instance triose phosphate isomerase 1, 
phosphoglycerate kinase 1, phosphoglycerate mutase 1, and lactate dehydrogenase A 
(Blader et al. 2001). Findings in this study now suggest that T. gondii has only a minor, if 
any, impact on metabolic activities of myotubes and myoblasts. 
Since myoblasts and myotubes significantly differed in their central carbohydrate 
metabolism, an important issue was then analyzing its impact on the differential T. gondii 
bradyzoite formation in both cell types. Among other factors, this study uncovered the 
impact of sodium-L-lactate on T. gondii bradyzoite differentiation in SkMCs. 
Transcriptome analysis indicated that lactate dehydrogenase-D was upregulated in 
myotubes compared to myoblasts irrespective of T. gondii infection. Lactate 
dehydrogenase-D is an important enzyme that catalyzes the reversible conversion of 
pyruvate to lactate, i.e. the last step of anaerobic glycolysis. Addition of lactate to the 
medium did not show any effect on T. gondii stage conversion in myotubes but it sustained 
bradyzoite differentiation in myoblasts. This is inconsistent with previous studies where 
lactate has been identified as a soluble metabolite that support parasite growth and inhibit 
T. gondii stage conversion in Vero cells  but not in HFF cells which are normally 
permissive for bradyzoite differentiation under metabolic stress condition (Weilhammer et 
al., 2012). The different impact of lactate on T. gondii stage conversion in Vero cells and 
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HFF cells was due to differences in efficient release of lactate through glucose catabolism 
in these cell types. Lactate-induced inhibition of T. gondii stage conversion was further 
confirmed after upregulation of glycolysis in permissive cells by either addition of glucose 
or by overexpression of the host kinase Akt (Weilhammer et al., 2012). It is important to 
note that Weilhammer and colleagues investigated stress-induced stage conversion where 
lactate had an effect only in distinct cell types. The mechanism of lactate-induced stage 
conversion is not known but possibly other soluble mediators besides lactate are also 
involved in this process. Nevertheless, this study investigated spontaneous stage 
conversion of T. gondii in myotubes and lactate induced bradyzoite formation in myoblasts 
in vitro. Recently, Willkomm and colleagues demonstrated that lactate induces cell cycle 
withdrawal and initiates early but delays late differentiation of C2C12 myoblasts by 
increasing reactive oxygen species (Willkomm et al., 2014). This could explain the finding 
of this study that lactate induced T. gondii bradyzoite differentiation in myoblasts, since T. 
gondii spontaneously convert from tachyzoites to bradyzoites in differentiated myotubes 
(Figure 3.1; Swierzy & Lüder 2014).  
This study also uncovered the role of TCA cycle activities in T. gondii stage conversion in 
myotubes and myoblasts. TCA cycle was inhibited using phenyl acetic acid (PAA), an 
inhibitor of the PC which converts pyruvate into oxaloacetate, i.e. an important reaction of 
TCA cycle anaplerosis. Surprisingly, inhibition of PC slightly induced BAG1 mRNA 
expression in T. gondii residing within myotubes but not in those in myoblasts. This clearly 
suggests that increased fueling of pyruvate into the TCA cycle via PC as observed in 
myotubes is not important for triggering stage conversion of T. gondii in differentiated 
SkMCs. Importantly, the inhibition of the anaplerotic reaction exerted by the PC using 
PAA might not suffice for reducing total influx of glucose-derived carbon atoms into the 
TCA cycle because of the conventional conversion of pyruvate into citrate through the 
PDH complex. This view is indeed supported by our mass spectrometric analysis, 
indicating influx of glucose-derived carbon atoms into the TCA cycle through both the PC 
pathway and the PDH complex pathway. Thus, although myotubes channels carbon atoms 
derived from glucose more readily into the TCA cycle by an anaplerotic reaction than 
myoblasts, the inhibition of PC by PAA may not efficiently inhibit TCA cycle activities to 
subsequently reduce T. gondii stage conversion. Thus, increased total incorporation of 
carbon atoms into TCA cycle intermediates as observed in myotubes may nevertheless 
trigger T. gondii stage conversion. Interestingly, fueling of TCA cycle activities by 
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addition of the TCA cycle intermediate dimethyl-α-ketoglutarate (DMKG) indeed 
accelerated T. gondii BAG1 expression particularly in myoblasts and only to a lower extent 
in myotubes. Treatment of myoblasts with DMKG may hence have increased TCA cycle 
activities to levels as observed or similar to those observed in myotubes and this may have 
sustained T. gondii BAG1 expression in these cells. In contrast, further fueling of TCA 
cycle activities in myotubes might be inefficient to further support bradyzoite formation in 
T. gondii. It has to be mentioned that DMKG, although inducing BAG1 expression 
particularly in T. gondii residing in myoblasts, did not sustain tissue cyst formation. Thus, 
DMKG possibly accelerates only early steps of stage conversion in T. gondii but not later 
stages including cyst wall formation. How the inhibitors or modulators discussed above 
impact T. gondii stage conversion and whether they act on the host cells or the parasites 
carbohydrate metabolism needs to be further investigated in the future.  
T. gondii stage conversion occurs spontaneously in myotubes which showed lower 
incorporation of glucose-derived carbon atoms into the PPP product ribulose-5-phospahte 
as compared to myoblasts. It was thus hypothesized that low PPP activities might have a 
role in inducing stage conversion or vice versa that increased PPP activities might favor 
parasite growth and inhibit parasite stage differentiation. In this study, a role of reduced 
PPP activities on T. gondii stage conversion has been established. Two structurally 
different inhibitors of critical PPP enzymes, namely dehydroepiandrosterone (DHEA) and 
6-aminonicotinamide (6-AN) were used to inhibit PPP in T. gondii-infected myotubes and 
myoblasts. DHEA is a well-known uncompetitive inhibitor of the G6PDH, the rate limiting 
enzyme of the PPP (Gordon et al., 1995; Schwartz and Pashko, 2004). 6-AN is a 
competitive inhibitor of NADP
+
-dependent enzyme 6-phosphogluconate dehydrogenase 
(Tyson et al., 2000). Both inhibitors reduce intracellular NADPH levels by inhibiting the 
PPP in different cell types (Rawat et al., 2012; Patel et al., 2014) . Herein, it was shown 
that inhibition of the PPP in T. gondii-infected myotubes and myoblasts using DHEA 
accelerated T. gondii BAG1 mRNA expression and tissue cyst formation and at the same 
time reduced parasite replication strongly indicating T. gondii stage conversion (Figure 
3.13). A similar effect on T. gondii stage conversion was also found in myotubes and 
myoblasts treated with 6-AN to inhibit the 6-phosphogluconate dehydrogenase. 
Interestingly, the effect of DHEA and 6-AN was generally more pronounced on stage 
conversion of T. gondii in myoblasts although it was also measured in myotubes. This 
suggests that inhibiting the higher PPP activities as observed in myoblasts is more efficient 
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in inducing T. gondii stage conversion than a further decrease of the low PPP activities as 
observed in myotubes. The effect of DHEA on the inhibition of PPP has been 
demonstrated in myotubes and myoblasts by measuring NADPH. Reduced level of 
NADPH and higher ratios of NADP
+
/NADPH in DHEA-treated myotubes and myoblasts 
as compared to control confirmed the DHEA-mediated inhibition of PPP. Again, how these 
inhibitors impact stage conversion in T. gondii and whether they act on the host cell or 
rather the parasite itself needs further validation. However, the fact that two different 
inhibitors targeting different enzymes show similar results in these analyses rather argues 
for an effect via the validated targets of these drugs, i.e. on the mammalian enzymes but 
not the parasite enzymes.  
Together, these functional results indicate that lower PPP and higher TCA cycle activities 
in myotubes can trigger T. gondii stage conversion in SkMCs. 
 
4.4 Redox homeostasis modulate T. gondii stage conversion in SkMCs 
The mechanism by which reduced PPP activities in myotubes support T. gondii stage 
conversion has also been investigated in this study. As discussed above, one of the main 
purposes of glucose metabolism through the PPP is the production of the reducing 
equivalent NADPH in the cytoplasm. Here, it was confirmed that the reduced PPP 
activities in myotubes lead to the production of lower levels of NADPH and higher 
NADP
+
/NADPH ratios as compared to myoblasts which catabolize more glucose through 
the PPP. Reduced levels of NADPH in myotubes may provide only insufficient cellular 
antioxidants, i.e reduced glutathione for neutralization of ROS. It was therefore 
hypothesized that low levels of NADPH may lead to increased intracellular ROS in 
myotubes thereby affecting T. gondii stage conversion. Remarkably, this study revealed 
that ROS levels in myotubes were even lower as compared to myoblasts irrespective of T. 
gondii infection (Figure 3.20). However, this finding is consistent with other studies where 
the authors showed that differentiation of L6E9 myoblasts into myotubes is also 
accompanied by a decrease in intracellular ROS production (Lyons et al., 2004; Jahnke et 
al., 2009). Thus, despite harboring higher levels of NADPH as compared to myotubes, 
myoblasts showed increased intracellular ROS. Since myoblasts do not considerably 
sustain T. gondii stage conversion this clearly argues against a significant impact of the 
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higher ROS levels as observed in myoblasts in triggering parasite differentiation. The 
reason for higher ROS in myoblasts might be due to the high metabolic activity and the 
highly proliferative nature of the cells. Alternatively, high levels of cytosolic NADPH can 
act as substrate for the NADPH oxidase (NOX) to reduce molecular O2 to superoxide 
anions (O2
-
). This NADPH-dependent ROS production has been detected in skeletal 
muscle (Wang et al., 2009; Barbieri and Sestili, 2012) and  cardiac muscle (Heymes et al., 
2003).
 
It has to be noted that intracellular ROS is considered an important regulatory factor 
in the differentiation of SkMCs (Barbieri and Sestili, 2012).  
Although high levels of ROS do obviously not trigger stage conversion in T. gondii (see 
above), I wondered whether a distinct physiological range of concentrations of endogenous 
ROS has any impact on T. gondii stage conversion in myotubes. Modulation of 
endogenous ROS using the antioxidant N-acetyl cysteine (NAC) indeed inhibited 
bradyzoite-specific BAG1 mRNA expression and tissue cyst formation while supporting 
robust parasite replication (Figure 3.21). NAC is widely used as an antioxidant that 
scavenges intracellular ROS either by increasing levels of the cellular antioxidant reduced 
glutathione or by directly inactivating ROS through neutralization (Aruoma et al., 1989; 
Lasram et al., 2015). In previous studies, NAC has been recognized as effective 
antioxidant against the antitumor quinolone, 5-Nitroso-8-quinolinol (NSC3852) that also 
has anti-T. gondii activity in vitro. At low concentration (78.6 nM), NSC3852 is able to 
inhibit T. gondii tachyzoite growth in HFF cells by a ROS-dependent mechanism, since 
concomitant treatment with 5-20 mM NAC showed increased tachyzoite growth in 
presence of NSC3852 (Strobl et al., 2009). In another study, it was shown that expression 
of the phosphoinositide-3-kinase (PI3K)/Akt-dependent NOX4 is required for controlling 
T. gondii proliferation by human retinal pigment epithelial cells. Consequently, decreasing 
ROS production using siRNA-mediated knockdown of host NOX4 strongly supported T. 
gondii replication (Zhou et al., 2013). However, whether the increased parasite growth as 
observed in these studies after NAC treatment or NOX4 knockdown is accompanied with a 
decrease in bradyzoite formation has not been tested. Nevertheless, these results provide a 
clear link between ROS and T. gondii growth and this study also provides evidence that 
decreasing ROS in SkMCs by using NAC favor parasite growth and inhibits bradyzoite 
formation. It has to be stressed that NAC had not any direct effect on parasite for this 
inhibition of stage conversion as NAC showed increased BAG1 mRNA expression in 
extracellular T. gondii. The possible mechanism of ROS on inhibition of T. gondii 
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replication and induction of stage conversion could be explained by two ways. Firstly, 
ROS as for instance oxygen superoxide can react with essential lipids, proteins and nucleic 
acids of the parasite which may lead to parasite growth inhibition and induction of stage 
conversion. Secondly, low concentrations of ROS act as signaling molecules in various 
biological pathways as for instance the phosphoinositide-3-kinase (PI3K)/Akt pathway, the 
nuclear factor kappa-beta (NF-kB) and mitogen-activated protein kinase (MAPK) 
pathways or may activate insulin like growth factor (IGF)-1 and peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC1-α) to control host or parasite gene 
expression which may affect T. gondii growth and stage conversion (Barbieri and Sestili, 
2012; Zhang et al., 2016). 
Another antioxidant was also used in this study to further confirm an effect of ROS on T. 
gondii bradyzoite differentiation. Tiron (4,5- dihydroxy-1,3-benzene-disulfonic acid) has 
been selected because tiron is a vitamin E analog that can scavenge ROS by directly 
neutralizing hydroxyl radicals (•OH) and superoxide anions (O2
-
). Tiron can also protect 
cells from oxidative stress by chelating metal ions (Krishna et al., 1992). Surprisingly, data 
showed that tiron even accelerated BAG1 mRNA expression but not tissue cyst formation 
in both myotubes and myoblasts. Thus, with regard to BAG1 mRNA expression, tiron 
exerted an opposite effect on T. gondii than NAC. However, it was subsequently 
recognized that tiron at increased concentrations completely halted parasite cell cycle 
progression and also host cell proliferation. This suggested that tiron-induced BAG1 
expression is not due to its effect on ROS modulation in the host cell, but rather to the 
inhibition of host and parasite replication. It has been previously reported that tiron inhibits 
cell cycle progression by increasing the percentage of cells in S-phase of cell cycle 
(Monticone et al., 2014).  
In addition to the NAC experiments discussed above, an additional functional link between 
ROS production and T. gondii stage conversion in myotubes has been established in this 
study. Thus, increasing ROS levels using the chemical agent luperox dose-dependently 
induced T. gondii BAG1 mRNA expression and tissue cyst formation in both myotubes 
and myoblasts. In addition, such stage differentiation was accompanied by reduced parasite 
growth. Similar effects of oxidants on T. gondii BAG1 mRNA expression were observed 
after treatment with another ROS inducing agent, i.e. H2O2.  Thus, increasing ROS in 
SkMCs can accelerate bradyzoite formation whereas scavenging ROS favors parasite 
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growth and reduces bradyzoite formation. Taken together, these studies suggest that host 
cell mediated endogenous ROS at physiological concentrations may trigger T. gondii stage 
conversion in myotubes. 
 
4.5 Host cell cycle and its impact on T. gondii bradyzoite differentiation 
in SkMCs 
Recently, it has been established that cell cycle withdrawal in myotubes is accompanied by 
increased expression of Testis specific Y-encoded like protein2 (Tspyl2) mRNA and 
thereby supports T. gondii bradyzoite differentiation and tissue cyst formation as observed 
in myotubes. Importantly, inhibiting host cell cycle withdrawal by knockdown of Tspyl2 
abrogated bradyzoite formation in myotubes (Swierzy and Lüder, 2014). Since differential 
cell cycle regulation was also identified herein as a major difference in the transcriptomes 
of T. gondii-infected myotubes and myoblasts, the impact of the host cell cycle on T. 
gondii bradyzoite differentiation has been further investigated in this study. Indeed, the cell 
cycle is one of the major differences between terminally differentiated SkMCs, i.e. 
myotubes and its proliferating precursors, i.e. myoblasts (Shen et al., 2003). Myotubes are 
permanently arrested at G1/G0 phase and this is also accompanied by the muscle 
differentiation process. Therefore, two different pharmacological cell cycle inhibitors, 
aphidicolin (APH) and mimosine (MIM) were selected to inhibit host cell proliferation in 
SkMCs and to thereby investigate their impact on T. gondii stage conversion in myotubes 
and myoblasts. APH and MIM are well-known reversible late G1/S inhibitors that have 
been used for studying different parasite-infected host cells (Bohne et al., 1994; Naughton 
and Bell, 2007). Whereas APH prevents cell proliferation by inhibiting DNA polymerase-α 
(Krokan et al., 1981), MIM, a plant-derived non-protein amino acid, blocks DNA synthesis 
by decreasing the cellular dNTP concentration through regulation of the ribonucleotide 
reductase (Dai et al., 1994; Gilbert et al., 1995). Herein, it was observed that T. gondii 
residing in both myotubes and myoblasts upregulated BAG1 mRNA expression in 
presence of APH and MIM (Figure 3.27A). Furthermore, APH and MIM inhibited both 
host and parasite cell cycle progression thereby leading to the induction of bradyzoite 
differentiation. However, from the results it was difficult to decide whether the both 
inhibitors triggered bradyzoite formation via inhibiting the host cell cycle or via a direct 
effect on parasite replication. Indeed, immunofluorescence analysis confirmed that parasite 
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replication was completely blocked in myotubes and myoblasts particularly at higher 
concentrations of these inhibitors. This resembles findings of  Shaw and colleagues who 
showed that T. gondii DNA replication is blocked by these drugs even after a short 
treatment (Shaw et al., 2001). Surprisingly, T. gondii tissue cyst formation was only 
induced by moderate concentrations of APH and MIM but was similar to control levels 
when treated with higher concentrations of the inhibitors. Thus, the relatively low number 
of tissue cysts as observed after treatment of myoblasts and myotubes with high 
concentrations of both cell cycle inhibitors appears to be inconsistent with the strongly 
increased BAG1 mRNA expression. It might indicate that T. gondii stage conversion as 
observed in the presence of APH and MIM is not only due to inhibiting the host cell cycle 
but possibly also to a direct effect on the parasite. Since reduced cell cycle progression is 
required for bradyzoite formation, this could increase BAG1 expression in APH- and 
MIM-treated myotubes and myoblasts. But exactly how APH and MIM induce bradyzoite 
differentiation in SkMCs through directly affecting the parasite is currently unknown. 
This study highlighted that several cell cycle inhibitors including p21
Waf1/Cip1
 were 
upregulated in myotubes after 7 days of differentiation from myoblasts by differentiation 
medium containing 2% horse serum. P21 mRNA expression was 6.7-fold higher in 
myotubes as compared to myoblasts irrespective of infection as revealed by RNAseq. 
Similar patterns of increased expression of p21 in myotubes were also observed by RT-
qPCR. P21 is an important cell cycle inhibitor of the CIP/KIP family that can inhibit 
proliferation at the G1 or G2 phase of the cell cycle by inactivating different cyclin-CDK 
complexes (Baus et al., 2003; Gillis et al., 2009). In addition, p21 has a strong affinity to 
bind with PCNA which is an essential cofactor of the DNA polymerase and thereby 
inhibits DNA synthesis in the S-phase of the cell cycle (Podust et al., 1995; Gulbis et al., 
1996). The up-regulation of p21 in myotubes as compared to myoblasts irrespective of T. 
gondii infection accords with previous studies where p21 was highly regulated in the 
course of C2C12 differentiation (Shen et al., 2003; Swierzy and Lüder, 2014). It clearly 
correlates with the fact that myotubes but not myoblasts are cell cycle arrested, terminally 
differentiated cells. Consequently, small interfering RNA (siRNA)-mediated knockdown 
of p21 in C2C12 myoblasts demonstrated that p21 is essential for myoblasts differentiation 
into myotubes. Indeed, p21-deficient myoblasts did not express myosin heavy chain 
(MyHC), a common marker of muscle differentiation thereby clearly indicating inhibition 
of myotubes formation. It has been shown that p21 deficiency increases cell cycle 
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progression and muscle cell proliferation in p21 knockout mice thereby delaying 
regeneration of skeletal muscle tissue after injury (Chinzei et al., 2015). In contrast, in 
vitro studies have shown that p21 suppression does not impact on differentiation and 
fusion of primary mouse myoblasts into myotubes (Biferi et al., 2015). In knockout mice, 
double mutants of p21 and p57 were required for inhibition of skeletal muscle 
differentiation while neither single mutant showed an effect on the differentiation process 
(Zhang et al., 1999). These findings reinforce the conclusion that loss of p21 expression 
can be compensated by other cell cycle inhibitors including p57 and is not the only cell 
cycle regulator required for skeletal muscle differentiation.  
Remarkably, p21 knockdown in SkMCs supported robust parasite replication but 
surprisingly did not inhibit BAG1 mRNA expression and tissue cysts formation. 
Conversely, p21 knockdown even induced BAG1 mRNA expression. This suggests that 
expression of the host cell cycle regulator p21 significantly regulates parasite growth but 
not T. gondii stage conversion. Surprisingly, higher parasite replication did not correlate 
with T. gondii BAG1 expression and tissue cysts formation. A previous study showed that 
reduced parasite replication is required for T. gondii stage conversion (Bohne et al., 1994). 
Expression of BAG1 mRNA and sustained parasite growth might be due to the presence of 
a population of ‘intermediate’ bradyzoites which express both tachyzoite and bradyzoite 
markers and show 85% subpopulation at late S/G2 phase of the parasite cell cycle. Only 
mature bradyzoites arrest their cell cycle at the G1 or G0 phase, thereby developing into 
the non-replicating or slowly replicating parasite form (Radke et al., 2003). However, to 
find out the exact mechanism of this unexpected result of increased BAG1 mRNA 
expression and concomitant parasite replication, p21 knockdown myoblasts and wildtype 
cells can be used to investigate in further detail the cell cycle stage of highly proliferative 
parasites that at the same time express relatively high levels of BAG1.  
In a previous study by Swierzy and colleagues, the authors showed that knockdown of the 
host cell cycle regulator Tspyl2, i.e. an upstream molecule of p21 inhibits myotubes 
formation and concomitantly inhibits bradyzoite differentiation. At the same time, parasite 
replication was strongly supported by knockdown of Tspyl2 in SkMCs (Swierzy and 
Lüder, 2014). In another study, the human orthologue of Tspyl2, namely cell division 
autoantigen (CDA)-1 was identified as inhibitor of cell growth and proliferation by 
upregulation of p21 through either p53- or pERK1/2-dependent mechanisms (Tu et al., 
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2007; Toh et al., 2010). Therefore, the analysis of p21 knockdown in SkMCs as reported 
here now provides evidence that the function of Tspyl2 on T. gondii stage differentiation is 
mediated by a p21-independent mechanism. In addition to inhibition of the cell cycle, 
knockdown of Tspyl2 has been shown to inhibit differentiation of proliferating C2C12 
myoblasts into poly-nucleated myotubes (Swierzy and Lüder, 2014). Furthermore, Tspyl2 
also functions as a nucleosome assembly protein (NAP) thereby regulating gene expression 
in another terminally differentiated and cell cycle arrested cell type, i.e.  neurons by 
interacting with calmodulin-associated serine/threonine kinase (Wang et al., 2004; Tsang 
et al., 2014). Recently, Tspyl2 has been identified as a positive regulator of transforming 
growth factor (TGF)-β dependent cell cycle arrest in human HaCaT cells through 
interacting with the transcriptional complex REST (Epping et al., 2015). Therefore, the 
role of Tspyl2 on host cell cycle regulation and on T. gondii stage conversion in SkMCs 
may relate to these pathways as well. Which of these other Tspyl2-dependent pathways 
might regulate T. gondii stage conversion remains currently unclear and is an important 
issue for further analysis. 
 
 
Figure 4.1: Scheme on factors that induce T. gondii bradyzoite differentiation in myotubes 
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Together, the results of the study establish that metabolic traits of myotubes as a reduced 
PPP activity, increased TCA cycle activities and distinct levels of endogenous ROS as 
observed in myotubes may impact T. gondii differentiation to the bradyzoite stage (Figure 
4.1). Furthermore, it shows that T. gondii stage conversion in SkMCs occurs in a host cell 
p21-independent manner and suggests that Tspyl2 regulates bradyzoite formation by other 
means than p21 (Figure 4.1).  However, the molecular mechanisms of how these factors 
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Supplementary Table 3.1: Top30 uniquely upregulated DEGs in T. gondii-infected 
myoblasts versus myotubes 
Ensemble ID gene name description log2Fold 
Change 
p-value 
ENSMUSG00000095419 Gm14328 predicted gene 14328 2.53 4.5208E-06 
ENSMUSG00000042607 Asb4 ankyrin repeat and SOCS box-
containing 4  
2.51 0.0015546 
ENSMUSG00000004872 Pax3 paired box 3  2.49 0.00105264 
ENSMUSG00000044103 Il1f9 interleukin 1 family, member 9  2.41 0.00031793 
ENSMUSG00000096755 Gm20746 predicted gene, 20746  2.35 0.00216651 
ENSMUSG00000092819 Gm23639 predicted gene, 23639  2.31 0.00106358 
ENSMUSG00000029372 Ppbp pro-platelet basic protein  2.27 0.00086012 
ENSMUSG00000084331 Gm8163 predicted gene 8163  2.23 0.00537326 
ENSMUSG00000079008 Gm14124 predicted gene 14124  2.22 0.00587077 
ENSMUSG00000091623 Gm17092 predicted gene 17092  2.14 0.00473877 
ENSMUSG00000075478 Slitrk1 SLIT and NTRK-like family, 
member 1  
2.11 0.00969976 
ENSMUSG00000043782 Ccdc64b coiled-coil domain containing 64B 2.09 0.01048871 
ENSMUSG00000071715 Ncf4 neutrophil cytosolic factor 4  2.05 0.00216474 
ENSMUSG00000043340 6530409C15Rik RIKEN cDNA 6530409C15 gene  2.05 0.00710414 
ENSMUSG00000064023 Klk8 kallikrein related-peptidase 8  2.04 0.00499059 
ENSMUSG00000093245 Mir677 microRNA 677  2.03 0.01249689 
ENSMUSG00000054568 Usp17la ubiquitin specific peptidase 17-
like A  
2.03 0.00012613 
ENSMUSG00000087017 4930417H01Rik RIKEN cDNA 4930417H01 gene  1.98 0.01100347 
ENSMUSG00000087819 Gm25117 predicted gene, 25117  1.98 0.00127121 
ENSMUSG00000079304 4933413G19Rik RIKEN cDNA 4933413G19 gene 1.97 0.00669523 
ENSMUSG00000065663 Gm22579 predicted gene, 22579  1.97 0.00316963 
ENSMUSG00000090362 Vmn2r79 vomeronasal 2, receptor 79  1.97 0.01061651 
ENSMUSG00000093548 Gm6407 predicted gene 6407  1.96 0.00893079 
ENSMUSG00000082408 Gm13545 predicted gene 13545  1.95 0.01722413 
ENSMUSG00000034764 1700006J14Rik RIKEN cDNA 1700006J14 gene  1.95 0.01794258 
ENSMUSG00000041134 Cyyr1 cysteine and tyrosine-rich protein 
1  
1.93 0.02026058 
ENSMUSG00000052504 Epha3 Eph receptor A3  1.92 0.00406016 
ENSMUSG00000083291 Gm13679 predicted gene 13679  1.91 0.00156182 
ENSMUSG00000071658 Gng3 guanine nucleotide binding 
protein (G protein), gamma 3  
1.91 0.01564742 
ENSMUSG00000081302 Gm12020 predicted gene 12020  1.91 2.0329E-06 
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Supplementary Table 3.2: Top30 uniquely downregulated DEGs in T. gondii-infected 
myoblasts versus myotubes 
Ensemble ID gene name description log2Fold 
Change 
p-value 
ENSMUSG00000086449 9030204H09Rik RIKEN cDNA 9030204H09 
gene  
-2.89 0.000182875 
ENSMUSG00000043029 Trpv3 transient receptor potential 
cation channel, subfamily V, 
member 3  
-2.87 2.13361E-05 
ENSMUSG00000038738 Shank1 SH3/ankyrin domain gene 1  -2.76 0.000334785 
ENSMUSG00000068348 Gm10238 predicted pseudogene 10238  -2.67 0.000390624 
ENSMUSG00000028354 Fmn2 formin 2  -2.49 0.000851051 
ENSMUSG00000055865 Fam19a3 family with sequence similarity 
19, member A3  
-2.48 0.001958978 
ENSMUSG00000021313 Ryr2 ryanodine receptor 2, cardiac  -2.45 0.001314366 
ENSMUSG00000073052 D130052B06Rik RIKEN cDNA D130052B06 
gene  
-2.42 0.002594387 
ENSMUSG00000076897 Traj32 T cell receptor alpha joining 32  -2.40 5.2548E-05 
ENSMUSG00000051225 Fam83a family with sequence similarity 
83, member A  
-2.40 0.00141186 
ENSMUSG00000057723 Krt33b keratin 33B  -2.38 0.003216406 
ENSMUSG00000021953 Tdh L-threonine dehydrogenase  -2.35 0.003425066 
ENSMUSG00000047343 Mettl21c methyltransferase like 21C  -2.35 0.00321369 
ENSMUSG00000087028 Gm13387 predicted gene 13387  -2.34 0.003750199 
ENSMUSG00000039661 Dusp26 dual specificity phosphatase 26 
(putative)  
-2.30 0.004655933 
ENSMUSG00000021490 Slc34a1 solute carrier family 34 
(sodium phosphate), member 1  
-2.24 0.005531173 




ENSMUSG00000097860 Gm26857 predicted gene, 26857  -2.20 0.003592543 
ENSMUSG00000050201 Otop2 otopetrin 2  -2.17 0.002750153 
ENSMUSG00000004609 Cd33 CD33 antigen  -2.14 0.008952032 
ENSMUSG00000086607 4930511M06Rik RIKEN cDNA 4930511M06 
gene  
-2.13 0.005891531 
ENSMUSG00000007279 Scube2 signal peptide, CUB domain, 
EGF-like 2  
-2.12 0.001609105 
ENSMUSG00000071392 Ect2l epithelial cell transforming 
sequence 2 oncogene-like  
-2.12 0.004192352 
ENSMUSG00000096948 Gm4221 predicted gene 4221  -2.11 0.003519203 
ENSMUSG00000030336 Cd27 CD27 antigen  -2.09 0.001688153 
ENSMUSG00000087600 Pmepa1os prostate transmembrane 
protein, androgen induced 1, 
opposite strand  
-2.09 0.005689734 
ENSMUSG00000032572 Col6a4 collagen, type VI, alpha 4  -2.08 0.000137108 
ENSMUSG00000050097 Ces2b carboxyesterase 2B  -2.08 0.010970546 
ENSMUSG00000023153 Tmem52 transmembrane protein 52  -2.08 0.011110238 
ENSMUSG00000020830 Vmo1 vitelline membrane outer layer 
1 homolog (chicken) 
-2.07 0.010777209 
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Supplementary Table 3.3:  List of differentially regulated genes in T. gondii-infected 
myotubes versus non-infected myotubes 
Ensemble ID gene name description log2Fold 
Change 
p-value 
ENSMUSG00000071419 Rps15-ps2 ribosomal protein S15, 
pseudogene 2  
3.26 6.9311E-22 
ENSMUSG00000068240 Gm11808 predicted gene 11808  2.73 1.1944E-14 
ENSMUSG00000084817 Gm5526 predicted pseudogene 5526 2.83 1.4118E-14 
ENSMUSG00000082536 Gm13456 predicted gene 13456  1.60 3.2711E-13 
ENSMUSG00000080921 Rpl38-ps2 ribosomal protein L38, 
pseudogene 2  
3.57 6.2048E-13 
ENSMUSG00000090243 Gm16103 predicted gene 16103  2.86 4.6324E-08 
ENSMUSG00000083621 Gm14586 predicted gene 14586  2.73 9.3046E-08 
ENSMUSG00000082456 Gm11598 predicted gene 11598  3.41 1.7094E-06 
ENSMUSG00000083327 Vcp-rs valosin containing protein, related 
sequence  
1.07 1.0493E-05 
ENSMUSG00000043192 Gm1840 predicted gene 1840  1.17 1.0493E-05 
ENSMUSG00000091449 Gm10269 predicted gene 10269  2.67 2.8868E-05 
ENSMUSG00000043618 Eif5al3-ps eukaryotic translation initiation 
factor 5A-like 3, pseudogene  
2.48 3.0077E-05 
ENSMUSG00000043483 Gm6863 predicted gene 6863  1.64 3.4035E-05 
ENSMUSG00000067344 Rps25-ps1 ribosomal protein S25, 
pseudogene 1  
2.45 0.00012335 
ENSMUSG00000082420 Gm6517 predicted gene 6517  1.35 0.00013623 
ENSMUSG00000080875 Gm7332 predicted gene 7332  2.41 0.00017536 
ENSMUSG00000045690 Wdr89 WD repeat domain 89  0.72 0.00080566 
ENSMUSG00000074479 Gm10704 predicted pseudogene 10704  1.89 0.00089356 
ENSMUSG00000069682 Gm10275 predicted pseudogene 10275  1.56 0.00089356 
ENSMUSG00000066554 Gm10167 predicted pseudogene 10167  1.29 0.0013283 
ENSMUSG00000063902 Gm7964 predicted gene 7964  0.66 0.00217238 
ENSMUSG00000059970 Hspa2 heat shock protein 2  0.69 0.00282959 
ENSMUSG00000081999 Gm13461 predicted gene 13461  1.58 0.00282959 
ENSMUSG00000058809 Hspd1-ps3 heat shock protein 1 (chaperonin), 
pseudogene 3  
1.97 0.00308245 
ENSMUSG00000039684 Gm5422 predicted pseudogene 5422  1.32 0.0032471 
ENSMUSG00000084280 Gm11972 predicted gene 11972  2.72 0.0032471 
ENSMUSG00000084163 Gm11901 predicted gene 11901  1.60 0.00465211 
ENSMUSG00000060068 Gm12222 predicted gene 12222  2.45 0.00536265 
ENSMUSG00000079139 Gm4204 predicted gene 4204  0.86 0.00614431 
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ENSMUSG00000079297 Gm2223 predicted pseudogene 2223  1.65 0.00984243 
ENSMUSG00000049494     1.16 0.0159097 
ENSMUSG00000020178 Adora2a adenosine A2a receptor  1.56 0.01947589 
ENSMUSG00000074800 Gm4149 predicted pseudogene 4149  2.18 0.01947589 
ENSMUSG00000046341 Gm11223 predicted gene 11223  1.97 0.01973754 
ENSMUSG00000097245 Gm5421 predicted gene 5421  1.14 0.02101872 
ENSMUSG00000064317 Gm10146 predicted gene 10146  2.48 0.02101872 
ENSMUSG00000071141 Rpl36a-ps3 ribosomal protein L36A, 
pseudogene 3  
2.11 0.02222175 
ENSMUSG00000083240 Gm13453 predicted gene 13453  2.38 0.02573356 
 
 
Supplementary Table 3.4: List of differentially regulated genes in T. gondii-infected 
myoblasts versus non-infected myoblasts 
 
Ensemble ID gene name description log2Fold 
Change 
p-value 
ENSMUSG00000071419 Rps15-ps2 ribosomal protein S15, 
pseudogene 2  
3.32 7.85E-28 
ENSMUSG00000082536 Gm13456 predicted gene 13456  1.85 3.94911E-18 
ENSMUSG00000080921 Rpl38-ps2 ribosomal protein L38, 
pseudogene 2  
3.47 2.8401E-15 
ENSMUSG00000084817 Gm5526 predicted pseudogene 5526  2.53 2.8401E-15 
ENSMUSG00000083621 Gm14586 predicted gene 14586  2.91 1.41679E-11 
ENSMUSG00000090243 Gm16103 predicted gene 16103  3.15 5.74158E-11 
ENSMUSG00000068240 Gm11808 predicted gene 11808  2.15 4.16872E-10 
ENSMUSG00000058809 Hspd1-ps3 heat shock protein 1 
(chaperonin), pseudogene 3  
2.56 6.20514E-10 
ENSMUSG00000043618 Eif5al3-ps eukaryotic translation initiation 
factor 5A-like 3, pseudogene  
2.33 1.15634E-09 
ENSMUSG00000043192 Gm1840 predicted gene 1840  1.54 3.99799E-09 
ENSMUSG00000083327 Vcp-rs valosin containing protein, 
related sequence  
1.21 3.58062E-08 
ENSMUSG00000069682 Gm10275 predicted pseudogene 10275 1.96 1.2285E-07 
ENSMUSG00000066554 Gm10167 predicted pseudogene 10167  1.38 1.51298E-07 
ENSMUSG00000095419 Gm14328 predicted gene 14328  3.53 2.14701E-07 
ENSMUSG00000058126 Tpm3-rs7 tropomyosin 3, related sequence 
7  
1.26 4.98655E-07 
ENSMUSG00000067344 Rps25-ps1 ribosomal protein S25, 
pseudogene 1  
2.44 1.46785E-06 
ENSMUSG00000043483 Gm6863 predicted gene 6863  1.67 1.49389E-06 
ENSMUSG00000082456 Gm11598 predicted gene 11598  3.04 2.98958E-06 
ENSMUSG00000045690 Wdr89 WD repeat domain 89  0.79 9.59556E-06 
ENSMUSG00000063902 Gm7964 predicted gene 7964  0.74 1.03599E-05 
ENSMUSG00000084280 Gm11972 predicted gene 11972  3.16 2.01534E-05 
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ENSMUSG00000091449 Gm10269 predicted gene 10269  2.19 3.64408E-05 
ENSMUSG00000084163 Gm11901 predicted gene 11901  1.75 8.95066E-05 
ENSMUSG00000082420 Gm6517 predicted gene 6517  1.33 0.000116755 
ENSMUSG00000025225 Nfkb2 nuclear factor of kappa light 
polypeptide gene enhancer in B 
cells 2, p49/p100  
0.52 0.000120184 
ENSMUSG00000080875 Gm7332 predicted gene 7332  2.01 0.000120184 
ENSMUSG00000017737 Mmp9 matrix metallopeptidase 9  3.03 0.000143602 
ENSMUSG00000079139 Gm4204 predicted gene 4204 0.92 0.000239843 
ENSMUSG00000081308 Gm14480 predicted gene 14480 3.35 0.000266767 
ENSMUSG00000049494   1.23 0.000276971 
ENSMUSG00000095908 Gm5576 predicted pseudogene 5576  2.90 0.000349203 
ENSMUSG00000081792 Anp32b-ps1 Bacidic (leucine-rich) nuclear 
phosphoprotein 32 family, 
member B, pseudogene 1  
1.96 0.000443491 
ENSMUSG00000051255 Gm6563 predicted pseudogene 6563  1.10 0.000608142 
ENSMUSG00000089764 Gm16580 predicted gene 16580  1.07 0.000608142 
ENSMUSG00000076999 Gm22426 predicted gene, 22426  2.67 0.000626824 
ENSMUSG00000043889 Gm8399 predicted gene 8399  1.24 0.000701962 
ENSMUSG00000020178 Adora2a adenosine A2a receptor  1.80 0.000881955 
ENSMUSG00000046341 Gm11223 predicted gene 11223  1.58 0.00133387 
ENSMUSG00000081999 Gm13461 predicted gene 13461  1.43 0.002059009 
ENSMUSG00000082044 Gm14284 predicted gene 14284  2.01 0.002093637 
ENSMUSG00000079297 Gm2223 predicted pseudogene 2223 1.65 0.002478247 
ENSMUSG00000084384 Gm12251 predicted gene 12251  2.20 0.002478247 
ENSMUSG00000044751 Gm12231 predicted gene 12231  1.92 0.003009955 
ENSMUSG00000071041 Gm15210 predicted gene 15210  1.06 0.00424674 
ENSMUSG00000081603 Gm14681 predicted gene 14681 1.31 0.004965718 
ENSMUSG00000085783 Gm9816 predicted pseudogene 9816  1.27 0.005982894 
ENSMUSG00000081302 Gm12020 predicted gene 12020  1.52 0.006793115 
ENSMUSG00000068631 Gm7676 predicted gene 7676 1.66 0.009511183 
ENSMUSG00000039684 Gm5422 predicted pseudogene 5422  1.12 0.009511183 
ENSMUSG00000080966 Gm6263 predicted gene 6263  2.14 0.010630767 
ENSMUSG00000075268 Gm10819 predicted gene 10819  1.96 0.012875706 
ENSMUSG00000060214   1.19 0.013999197 
ENSMUSG00000068706 Gm10250 predicted pseudogene 10250  1.37 0.015244317 
ENSMUSG00000083477 Gm5555 predicted pseudogene 5555  1.76 0.016790782 
ENSMUSG00000030735 Gm9755 predicted pseudogene 9755  1.48 0.016890583 
ENSMUSG00000071141 Rpl36a-ps3 ribosomal protein L36A, 
pseudogene 3  
1.87 0.019070742 
ENSMUSG00000083899 Gm12346 predicted gene 12346  0.89 0.029460631 
ENSMUSG00000080776 Gm12174 predicted gene 12174  1.82 0.029460631 
ENSMUSG00000084416 Rpl10a-ps1 ribosomal protein L10A, 
pseudogene 1  
0.99 0.029460631 
ENSMUSG00000079225 Gm9531 predicted gene 9531 1.78 0.032012533 
ENSMUSG00000083396 Gm15542 predicted gene 15542  2.13 0.039258034 
ENSMUSG00000074800 Gm4149 predicted pseudogene 4149 1.86 0.039258034 
ENSMUSG00000063696 Gm8730 predicted pseudogene 8730  1.49 0.039258034 
ENSMUSG00000064317 Gm10146 predicted gene 10146  1.94 0.042426496 
ENSMUSG00000078238 Gm12854 predicted gene 12854  1.40 0.044005604 
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ENSMUSG00000081578 Gm12611 predicted gene 12611  2.34 0.045880403 
ENSMUSG00000062093 Gm10110 predicted gene 10110  1.13 0.045880403 
ENSMUSG00000024164 C3 complement component 3  2.63 0.049628066 
ENSMUSG00000081406 Rps6-ps4 ribosomal protein S6, 
pseudogene 4  
2.37 0.049628066 
ENSMUSG00000089999 Gm6485 predicted gene 6485  1.60 0.049865068 
 
 
Supplementary Table 3.5: List of DEGs involved in glycolysis in non-infected and T. 
gondii-infected myotubes and myoblasts 













Hexokinase-II 3843.84 3874.96 2391.08 2495.12 1.55 0.00158687 
Glucose phosphate 
isomerase-I 
14177.17 14704.36 9846.05 9601.52 1.53 
4.26657E-05 
Phosphofructokinase-I 25088.74 24814.43 2274.60 2232.22 11.12 1.48889E-52 
Aldolase-A 65565.43 66298.06 35486.08 32972.81 2.01 8.35789E-08 
Glyceraldehyde-3P- 
dehydrogenase 
682.54 626.26 690.25 702.93 0.89 0.261487467 
Triphosphate isomerase-I 24513.19 25013.36 21443.78 20423.83 1.23 0.135664454 
Phosphoglycrate kinase-I 2036.55 2126.56 1929.35 1788.71 1.19 0.372127957 
Phosphoglycerate 
mutase-II 
3313.57 3115.43 106.21 83.41 37.35 
5.11824E-34 
Enolase 3, beta-muscle 51401.92 47390.09 19764.94 16469.75 2.88 3.33734E-19 
Pyruvate kinase 56685.11 56932.92 64899.77 60942.09 0.93 0.576795898 
Lactate dehydrogenase-D 11.47 12.76 2.68 3.29 3.88 0.002190597 
 
Note: Ninf: Non-infected, Inf: T. gondii-infected, MTs: Myotubes, MBs: Myoblasts, FC: Fold change, 
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Supplementary Table 3.6: List of DEGs involved in TCA cycle in non-infected and T. 
gondii- infected myotubes and myoblasts 















1465.98 1439.76 921.79 921.90 1.56 4.11758E-15 
Citrate synthase  12121.37 12617.61 17264.04 17571.94 0.72 2.71997E-08 
Aconitase-II 15883.56 15802.30 11676.62 11639.58 1.36 5.60364E-06 
Isocitrate 
dehydrogenase 2 
















3532.83 3600.27 4211.05 4092.49 0.88 
0.197569596 
Malate 








1590.14 1703.32 3550.36 3483.44 0.49 
3.47131E-11 
 
Note: Ninf: Non-infected, Inf: T. gondii-infected, MTs: Myotubes, MBs: Myoblasts, FC: Fold change, 
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Supplementary Table 3.7: List of DEGs involved in the pentose phosphate pathway in 
non-infected and T. gondii- infected myotubes and myoblasts 


















1151.64 1161.26 4002.39 4318.99 0.27 8.52947E-61 
6-phospho- 
gluconolactonase 
2285.01 2288.07 2714.66 2355.19 0.97 0.917819246 
6-phosphogluconate 
dehydrogenase 
4508.70 4259.35 10217.70 9879.02 0.43 2.46997E-13 
Ribose-5-phosphate 
isomerase 
496.18 482.39 628.25 619.27 0.78 0.016798579 
Transketolase 1049.58 1124.96 2828.63 2828.78 0.40 3.29912E-08 
Transaldolase-I 3507.40 3399.36 4717.46 4097.25 0.83 0.325393781 
 
Note: Ninf: Non-infected, Inf: T. gondii-infected, MTs: Myotubes, MBs: Myoblasts, FC: Fold change, 
RPKM (Average RPKM from three independent biological replicates) 
 
Supplementary Table 3.8: List of DEGs involved in glycogen metabolism in non-
infected and T. gondii- infected myotubes and myoblasts 














3843.84 3874.96 2391.08 2495.12 1.55 0.00158687 
Phosphoglucomutase-II 
 




4236.06 4268.94 3400.56 3088.90 1.38 4.51381E-05 
Glycogenin 
 
4430.68 4441.82 1653.29 1518.17 2.92 1.67296E-35 
Glycogen synthase-I 
 
8084.66 8069.19 1951.75 1837.02 4.39 1.48889E-52 
Branching enzyme 
 
764.14 809.71 687.59 723.33 1.12 0.281891944 
Glycogen phosphorylase 
 
8609.45 8544.74 229.01 235.53 36.28 3.95621E-14 
Debranching enzyme 
 
4833.23 4946.81 1796.73 1872.06 2.64 3.02017E-09 
 
Note: Ninf: Non-infected, Inf: T. gondii-infected, MTs: Myotubes, MBs: Myoblasts, FC: Fold change, 
RPKM (Average RPKM from three independent biological replicates) 
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Supplementary Table 3.9: List of DEGs involved in cell cycle regulation in non-















P21 57791.013 55664.455 8631.226 8302.2580 6.704 6.97541E-52 
P53 and DNA 
damage 
regulated-I 
2665.479 2514.2973 1508.159 1329.9731 1.890 
2.35322E-06 
P57 294.561 256.21666 93.7548 84.61721 3.027 1.47466E-10 
P27 2307.542 2401.2136 2077.2920 2055.0977 1.168 0.012060258 
Retinoblastoma
1 (RB1) 
3728.590 3861.1401 1661.973 1735.7367 2.224 
2.06244E-05 
CyclinA2 1392.712 1492.968 6962.999 7262.305 0.205 2.71989E-87 
CyclinB1 281. 709 288.22866 1525.5039 1533.8542 0.187 3.22722E-55 
CyclinB2 850.556 893.039 3356.735 3023.042 0.295 5.75517E-18 
CyclinC 901.763 866.0563 1293.018 1269.509 0.682 1.55291E-09 
CyclinD1 1753.484 2008.287 10498.170 10800.078 0.185 2.46947E-28 
CyclinD2 604.857 682.1955 1863.534 2302.278 0.296 2.6401E-06 
CyclinE1 330.487 358.3018 1518.631 1551.325 0.230 1.05932E-34 
CyclinE2 274.060 360.7402 1147.27 1321.349 0.273 1.18921E-33 
CDK1 1560.276 1718.158 8968.375 8376.256 0.205 1.9079E-23 
CDK2 1650.460 1646.989 2136.575 2143.399 0.768 8.09482E-05 
CDK4 6699.051 6730.020 15583.254 15474.768 0.435 4.7623E-13 
CDK6 162.473 219.006 492.603 718.746 0.305 5.2045E-05 
CDK8 531.157 551.841 1059.251 1065.921 0.518 5.5133E-12 
P18 961.992 1000.329 1683.769 1573.919 0.636 1.04844E-06 
TSPY-like2 740.515   712.086  862.742  807.013 0.88 0.058085214 
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983.010 954.0822 2944.851 3006.691 0.317 2.23211E-37 
 
Note: Ninf: Non-infected, Inf: T. gondii-infected, MTs: Myotubes, MBs: Myoblasts, FC: Fold change, 
















Chapter 7: Curriculum Viate 2017 
 





Name: Md. Taibur Rahman 
Father’s Name: Md. Abdus Samad 
Mother’s Name: Amena Begum 
Gender: Male, Date of birth: 04 November 1985 
Birth place: Dinajpur, Nationality: Bangladeshi 
Present address: Robert Koch Str. 38, App.-1021, 37075, Göttingen 
Contact address: Department of Biochemistry and Molecular Biology,  
University of Dhaka, Dhaka-1000, Bangladesh. Email: taibur@du.ac.bd 
 
EDUCATIONAL BACKGROUND: 












































Science 2000 First 
Division 
(79%) 




Chapter 7: Curriculum Viate 2017 
 
Page | 167  
 
EMPLOYMNET EXPERIENCES: 
September 2014 to present: PhD student, Institute of Medical Microbiology, University 
of Goettingen, Germany 
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April 2009 to June 2010: Research Officer, Immunology Laboratory, International Centre 
for Diarrheal Disease Research, Bangladesh 
 March 2008 to March 2009: Thesis student (MSc), Immunology Laboratory, 
International Centre for Diarrheal Disease Research, Bangladesh. 
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Computer fundamentals, MS office, program C++, SPSS, Sigma-Stat, Sigma-Plot, Mega-
4, Graph Pad, Bioinformatics tools: NCBI, Venn diagram, DAVID analysis tools. 
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Biochemistry and Molecular Biology, University of Dhaka, Bangladesh.  
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2014: PhD fellowship, Erasmus Mundus (Interweave), University of Göttingen, Germany. 
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